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Chapter 1
General introduction and outline of the thesis

Introduction
Crohn’s disease is a chronic inflammatory disorder, which may affect any part of the
gastrointestinal tract and may include extra-intestinal tissues. Involved parts of the bowel
may demonstrate chronic transmural focal inflammation with or without granulomatous
lesions of the intestinal mucosa. Probably due to the transmural nature of inflammation,
Crohn’s disease is frequently complicated by the development of fistulae and bowel
strictures. The spontaneous course of the disease is characterized by relapses and periods
of remission (1) and therefore, Crohn’s disease imposes substantial personal burden over
a long period for many patients (2,3). The etiology of Crohn’s disease is complex and
largely unknown. There is overlap between Crohn’s disease and ulcerative colitis.
However, due to differences in the nature of inflammation, disease behavior and
epidemiology, Crohn’s disease is considered as a distinctive disease from ulcerative
colitis. Epidemiologic data support a clear role for polygenetic susceptibility (4-6).
Besides genetic factors, environmental factors and enteric micro flora may play a role in
the pathogenesis of Crohn’s disease. Concerning genetic susceptibility, a wide variety of
genes coding for proteins involved in the immune system were postulated to be
associated with Crohn’s disease. However, as recently shown, NOD2/CARD15 was the
first susceptibility gene, which was undoubtedly associated with Crohn’s disease (7-9).
This gene plays a role in a cellular pathway between recognition of bacterial fragments
and the final immunologic cellular response (10). The discovery of a true susceptibility
gene for Crohn’s disease is a major breakthrough in the understanding of the etiology.
However, until now, genotype analysis has no clinical consequences in individual
patients, as NOD2/CARD15 variants are present in a minority of patients and also in
apparently healthy individuals (11,12). The search for additional susceptibility genes is
ongoing. Concerning environmental factors, smoking is the most established risk factor
for Crohn’s disease. In most of the studies, a positive smoking history seems to enlarge
the risk of developing Crohn’s disease, and worsens the course of disease over time (13-
20). Recently was shown that smoking may also impair the efficacy of medical therapy
(21). Therefore, advices to quit smoking belong to the therapy for patients with Crohn’s
disease.
Because the precise etiology of Crohn’s disease remains unclear, no causal therapy is
available. Furthermore, Crohn’s disease is a life-long disorder and therefore, either
medical or surgical therapy should focus on the long-term outcomes. Medical therapy
primarily focuses on reduction of mucosal inflammation, which may result in symptom
reduction and in the reduction of complications, such as formation of stenoses, fistulae
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or abscesses. However, even with the growing arsenal of medical therapies, surgery is
still frequently needed in refractory patients or in case of disease related complications
(22). The large number of available compounds to treat Crohn’s disease can be separated
in several categories. These categories are traditionally ordered by a step up strategy,
beginning with relatively safe, but less effective compounds to more effective
compounds, which might be more toxic. For the therapy of Crohn’s disease, four
catagories can be recognised. The first category contains 5-aminosalicylate derivates, the
second corticosteroids, the third immunomodulatory agents such as azathioprine and
cyclosporine (23,24) and the fourth category contains newer biological therapies. At
present, the first three categories are considered as conventional therapy. Besides these
categories, there is some role for the use of antibiotics in Crohn’s disease, especially in
patients with large bowel involvement, ulcers at a surgical anastomosis and fistulae (25-
30). Furthermore, nutrition plays a role in the management of patients with Crohns
disease as supportive or primary therapy. Supportive therapy aims to correct
malnutrition and nutrient deficiencies. Enteral or parenteral nutrition as primary
treatment may benefit subgroups of patients with Crohn’s disease and is widely
practised in paediatric patients. 
The number of biological therapeutic strategies that has been evaluated, or will be
evaluated in Crohn’s disease, is rapidly growing (31-36). There are several explanations
for this interest in development of biological therapies. At first, both efficacy and safety
of the three conventional categories is limited. Secondly, the knowledge of the
immunopathogenic mechanisms has increased dramatically. Finally, the success of
infliximab, which is a chimeric monoclonal antibody to TNF-alpha, in clinical trials has
encouraged the research for other effective agents (37-42). Concerning efficacy and
safety, the ultimate question that needs to be answered is what the cost-benefit ratio is
of new agents, compared to the conventional treatment strategies. The aim of the present
thesis is to determine safety and efficacy of conventional medical therapy, including
budesonide and 6-thioguanine in Crohn’s disease.
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Outline of the thesis
Chapter 2 In clinical trials evaluating efficacy of therapy for inflammatory bowel
disease, activity indices are needed in order to quantify disease activity.
Chapter 2 reviews disease specific activity indices, which have been used
in previous trials.
Chapter 3 5-Aminosalicylates are used on a large scale in patients with inflammatory
bowel disease. Major advantage of these compounds is the beneficial safety
profile. However, concerns have been raised among potential
nephrotoxicity. This chapter describes a retrospective cohort analysis
exploring the relationship between changes in renal function and the
history of 5-aminosalycilates in patients with Crohn’s disease.
Chapter 4 Osteoporosis is a frequent complication in patients with Crohn’s disease.
Although corticosteroids have been pointed out as major risk factor in these
patients, the etiology is more complex. In this chapter, a cohort analysis is
presented, exploring risk factors for low bone mineral density in Crohn’s
disease patients at risk for osteoporosis.
Chapter 5 The frequency of impaired bone mineral density is high in patients with
Crohn’s disease. If the exposure to potential risk factors for osteoporosis
persists, further decline in bone density over time is expected. The present
longitudinal study explores changes in bone density over time in relation
with potential risk factors.
Chapter 6 The evidence for genetic susceptibility to osteoporosis is growing. In this
chapter, genetic risk factors for osteoporosis have been studied in patients
with Crohn’s disease.
Chapter 7 Budesonide is a locally active corticosteroid, which use may result in high
efficacy with limited corticosteroid related adverse events. In chapter 7, a
randomized, prospective, double blind, multi-centre, maintenance trial
with budesonide, in patients with Crohn’s disease is presented.
Chapter 8 Azathioprine and 6-mercaptopurine have proven efficacy in the treatment
of inflammatory bowel disease. However, concerns among safety limited
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the wide spread use of these thiopurines. This chapter reviews the safety of
thiopurines in the treatment of inflammatory bowel disease.
Chapter 9 This chapter describes a retrospective survey in patients with Crohn’s
disease, exploring the occurrence of adverse events in patients treated with
azathioprine.
Chapter 10 One of the strategies to reduce toxicity of thiopurines is to administer a
down stream effective metabolite of azathioprine. 6-Thioguanine is such a
compound. This chapter shows the results of a short-term safety analysis in
a prospective open label trial with 6-thioguanine in inflammatory bowel
disease.
Chapter 11 6-Thioguanine might be an attractive alternative in the treatment of
inflammatory bowel disease patients, intolerant to azathioprine or 6-
mercaptopurine. In this chapter, the results of a one-year maintenance trial
with 6-thioguanine are presented.
Chapter 12 In dit Nederlandstalige overzicht wordt de medicamenteuze behandeling
van patiënten met een inflammatoire darmziekte besproken, waarbij de
nadruk ligt op momenteel geregistreerde geneesmiddelen voor deze
indicatie.
Chapter 13 This chapter summarizes the results of the present thesis.
Chapter 14 Nederlandse samenvatting van dit proefschrift.
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Chapter 2
Assessment of disease activity 
in inflammatory bowel disease; 
relevance for clinical trials
A.H.J. Naber, D.J. de Jong
The Netherlands Journal of Medicine 2003;61:13-18

Abstract
In patients with inflammatory bowel disease, assessment of disease activity is important
in order to monitor and adjust therapy. In individual patients, disease evaluation is
largely based on subjective symptoms. However, for disease evaluation in clinical trials,
an objective and reproducible disease activity index is needed. At present, a number of
activity indices are available for Crohn's disease and for ulcerative colitis. These indices
may be distinguished in more subjective clinical indices, more objective endoscopic and
histological indices and in indices with combinations of both subjective and objective
parameters. In the design of a new clinical trial, an appropriate disease activity index
should be selected, which is based on the patient selection criteria and on the aims of the
study. 
Introduction
In clinical practice, the subjective assessment of disease activity is relevant for the
treatment of individual patients with inflammatory bowel disease (IBD). For disease
evaluation in clinical trials, this subjective assessment of disease activity should be
translated in an objective disease activity index. Preferably, the index consists of as few
variables as possible, which are easily obtainable in any hospital, and applicable in a
majority of the patients. Furthermore, the index should be validated, objective,
reproducible and accepted by physicians and investigators. Such an instrument is
necessary to define the characteristics of patients taking part in therapeutic trials, and to
compare the results of treatment. It may be expressed in discrete classes or as a
continuous numerical scale. Because of the differences in objectives of the studies and
the variability in patient characteristics, no single disease activity scoring system can be
applied for both ulcerative colitis and Crohn’s disease.  In the 50's and 60's of the 20th
century the first disease activity indices were introduced (1,2). For disease activity in
ulcerative colitis, Truelove and Witts introduced a three-grade scale of absent, mild,
moderate and severe disease (Table 1). For Crohn's disease, Best et al. developed the
Crohn's disease activity index (CDAI), which has been used on a large scale in clinical
trials. After multivariable regression analysis 8 out of 18 variables were included in the
CDAI (Table 2)(3,4). The recent introduction of (potential) new drugs in the treatment of
inflammatory bowel diseases has revived the interest in the assessment of disease
activity. In the design of a new clinical trial, it is essential to select the appropriate index
to answer the aims of the study. In Table 3, the main factors influencing the choice for a
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disease index are summarised. Recently, an international group of experts have
published a consensus on endpoints for clinical trial in Crohn’s disease (5).
Indices in Crohn’s disease
The most frequently used index for the assessment of disease activity in Crohn’s disease
is the CDAI (Table 2). The outcome of the CDAI varies between 0 and 600 points. A score
below 150 is associated with clinical remission, 150-219 with mildly active disease, 220-
450 with moderately active disease and above 450 with very severe disease. This index
is used in trials to select groups of patients based on the severity of the disease activity
and to evaluate the effect of treatments. In most studies complete remission is defined
by a value of less than 150 points, and clinical response is characterised by a decrease in
CDAI of more than 70 to 100 points. The CDAI is also used to monitor patients for
worsening of the disease during a trial. Relapse or re-activation of disease is defined as
an increase in CDAI by more than 150 points or a score above 150 together with an
increase by more than 50-100 points (not well defined). An increase of the index by more
than 60-100 points or a disease activity of more than 200 at the end of the treatment
period indicates treatment failure. Although it is broadly applied in clinical trials,
substantial criticism has been raised. The inter-observer variability can be substantial
because of differences in interpretation in variables that are part of the CDAI (6). This is
due to the subjective variables that are included in the index. For instance, the patient
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Table 1
Truelove-Witts severity categories of ulcerative colitis.
Mild Diarrhoeas < 4 times /day, non-bloody
No fever
Pulse rate  < 90 /Min
ESR < 30 mm/h
Moderate Intermediate between mild and severe
Severe Diarrhoeas > 4 times /day, bloody
Haemoglobin 75% or below
Evening temperature  > 37.5 ºC
Pulse rate  > 90 /Min
ESR > 30 mm/h
ESR; erythrocyte sedimentation rate
scores important variables like “Abdominal pain” and “General well being”. Also the
number of liquid or soft stools is an important variable, more or less subjective, and
influenced by the presence or absence of the ileum. Overflow of bile acids in the colon
due to resection of the ileum and the subsequent interruption of the entero-hepatic cycle
may be the cause of diarrhoea without any inflammatory activity. Although it is a
relevant score for improvement or worsening of the complains of the patients, it is not
representative for disease activity in the intestinal wall. The CDAI is a complex index
and is difficult to calculate in daily clinical practice. A more suitable index has been
developed: the Harvey Bradshaw index or Simple Index (7). It includes five of the main
variables of the CDAI and is easier to calculate, but has the same disadvantages. Other
indices have been developed like the Therapeutic Goals Score (8), the Cape Town Index
(9) and the index of the Organisation Mondial de Gastroenterologie (OMGE) (10) of
which the Therapeutic Goals Score is not validated. These indices correlate quite well
and are appropriate for assessment of improvement of the complains of patients in
clinical trials.
For assessment of the quality of life in IBD patients, the Inflammatory Bowel Disease
Questionnaire (IBDQ) has been introduced (11-14). At present, this questionnaire is not
frequently used in clinical trials (15).
Because of the disadvantages of scoring systems mainly based on complains of the
patient, an index mainly based on objective variables has been developed. This Van Hees
Index or Dutch Index is partly based on symptoms of the patient but also on laboratory
data and physical examination (Table 4)(16). The Van Hees Index does not correlate well
with the indices mentioned above. Probably, the Van Hees Index is more appropriate for
trials in which disease activity should be assessed and correlated with the inflammatory
parameters such as cytokines. 
In fistulising Crohn's disease, the CDAI is not the most suitable index because the
presence or absence of fistulae is only one of a number of listed complications in the
index.  In 1980, the first attempt was made for an index evaluating fistula closure,
however, this index was not validated (8). Irvine proposed the Perianal Disease Activity
Index with 5 categories and five grades for each category (17). However, not all of the
fistulae are peri-anal and no consensus has been reached about the criteria on activity of
the fistulae, the period of inactivation of fistulae or the percentage of the number of
fistulae that should be inactive. Recently, a simple and easily reproducible fistula
drainage assessment score was described by Present at al (Table 5) (18). This index is
promising but should be validated in additional prospective trials.
The frequently applied indices to evaluate Crohn’s disease are summarised in Table 6
and for the separate indices, all contributing variables are indicated.
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Table 2
Crohn's Disease Activity Index (CDAI)
Sum of       Factor Subtotal
7 days
Number of liquid or soft stools _ _ _ 2 _ _ _
Abdominal pain1 _ _ _ 5 _ _ _
General well-being2 _ _ _ 7 _ _ _
Number of complications (presence or absence):
- Arthritis or arthralgia
- Iritis or uveitis
- Anal fissure, fistula or abscess _ _ _3 20 _ _ _
- Erythema nodosum, pyoderma gangrenosum, 
aphthous stomatitis      
- Other fistula
- Fever over 37.8 ºC
Loperamide or diphenoxylate for diarrhoea  __ 30 _ _ _
(none = 0, yes = 1)        
Abdominal mass (0 = none, 2 = questionable, 5 = definite) __ 10 _ _ _
Haematocryte (males 47- Ht (%), females 42- Ht (%)) __ 6 _ _ _
Body weight:
Body weight
( 1 - _______________________  ) X 100 = __ 1 _ _ _
Standard weight
CDAI  Total    _ _ _
1 Pain score per day: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
2 General well-being score per day: 0 = generally well, 1 = slightly under par, 2 = poor, 3 = very
poor, 4 = terrible.
3 Total number of complications from the list that are present. 
Besides these clinical indices also other methods can be used for assessment of disease
activity. Radiological methods like the small bowel and colon X-ray are widely used.
More recently also the sonography, computer tomography and the magnetic resonance
imaging techniques are applied. For external fistulae photography may be useful.
Disease activity may also be established by the nuclear scintigraphy such as the 111In-
labelled leukocyte scan. Furthermore, scoring systems are developed for the endoscopic
disease activity assessment. Most frequently applied and also well validated is the
Crohn’s Disease Endoscopic Index of Severity (CDEIS)(19). Rutgeerts et al have
described an endoscopic score for activity of Crohn's disease after surgical resection of
the ileum (20,21). Korelitz and Sommers (22) and D’Haens et al (23) have proposed
histological scores to evaluate the effect of medical treatment. The clinical relevance of
these indices is a matter of debate because clinical symptoms will not only be influenced
by the focal signs of the severity of the inflammatory process but also by the location and
extent. However, these indices may be relevant in studies aiming at the effect of
interventions on the inflammatory process in the intestinal mucosa.
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Table 3
Factors influencing the choice for a disease index in IBD
Aims of the study
Inflammatory activity
Symptoms of disease activity noticed by the patient: clinical activity
Quality of life 
Endoscopic score or histological score
Disease variables
Crohn's disease or ulcerative colitis
Active disease, disease in remission, chronic active disease or refractory disease
Period of disease free interval
Effects on drug treatments 
Location of the disease activity
Extra intestinal localizations: arthritis 
Patient with a stoma or without
Adults or children, age at onset or diagnosis
Fistula: site, entero-cutanous, post operative 
Perforating or non-perforating disease
Structuring or non-structuring disease
Number of surgical resection
Extra intestinal symptoms.
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Table 4
Van Hees Index (VHI)
Serum albumin g/L __  X –5.48 _ _ _
ESR mm/h       __   X 0.29 _ _ _
Quetelet: __   X -0.22 _ _ _
Weight
_______  = 
Height 2
Abdominal mass    __  X   7.83 _ _ _
1 = 0
2 = questionable
3 = <6 cm
4 = 6-12 cm
5 = >12 cm
Gender __  X -12.3 _ _ _
1 = male
2 = female
Temperature ºC                 __  X 16.4 _ _ _
Consistency of the stools  __  X 8.46 _ _ _
1 = normal
2 = soft
3 = liquid
Resection __  X -9.17 _ _ _
1 = none
2 = yes
Extra intestinal manifestations __  X 10.7 _ _ _
1 = none
2 = yes
Total     _ _ _
subtract                                                                                                                    -209
VHI  _ _ _
ESR; erythrocyte sedimentation rate 
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Table 5
Fistula Drainage Assessment
Improvement
Closure of individual fistulas defined as no fistula drainage despite gentle
finger compression. Improvement defined as a decrease from baseline in the
number of open draining fistulas of ≥50% at least 2 consecutive visits (i.e. at
least 4 weeks)
Remission
Closure of individual fistulas defined as no fistula drainage despite gentle
finger compression. Remission defined as closure of all fistulas that were
draining at baseline for at least 2 consecutive visits (i.e. at least 4 weeks)
Table 6
Disease activity indices in Crohn’s disease
CDAI Harvey- VHI Oxford Cape Town
Bradshaw Index Index
Abdominal pain X X X X
Bowel habits X X X X X
Perianal complications X X
Other complications X X X X X
Palpable mass X X X X X
Body weight X X X
Haemoglobin level X X X
Well-being X X X
Anti-diarrhoeal drugs X
Quetelet index X
Temperature X X X
Serum albumen X
ESR X
Sex X
Bowel resections X
Tenderness X X
Fistula X
CDAI; Crohn's disease activity index, VHI; Van Hees Index, ESR; erythrocyte
sedimentation rate. 
Indices for ulcerative colitis
In ulcerative colitis, the intestinal inflammation is confined to the colon mucosa. In
active disease, this results in specific symptomatology with frequent diarrhoea and
blood loss. The first index to quantify disease activity in IBD patients was based on these
symptoms and developed for ulcerative colitis specifically (1,2). This Truelove-Witts
score was mainly used to characterise a severe relapse (Table 1) and was frequently used
in clinical trials. Disadvantage of the index is the difficulty to classify a number of
patients to the appropriate disease category and changes in disease activity over time are
difficult to quantify. Other activity indices were proposed by various authors (24-30).
The index by Talsted and Gjone (24) consists of 15 variables and is not applicable due to
its complexity. Also the Powell-Tuck index (25), consisting of 10 items, has a low
feasibility. Endoscopic assessment of disease activity is important, because complains of
a patients not always represent the severity and extent of the disease. Severe proctitis of
10 cm, or less, may provoke more complains than a moderate colitis over more than half
of the colon. An other advantage of endoscopy is the opportunity to obtain biopsies.
Histology obtained in a remission period may demonstrate features of acute
inflammation, which increases the risk on a relapse (31). Furthermore, dysplasia and
malignant tumours may be established by endoscopy (32). Based on endoscopic
findings, Dick et al introduced a five-scale endoscopic index (33) and Rachmilewitz
developed an endoscopic index, scoring for granularity, vascular pattern, vulnerability
and mucosal damage. The Rachmilewitz score is numerical and has been used in clinical
trials (29). The Baron scale, distinguishing three grades of activity, is the most used score
to evaluate the degree of activity endocopically (34). In order to combine the advantages
of the clinical Truelove score (1,2) and the endoscopic Baron scale (34), the Mayo score
was developed (30). Currently, the Mayo score is favourite in clinical studies. In Table 7
indices for the activity of ulcerative colitis are summarised, with the contributing
variables.
Conclusions
For the evaluation of IBD in clinical trials, a variety of disease activity indices are
available. The patient selection criteria and aims of the study are major determinants to
select the activity index of choice. In Crohn's disease patients, the Van Hees Index as an
overall index seems suitable to evaluate inflammatory disease activity. For local mucosal
monitoring, endoscopic and histological indices are the preferable methods. For the 
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quality of life evaluation, the IBDQ is preferable. To evaluate the clinical effect of
treatment in a group of patients the CDAI is suitable. Furthermore, CDAI is most widely
used in previous trials which enables comparisons with previous results. For evaluation
of fistulising disease, specific indices are suggested. 
For ulcerative colitis, classification of the extent of the inflammation is essential. This can
be performed by endoscopy or X-ray examination of the bowel. For the assessment of
disease activity, clinical scoring lists are available. The preferable activity index contains
endoscopic as well as clinical variables.
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Table 7
Most frequently used indices in ulcerative colitis
Index
Powell-Tuck Sutherland Rachmilewitz Mayo
Bowel frequency X X X X
Blood in stools X X X X
Well-being X X
Abdominal pain X X
Stool consistency X
Nausea X
Weight loss X
Extraintestinal signs X X
Fever X
ESR X
Physician's global assessment X
Sigmoidoscopy X X X X
ESR; erythrocyte sedimentation rate
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Abstract
Background: A number of case reports concerning irreversible renal failure due to 5-
aminosalicylates (5-ASA) have been published. Renal biopsies disclosed acute or
chronic interstitial nephritis in most cases. The aim of the present study was to
investigate the effect of long-term use of 5-ASA on renal function in patients with
Crohn’s disease. 
Methods: Retrospective survey in 200 consecutive Crohn’s disease patients
consulting our outpatient gastroenterology clinic. Endogenous creatinine clearance
(ECC) was estimated from serum creatinine with the Cockroft & Gault formula,
which takes into account age, weight and gender. The first available ECC was chosen
close to the start of 5-ASA and the second was the most recent ECC available at time
of the study.
Results: In 153 patients (59 male, 94 female), sufficient data were available for
analysis. Mean age at the first ECC was 31 ± 12 years. The interval between the first
and second ECC was 11 ± 8 years, the mean duration of 5-ASA treatment 9 ± 7 years
and the cumulative dose amounted 9 ± 9 kilogram. No interstitial nephritis was
reported in these patients. The mean ECC declined from 100 ± 25 to 92 ± 28 ml/min
(p <0.01), with a yearly decline of 0.3 ± 5 ml/min. In a multiple linear regression
model, the duration of the interval was a significant independent predictor for the
change in ECC (p < 0.0001) and the effect of the cumulative 5-ASA dose was not
significant (p = 0.30). In all 8 patients with the largest decline in ECC (>35%)
important co-morbidity causing renal function impairment was present.
Conclusion: The mean decline in ECC of 0.3 ml/min per year in Crohn’s disease
patients does not exceed the decline expected from physiologic ageing of 0.4 - 1
ml/min per year. Long-term use of 5-ASA therefore is not detrimental for renal
function. However, interstitial nephritis due to 5-ASA may rarely occur, therefore we
still advocate measurements of serum creatinine before and during treatment. 
Introduction
In patients with inflammatory bowel disease (IBD), 5-aminosalicylates (5-ASA) are
used on a large scale. Free 5-ASA is unstable in acid and largely absorbed in the
proximal intestine. Therefore, formulations have been developed to target 5-ASA to
the inflamed intestinal tissue (1,2). The oldest compound containing 5-ASA is
sulfasalazine, which consists of 5-ASA and sulfapyridine, joined by a diazo bound.
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After administration of sulfasalazine, the diazo bound is degraded by the bacterial
flora in the colon. In IBD patients, 5-ASA appeared to be the active metabolite,
whereas sulfapyridine was associated with the majority of adverse events (3-5).
Mesalazine is the generic name for coated 5-ASA formulations, with delayed release
in the intestinal lumen. In mild to moderate active ulcerative colitis, both
sulfasalazine and mesalazine have proven efficacy in inducing and maintaining
clinical remission (6,7). This efficacy is accompanied by a mild toxicity profile. At
present, the efficacy of 5-ASA formulations as maintenance strategy in Crohn’s
disease is a matter of debate (8). A major advantage of these agents is the safety
profile. However, a number of cases have been reported with 5-ASA related
nephrotoxicity, which may be potentially irreversible (9-15). In most cases, renal
failure was caused by an acute or chronic interstitial nephritis, which may be an
idiosyncratic and dose unrelated adverse event. However, in previous animal studies,
5-ASA related nephrotoxicity was dose dependent, although nephrotoxicity was only
apparent at doses, which were much higher compared with doses used in humans
with IBD (16). In patients, high doses of 5-ASA also caused renal tubular injury as
reflected by an increased excretion of markers for tubular toxicity. In IBD patients, the
frequency of acute and severe renal impairment seems to be less than one out of 500
patients treated with 5-ASA (17). Remarkably, 5-ASA related nephrotoxicity was more
frequent in mesalazine treated patients, compared to sulfasalazine treated patients
(18). This might be explained by differences in small bowel absorption of free 5-ASA
or acetylated 5-ASA and the resulting higher serum concentrations of 5-ASA (2).
Recently, studies have suggested that nephrotoxicity of 5-ASA may be limited.
Mahmud and colleagues were unable to demonstrate nephrotoxicity after a 6 months
course of mesalazine in a low dose of 1.2 g per day in a prospective study in patients
with ulcerative colitis (19). In a large European registry containing more than 1500
IBD patients, reported during a follow-up of one year, the incidence of renal failure
was not increased in patients using 5-ASA (20). However, in this study the authors
were unable to investigate a dose relationship. Taken together, it remains unclear if
long-term cumulative nephrotoxicity does exist in patients treated with relative high
doses of 5-ASA over years. In our clinic, almost all patients with Crohn’s disease were
treated with 5-ASA for maintenance therapy, in the past. Furthermore, additional
immune suppressive therapy was added based on disease activity. The aims of the
present study were to investigate whether long-term use of 5-ASA has detrimental
effects on renal function over time in patients with Crohn’s disease, and if changes in
renal function were related to disease phenotypes or the type of 5-ASA used. 
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Methods
Patients
Two hundred consecutive patients with confirmed Crohn’s disease, consulting our
outpatient clinic of Gastroenterology and Hepatology, were eligible for the study.
Medical records from these patients were reviewed for the study. The following data
were obtained retrospectively: medical history, age at diagnose of Crohn’s disease,
gender, length, location of Crohn’s disease, history of fistulae or bowel resections,
history for urolithiasis and use of medication since the diagnosis of Crohn’s disease.
Serum creatinine level and body weight were obtained from the most recent visit to
our clinic, together with values from the history, which were the close to the start of
treatment with 5-ASA. The cumulative doses of orally administered mesalazine and
sulfasalazine were calculated from start and stop dates of each dose adjustment. With
respect to the use of 5-ASA, patients were divided into the following subgroups:
patients without a history of 5-ASA, those with a history of sulfasalazine, a history of
mesalazine or a history of both compounds. Patients were excluded from the analysis
if inappropriate data concerning medical history, use of medication for Crohn’s
disease or renal function were available. All data obtained were collected in an
anonymous database for the analysis, which was approved by the local medical
ethical committee.
Assessment of renal function
In our practice, renal function was monitored by measuring levels of serum creatinine
in patients using 5-ASA. Since creatinine excretion was not regularly measured, we
were unable to calculate endogenous creatinine clearances (ECC). Therefore, ECC
was estimated from serum creatinine with the Cockroft & Gault formula, which takes
into account age, weight and gender (21). The ECC (in ml/min) was calculated by the
following formula: (140-age)*bodyweight divided by 0.81*serum creatinine (in
µmol/l). Due to differences in body composition, a correction factor of 0.85 was used
for females. The first ECC was estimated from available data close to the start of 5-
ASA and the second was the most recent ECC available at time of the study. In case
no 5-ASA was administered in the history, the first ECC was estimated from the first
available data after the onset of Crohn’s disease. The annual change in ECC was
calculated in each patient over the observed interval between the initial and most
recent ECC. In the 5% of patients with the largest decline in ECC, medical history was
reviewed for causal factors influencing renal function.
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Statistical analysis
Differences between groups were analyzed using two sample t tests or Wilcoxon Mann
Whitney tests when appropriate. Correlations were analyzed using Spearman rank
coefficients of correlation. To determine predictive factors for the change in ECC, linear
regression analysis was performed with the duration of the interval, the cumulative
dose of 5-ASA, type of 5-ASA, age at diagnosis of Crohn's disease and disease location
as independent variables. Two-tailed values were used and p values < 0.05 were
considered statistically significant. Results were expressed as mean ± standard deviation
in case of normal distribution or median (range). The SPSS 12.0 package was used for all
tests. 
Results
Patients
In 47 out of 200 patients, insufficient data were available in the medical documents. This
was mainly due to patients, referred to our center after a long history of medical
treatment in other hospitals. Therefore, 153 patients were studied (59 male). The
characteristics of these patients are shown in Table 1. Mean age at the first ECC was 31.3
± 12 years, with a duration of Crohn’s disease of 2.9 ± 4.8 years. A history of 5-ASA
during the study interval was present in 152/153 patients. In none of these patients,
interstitial nephritis was reported. The interval between first and second ECC was 11.5
± 7.7 years and in this interval, the duration of 5-ASA treatment was 8.6 ± 7.0 years. The
median cumulative dose of oral 5-ASA formulations during the interval was 6.5
kilogram (range 0-55.2 kg), with a median daily dose of 2.8 g (range 0-5.4 g). In Table 2,
the history of 5-ASA is shown for the subgroups of patients with exposure to
mesalazine, sulfasalazine or both mesalazine and sulfasalazine. None of the patients
studied used olsalazine or balsalazide, because balsalazide is not registered in the
Netherlands and olsalazine was prescribed for ulcerative colitis in our center. In 11 out
of the 153 patients, a history of urolithiasis was reported.
Annual change in ECC
The ECC declined from 100 ± 25 to 92 ± 28 ml/min (p <0.01), which corresponded with
an annual decline of 0.3 ± 5 ml/min. The annual decline in these patients was negatively
correlated with the duration of the interval (r= -0.17; p <0.05), but not with the
cumulative dose of 5-ASA (r= -0.072; p = 0.4) or duration of treatment with 5-ASA (r= -
0.043; p = 0.6). The overall decline in ECC was significantly less in patients with a history 
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of mesalazine alone, compared to the 2 other groups, but the study interval and
exposure to 5-ASA were also significantly less (Table 2). Furthermore, there was a strong
correlation between dose and duration of 5-ASA and the duration of the interval (r= 0.72
and 0.67 respectively; p <0.0001). Therefore, in order to determine an independent effect
of 5-ASA on ECC, a multiple linear regression model was used with the overall change
in ECC as dependent variable (in ml/min). In this model, the duration of the interval
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Table 1
Clinical characteristics of Crohn’s disease patients
N = 153
Age at the first ECC (yr) 31.3 ± 12.0
Sex (male / female) 59 / 94
Age at onset of disease (yr) 28.7 ± 11.8
Duration of the interval (yr) 11.5 ± 7.7
Body weight at the first ECC (kg) 60.8 ± 11.9
Location of disease (n)
- Ileum 39 (26%)
- Colon 31 (20%)
- Ileum and colon 83 (54%)
History of fistula (n) 74 (48%)
Results given as number (%) or mean ± standard deviation. ECC; estimated
endogenous creatinine clearance.
Table 2
History of 5-aminosalicylates in 153 Crohn’s disease patients
Mesalazine Sulfasalazine Mixed 5-ASA
Number of patients (n) 56 14 82
Cumulative dose (kg) 3.0 (0.07-14.7)* 13.2 (0.09-30.3) 12.0 (0.09-55.2)
Time on therapy (yr) 3.8 ± 3.0* 11.8 ± 6.7 11.3 ± 6.5
Length of interval (yr) 5.2 ± 3.3* 17.8 ± 5.7 14.8 ± 7.3
Change in ECC (%) -1.3 ± 14.3‡ -14.9 ± 16.5 -9.1 ± 22.6
Results given as mean ± standard deviation in case of normal distribution or median
(range). ECC is estimated endogenous creatinine clearance. Significant differences
between groups were observed between the mesalazine group and the two other
groups (* p < 0.0001, ‡ p < 0.01) 
and age of onset of Crohn’s disease were significant independent predictors, but not the
cumulative dose or type of 5-ASA used or disease location (Table 3). With all variables
entered, the model predicts 20% of variation in the change in ECC. The change in ECC
was not different in the subgroups of patients, divided by disease location, history of
fistula or bowel resections.
32
Table 3
Multi-linear regression model. Dependent variable is change in ECC (in ml/min).
Variables Beta t Significance
Constant 2.1 0.04
Age at onset (yr) -0.22 -2.8 0.006
Study interval (yr) -0.48 -4.3 < 0.0001
Disease location -0.034 -0.42 0.7
5-ASA dose (g) -0.019 -0.19 0.8
Type of 5-ASA 0.19 1.9 0.06
ECC is estimated endogenous creatinine clearance. 5-ASA is 5-aminosalicylates 
Table 4
Characteristics of patients with the largest decline in renal function
Patient Age at 5-ASA Interval Time Contributing factors
final ECC dose (g) (yr) relation
(yr) with
5-ASA
1 55 0 1.6 No Dehydration
2 51 33.648 22.8 No ACE inhibitor and Diuretics
3 67 5.634 11.4 No Renal tuberculosis
Pyelonephritis
4 83 11.952 12.0 No Active colitis with weight loss
5 64 29.716 32.5 Unknown Active Crohn’s disease at final ECC
6 75 25.460 23.5 No Renal cysts
Urolithiasis
Malabsorbtion
7 56 130 20.8 No Dehydration due to short bowel
Urolithiasis
Pyelumstenosis with recurrent pyelonephritis
8 71 11.934 23.3 No Unknown*
* In patient 8, the decline in ECC was not recognized, because serum creatinine remained within the
normal range. 
Risk factors for renal function in patients with the largest decline
In the 5% of patients (n = 8) with the largest decline in ECC, important co-morbidity
affecting renal function was present (Table 4). Obstructing urolithiasis was present in 2
patients, recurrent pyelonephritis in 1 patients, dehydration and weight loss in 3
patients and in one patient ECC increased after onset of an angiotensin converting
enzyme inhibitor and diuretics. In none of these patients, a time relationship with the
use of 5-ASA was observed. 
Discussion
The primary aim of the present study was to explore whether long-term use of 5-ASA
has gradual detrimental effects on renal function over time, in patients with Crohn’s
disease. The population studied seems appropriate to answer this question, as patients
were exposed to varying amounts of 5-ASA ranging from 0 to 55 kg (mean 9.4 kg). These
large amounts were explained by the fact that 5-ASA compounds were prescribed as
first-line therapy in mild to moderate Crohn’s disease, which were initiated early in the
course of disease and continued as maintenance therapy for years. In this cohort of
patients, a significant decline in ECC of 0.3 ml/min per year of the study interval was
observed. The length of the interval was the strongest predictor for the observed decline
in ECC. Although large amounts of 5-ASA were used, no association with a change in
ECC was found. As length of the interval was the strongest predictor for the change in
ECC, the observed decline may result mainly from physiologic ageing. In physiologic
ageing, a decline in creatinine clearance of 0.4 - 1 ml/min per year was reported in
healthy subjects, already starting at relative young age (22-25). Although no control
group was included in this study, the mean decline in ECC of 0.3 ml/min per year in our
patients seems not to exceed the reported decline in normal ageing.
To enable detection of potential nephrotoxicity, we monitored serum creatinine before
and after onset of 5-ASA compounds at scheduled outpatient visits. Although the
retrospective nature of the present study was not suited to study dose-independent
idiosyncratic reactions, no interstitial nephritis due to 5-ASA was reported in 153
patients with Crohn’s disease. Previously, in IBD patients, the frequency of any renal
impairment during treatment with 5-ASA was reported to be about one out of 100 and
clinically significant renal impairment below one out of 500 patients treated (17). From
patients with the largest decline in renal function, we summarized potential
contributing factors in Table 4. In 7 out of 8 patients, plausible 5-ASA independent
explanations were present. In one patient, the change in ECC was not recognized
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clinically and therefore no further analysis for impairment of renal function was
performed. In one of these patients, decline in ECC was observed in absence of 5-ASA
during the interval and in this patient with a short bowel, chronic dehydration was
present.
In the present study, no signs for long-term cumulative nephrotoxicity of 5-ASA were
found in patients with Crohn’s disease. This is in agreement with earlier observations in
patients with ulcerative colitis (19,26). An advantage of the present study above
previous studies is that patients were exposed to long-term therapy with 5-ASA, with
variable degrees of cumulative exposure to 5-ASA. If chronic use of 5-ASA was a true
risk factor for renal impairment over time, an association between duration or dose of 5-
ASA and change in renal function should be expected. Therefore, the lack of a dose
relationship in our study extends the conclusions of a recent transversal study using a
large European registry (20). However, the retrospective design of our study also has
some disadvantages. At first, the annual decline in ECC was observed in an
uncontrolled fashion and therefore, no definite conclusions could be drawn about the
contribution of physiologic aging. Secondly, renal function was followed by serum
creatinine in these patients and ECC had to be estimated by using the Cockroft & Gault
formula. With this formula, the mean ECC may be estimated reliably in groups of
patients. However, in higher ranges of ECC, the formula seems to underestimate ECC,
whereas ECC seems to be overestimated in lower ranges (27). At third, mesalazine
prescriptions were frequently documented by the generic name and therefore, division
into smaller subgroups by the different formulations, which were available on the Dutch
market, was not feasible in this study. Finally, a number of factors, which may influence
renal function, such as nephrolithiasis, use of NSAIDs or hypertension, were not
routinely documented in the medical records.
In conclusion, in the present study long-term use of 5-ASA had no detrimental effects on
renal function. Furthermore, the mean negative annual change in ECC in these patients
seems not to exceed changes in physiologic aging. Although not observed in the present
study, interstitial nephritis due to 5-ASA may occur rarely, which may result in
irreversible renal failure. Therefore, we still advocate measurements of serum creatinine
before and during treatment. 
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Corticosteroid induced osteoporosis. 
Does it occur in patients with Crohn’s disease?
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Abstract
Objective: In Crohn’s disease osteoporosis is frequently found. However, the etiology of
osteoporosis remains unclear. Aim of the study was to determine predictive disease
related variables for impaired bone mineral density (BMD). Methods: Ninety-one
patients with Crohn’s disease, admitted for BMD assessment were enrolled in the study.
BMD was measured at the femoral neck and lumbar spine by dual energy X-ray
absorptiometry. Results were expressed as T-score and age and sex matched Z-score.
Data were obtained by a questionnaire and from the medical records. Stepwise linear
regression analysis was used to determine independent predictive variables for BMD.
Results: Mean age at BMD assessment was 41±12 years, duration of disease 11.6±8.5
years and body mass index (BMI) 23.0±4.1 kg/m2. Cumulative dose of steroids used
was 18.7±19.2g. Mean Z-scores were below zero (spine –1.1±1.3 SD and femur –1.1±1.2
SD; p < 0.0001). Twenty-seven patients (30%) fulfilled the WHO criteria for osteoporosis
and 46 patients (50%) for osteopenia. Osteoporotic patients used more corticosteroids,
had longer duration of disease, lower BMI and more bowel resections than patients with
normal BMD. However, in the linear regression analysis the only significant
independent predictors for BMD of the lumbar spine and femoral neck were BMI and
history of bowel resections. BMI and history of resections together accounted for 28% of
BMD Z-scores. Conclusion: BMI and a history of bowel resections were significant
predictive variables for BMD. Despite the high dose of steroids used in this study, no
detrimental effect could be demonstrated as independent predictor for osteoporosis. 
Introduction
In patients with inflammatory bowel disease, a high prevalence of osteoporosis is
reported. In particular patients with Crohn’s disease are prone to impaired bone mineral
density (BMD) (1). Knowledge of the etiology of osteoporosis is of importance, because
low BMD is an established risk factor for future fractures especially of the hip, vertebrae
and forearm (2,3). In Crohn's disease a number of risk factors influencing bone metabolism
are present. Primary disease related potential risk factors are the presence of
malabsorption and malnourishment (4), the presence of inflammation with high levels of
inflammatory mediators (5) and impaired physical activity (6). Malabsorption may
contribute to impaired BMD due to vitamin D and calcium deficiency (7) as does weight
loss (8). Other potential risk factors for osteoporosis are related to frequently used
therapies like the use of corticosteroids or to bowel resections with subsequent
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malabsorption. In general, deleterious effects of corticosteroids on bone metabolism are
well documented (9). Therefore, corticosteroids are thought to be an important risk factor
for osteoporosis in Crohn's disease. However, the results of cross-sectional and
longitudinal studies in patients with Crohn's disease are conflicting (table 1). Several
authors found negative correlations between corticosteroids used and BMD (10-17), but
others found no influence of corticosteroids on BMD (8, 18-20). Furthermore, Gosh et al
demonstrated an impaired BMD in Crohn’s disease at diagnosis without further bone loss
despite ongoing treatment with corticosteroids (21). The aim of the present study was to
investigate the correlation between BMD and potential disease related risk factors
influencing bone metabolism in a group of patients with a high risk for osteoporosis. The
lifetime dose of corticosteroids, the duration of Crohn's disease, body mass index, location
of disease and the history of bowel resections, as potential risk factors, were analysed in
patients with confirmed Crohn’s disease. 
Methods
Patients:
Patients with confirmed Crohn's disease attending the gastroenterology outpatient clinic
were eligible for the study if a BMD assessment was performed by dual energy X-ray
absorptiometry (DXA). Data were obtained retrospectively from the medical records. A
questionnaire was sent to all patients to obtain additional information about the history
of smoking, fractures and the use of hormonal contraceptives. The cumulative dose of
corticosteroids was obtained by calculating all doses of prednisolone equivalents
prescribed orally or intravenously. The body mass index (BMI) was calculated as
indicator of nutritional status (weight [kg]/height [m2]).
Bone mineral density assessment:
BMD (in g/cm2) of the lumbar spine and right femoral neck was measured by DXA
(Hologic Inc., Waltham, MA, USA, model QDR-1000). Results were expressed as a sex
and age matched Z-score defined as the number of standard deviations above or below
the mean of a sex and age matched reference group. Furthermore, a T-score was obtained
to establish the fracture risk. For the T-score, the reference group consisted of sex matched
young healthy adults at the age of the peak bone mass. Data from the reference groups
were supplied by the manufacturer (22,23). According to the World Health Organization
osteoporosis was defined as a T-score below -2.5 SD and osteopenia was defined by a T-
score below –1 SD but not more than 2.5 SD below the young adult average.
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Statistics:
Differences between groups were analyzed using two sample t tests or Wilcoxon Mann
Whitney tests when appropriate. Correlations were analyzed using Spearman rank
coefficients of correlation. To determine predictive factors for age and sex matched BMD
Z-scores, stepwise linear regression analysis was performed with the cumulative steroid
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Table 1
Corticosteroids as risk factor for osteoporosis in Crohn’s disease.
Author, year reference Methods Number Cumulative Study Support for
of dose of popu- steroids as
patients steroids (g)* lation riskfactor
Compston 1987 17 Cross-sectional 75 5.4 (0.6-81) IBD Yes
Motley 1988 20 Longitudinal 54 2.8 (0.3-7.3) IBD No
Pigot 1992 19 Cross-sectional 61 11.0 ± 15.3† IBD No
Motley 1993 13 Longitudinal 70 Not reported IBD Male: Yes
Female: No
Ghosh 1994 21 Longitudinal 30 Not reported IBD No
Bernstein 1995 16 Cross-sectional 49 Not reported IBD Male: No
Female: Yes
Silvennoinen 1995 15 Case-control 152 4.8 ± 6.9 IBD Yes
Roux 1995 14 Longitudinal 35 4.4 ± 3.9 IBD Yes
Bjarnason 1997 18 Cross-sectional 79 Not reported IBD No
Jahnsen 1997 12 Population 60 7.2 (1.0-51) Crohn Yes
based
Case-control
Robinson 1998 10 Cross-sectional 117 11.4 ± 14.9 Crohn Yes
Andreassen 1999 8 Case-control 113 3.5 (0-36.1) Crohn Weak
Cross-sectional
Schulte 1999 11 Longitudinal 61 1.7 ± 3.7 Crohn Weak
† Mean cumulative dose of steroids in subgroup of patiens with Crohn's disease.
‡ Cumulative dose during the interval of the longitudinal study.
* Mean ± SD or Median (range) 
dose, duration of disease, age of onset of Crohn's disease, BMI and performance of
bowel resections as independent variables. Two-tailed values were used and p values <
0.05 were considered statistically significant. Results were expressed as mean ± standard
deviation. The SPSS 9.0 package was used for all tests.
Results
Patients:
In 91 out of 350 Crohn's disease patients (26%), a DXA was performed because of a
potential high risk for osteoporosis. Therefore, 91 patients (29 male) with a mean age of
41.3 ± 13.3 years (range 21-77 years) and a duration of Crohn's disease of 11.6 ± 8.5 years
(range 0.2-37.3 years) were enrolled in the study. The clinical characteristics are given in
table 2. Crohn’s disease was confined to the small bowel in 23% of patients, and to the
colon in 24%. Bowel resections were performed in 59 patients (65%). Resections were
confined to the large bowel in 12 patients and to the small bowel in 36 patients. In 11
patients, large and small bowel segments were resected. In the 47 patients with small
bowel resections, the mean estimated length of resected small bowel was 60 ± 43 cm
(range 20-210 cm). Before BMD assessment 85 patients (93%) had used corticosteroids
with a cumulative dose of 18.7 ± 19.2 g (range 0-79 g). The mean BMI was 23.0 ± 4.1
kg/m2 (range 15-34 kg/m2). Vitamin D levels were measured before DXA assessment in
23 out of 91 patients. In 4 patients, vitamin D levels were below the normal range.
The questionnaire was completed in 66 patients (48 female). Estrogen containing
preparations were used by 43 of 48 women for contraception or menopausal symptoms
and 13 women were postmenopausal at time of the BMD assessment. A positive
smoking history was present in 49 of 66 patients. Eleven of 66 patients reported previous
fractures. However, 7 fractures occurred more then 1 year before diagnose of Crohn’s
disease. No hip or vertebral fractures were reported.
Bone mineral density
Osteoporosis of the lumbar spine or femoral neck was present in 27 patients (30%) and
osteopenia in 46 patients (51%). Osteopenia and osteoporosis were significant more
frequent at the femoral neck (47% and 25% respectively) than at the lumbar spine (40%
and 20% respectively; p < 0.05). Comparison of patients with osteoporosis and patients
with normal BMD revealed no difference in age of onset of Crohn’s disease or presence
of fistula. However patients with osteoporosis used significantly more corticosteroids
(23.3 ± 23.3 g versus 8.8 ± 9.1 g; p < 0.05), had longer duration of Crohn’s disease (15.4
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± 9.8 y versus 8.2 ± 5.9 y; p < 0.05) lower BMI (20.8 ± 3.2 kg/m2 versus 26.7 ± 4.8 kg/m2;
p < 0.05), a more frequent history of bowel resections (78% versus 56%; p< 0.05) and
more small bowel length resected (39 ± 43 cm versus 13 ± 17 cm; p< 0.05). The age and
sex matched Z-scores of both the lumbar spine and femoral neck were significantly
below zero (spine: -1,1 SD ± 1,3 and femoral neck: -1,1 SD ± 1,2; p<0,0001). Mean Z-
scores were not affected by a history of bowel resection, smoking, presence of fistulae or
by disease location. Z-scores for both the lumbar spine and femoral neck were not
significantly different in patients with or without previous fractures (–1.4 SD with
previous fractures versus –1.0 SD; p = 0.3) and with or without vitamin D deficiency
(spine: -1.6 SD ± 1.5 versus -1.1 SD ± 1.1; femoral neck: -1.0 SD ± 0.9 versus -1.0 SD ± 1.3).
Correlations
The lumbar spine BMD Z-score was inversely correlated with the cumulative dose of
corticosteroids and with disease duration (r= -0.24 and r= -0.23 respectively; p< 0.05).
The femoral neck Z-score was not correlated to the dose of corticosteroids and disease
duration (r = -0.12 and r = -0.10 respectively; p> 0.2). The Z-scores of both lumbar spine
and femoral neck were positively correlated with BMI (r= 0.47 and r= 0.46 respectively;
p<0.005). Correlations between BMI, dose of corticosteroids and duration of disease
were tested to determine potential confounding effects. BMI was not correlated to the
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Table 2
Clinical characteristics of patients with Crohn’s disease.
Number of patients 91
Male/ Female (n) 29/ 62
Age at BMD assessment (yr) 41.3 ± 13.3
Duration of disease (yr) 11.6 ± 8.5
Body Mass Index (kg/ m2) 23.0 ± 4.1
Patients with previous steroids (n(%)) 85 (93)
Cumulative dose of steroids (g) 18.7 ± 19.2
Duration of steroids (yr) 6.9 ± 6.7
Previous bowel resections (n(%)) 59 (65)
Presence of fistulae (n(%)) 44 (48)
Location of disease (%)
•Small bowel 23
•Large bowel 24
•Small and large bowel 53
Results are expressed as mean ± SD.
dose of corticosteroids or disease duration (r= 0.04 and r= 0.03 respectively; p> 0.7).
However, the dose of corticosteroids was correlated with disease duration (r= 0.43; p<
0.005). Therefore, a stepwise linear regression analysis was performed to analyse
independent predictive values for BMD.
Multilinear regression analysis
The independent variables tested in the model were duration of disease, cumulative
dose of corticosteroids, age of onset, history of bowel resections and body mass index.
The dependent variables were the Z-scores of the lumbar spine and femoral neck. In this
model significant predictive variables for both the femoral neck and lumbar spine BMD
were BMI and history of bowel resections, together accounting for 28% of the variation
in BMD Z-scores (table 3). BMI alone predicted 22% of variation in BMD. None of the
other variables were significant independent predictors for BMD and therefore excluded
in the model. If the length of small bowel resections was included in the model as
covariable instead of the overall history of bowel resections, no independent predictive
role was observed.
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Table 3
Predictive factors for BMD; Results of the multilinear regression analysis.
Variables Femoral neck Lumbar spine
B* Beta† P value B* Beta† P value
Included‡ Constant -4.26 < 0.0001 -4.41 < 0.001
BMI 0.15 0.51 < 0.0001 0.17 0.51 < 0.001
Resections -0.53 0.21 < 0.05 -0.69 0.25 < 0.01
Excluded: Age of onset 0.090 0.33 -0.037 0.69
Duration of CD 0.043 0.41 -0.11
0.28
Steroid dose -0.018 0.85 -0.14 0.13
* B regression coefficient.
† Standardised regression coefficient
‡ Model for the femoral neck predictive for 27% of variance in z-scores and for the
lumbar spine 28%.
Discussion
The aim of the present study was to find predictive factors for impaired BMD in patients
with Crohn’s disease. Low BMD is an established risk factor for future fractures. In
postmenopausal women, fracture risk increases by a factor of 1.5 to 3 for every 1 SD
decrease in BMD measured by DXA (2). In our study, only 19% of the patients had a
BMD of both the lumbar spine and femoral neck in the normal range. Therefore, 81% of
the patients studied had an increased risk of future fractures. However, the high
prevalence of osteopenia and osteoporosis in the current population might be caused by
selection of patients, who were treated in a tertiary center for inflammatory bowel
disease. The mean duration of Crohn’s disease in these patients was long, with a mean
dose of corticosteroids (18.7 g) which was remarkably higher then in previous reports
(table 1). The high exposure to corticosteroids makes our study population a suitable
model to determine effects of corticosteroids on BMD.
In general, detrimental effects of corticosteroids on bone metabolism are well
documented and sites with a high percentage of trabecular bone are most prone to the
effects of corticosteroids (9). In our study, patients with osteoporosis used more
corticosteroids compared to patients with normal BMD. However, because these
patients with osteoporosis also had longer disease duration, lower BMI and more
frequent bowel resections, a causal relation could not be concluded. To correct for
potential confounding effects, a stepwise regression analysis was performed. In the
regression analysis the cumulative dose of corticosteroids appeared not to be an
independent predictor for impaired BMD of the lumbar spine or femoral neck.
Therefore, even despite high amounts of corticosteroids used in these patients, an
independent detrimental effect on BMD could not be established. Furthermore, if
corticosteroids were the main risk factor for osteoporosis in Crohn’s disease,
osteoporosis would be expected more frequent at sites with most trabecular bone such
as the lumbar spine (9). In contrast, in our study the femoral neck was the site most
affected by osteoporosis. The higher prevalence of impaired BMD at the femoral neck
compared to the lumbar spine was previously reported in Crohn’s disease (16, 18, 24,
25). 
The strongest independent predictor for BMD in the present study was BMI, which
accounted for 22% of variation in BMD Z-score. A correlation between BMI or body
weight and BMD is in agreement with previous reports in both healthy subjects (26-29)
and patients with inflammatory bowel disease (10, 12, 15, 17, 19, 20, 30). Andreassen et
al performed DXA assessments at four sites in 113 patients with Crohn’s disease and 113
sex, age and weight matched controls and found no difference in BMD between patients
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and controls except for the trochanter in female patients (8). Correction for body weight
by a weight matched control group may explain the favorable outcome in their study.
However, the mean cumulative steroid dose of 3.5 g reported by Andreassen was much
lower with a shorter duration of disease in comparison with the present study. In
Crohn’s disease, BMI may be impaired due to malnutrition or malabsorption. However,
in the present study the mean BMI was in the normal range (23.0 ± 4.1 kg/m2) with an
impaired BMI below 19 kg/m2 in only 14% of patients.
The other independent predictor for impaired BMD in our study was a history of
bowel resections, which accounted for 6% of variation in BMD Z-scores. Bowel
resections, and small bowel resections in particular, may contribute to malabsorption
with weight loss and deficiencies of nutrients such as vitamin D. However, BMI did
not differ between patients with or without a history of small bowel resections and
the frequency of vitamin D deficiency in our study was not increased in patients with
a history of small bowel resections. Vitamin D levels were measured in 11 out of 47
patients with a history of small bowel resections and in 12 out of 44 patients without
small bowel resections. Vitamin D deficiency was present in 2 patients (18%) with
small bowel resections and 2 patients (17%) without these resections.Therefore, it is
unlikely that vitamin D deficiency explains the independent predictive role of bowel
resections for BMD. Performance of a bowel resection may also indicate more
aggressive disease, which by itself may contribute to the development of
osteoporosis. This can not be ruled out, because at present no index is available to
reliably quantify disease activity retrospectively over a long period of time. Bowel
resections as an etiological factor for osteoporosis was also suggested by Compston
et al since resections were performed in 52% of all 75 patients studied compared to
78% in the osteoporotic patients (17). This was confirmed by Robinson et al, who
reported impaired BMD after previous resections independent of the part of the
bowel resected (10). However, others were unable to show any influence of bowel
resections on BMD in patients with Crohn’s disease (12, 15, 18, 19, 31).
Other potential risk factors studied were age of onset of disease and duration of Crohn’s
disease. All these variables were non-predictive in the stepwise linear regression model.
The influence of the duration of Crohn’s disease on BMD was determined in several
longitudinal studies with conflicting results showing no bone loss in one study (21) and
up to 6.2% per year in steroid users in another study (14).
In a study by Silvennoinen et al smoking was found as a risk factor for osteoporosis in
female patients with inflammatory bowel disease (32). In our study no difference in
BMD was found between smokers and never smokers. This was in accordance with
Jahnsen et al and Ghosh et al (12,21).
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In our study, a normal BMD was observed in 19% of patients despite the presence of
several risk factors for osteoporosis. This may indicate an interindividual susceptibility
for osteoporosis. Therefore, gene polymorphisms encoding proteins involved in bone
metabolism or corticosteroid metabolism might be of importance in the development of
osteoporosis.
In conclusion: BMI is an important confounding factor in BMD assessment by DXA in
patients with inflammatory bowel disease. This study confirms that BMI is a major
independent predictive variable for BMD in patients with Crohn’s disease, which
accounts for 22% of variation in BMD Z-scores. A history of bowel resections is also a
significant predictive variable for BMD, although it accounts for only an extra 6% of
variation. Despite high cumulative doses of corticosteroids used in the present study
and a high prevalence of osteopenia and osteoporosis, no definite detrimental effect on
BMD was demonstrated.
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Abstract
Osteoporosis is frequent in Crohn’s disease. The aim of the study was to assess the rate
of bone loss over time retrospectively, and the influence of disease related factors on
bone loss. Twenty-nine patients (8 male), admitted for repeated bone mineral density
assessments (BMD) were enrolled. BMD measured by dual energy X- ray absoptiometry
was expressed in gram/cm2, and as sex and age matched Z score. The mean interval
between BMD assessments was 41 months, during which period 27 patients used
corticosteroids (mean dose 8.6 gram) and 21 patients some form of bone protective
medication. Initial Z scores at a mean age of 41 years were significantly below zero
(spine -1.6 ± 1.4; femur -1.4 ± 1.4). Over time, no change in absolute BMD was observed
accompanied by an improvement in Z scores. At the same time, an increase in body
weight and decrease in erythrocyte sedimentation rate (ESR) was observed. Multilinear
regression analysis demonstrated change in ESR as independent predictor for change in
femoral Z score. In conclusion, low BMD is frequent in CD, but decline of BMD over
time was not found despite ongoing use of corticosteroids.
Introduction
Osteoporosis and osteopenia are frequently found in patients with Crohn's disease. The
precise etiology of osteoporosis in Crohn's disease remains unknown and appears to be
multifactorial. Several risk factors for the development of osteoporosis have been
reported. Some of the potential risk factors for osteoporosis are directly related to
Crohn's disease, such as the presence of inflammation and the presence of
malabsorption. An inflammatory process may influence bone metabolism due to a direct
effect of pro-inflammatory mediators (1). Malabsorption in Crohn's disease may impair
bone metabolism due to weight loss and/ or due to calcium or vitamin D deficiency
(2,3). Furthermore, a decrease in physical activity may play a role in the development of
osteoporosis (4). Other risk factors for osteoporosis are related to the therapy for Crohn's
disease such as the use of corticosteroids and performance of bowel resections. Crohn's
disease is a chronic disorder and many threats for bone metabolism in these patients
persist over a long time. Therefore, a decline in bone mineral density (BMD) might be
expected with ongoing duration of Crohn's disease. However, a highly variable rate of
decline in BMD has been reported in previous studies in IBD (table 1). A correlation
between duration of disease and BMD has only been found in some of these reports (5-
8). The aim of the present study was to assess the rate of bone loss over time in patients
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with Crohn's disease and to investigate the influence of corticosteroids, disease activity
and body weight on BMD. 
Methods
Patients
In this retrospective study, Caucasian patients with confirmed Crohn's disease
consulting the outpatient clinic of the University Medical Center Nijmegen were eligible
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Table 1
Longitudinal studies on bone mineral density in IBD.
Author, year reference Patients Follow-up BMD Annual Significance Potential
(n) years (SD) parameter change in of annual risk factors
BMD % (SD) change for osteoporosis
Corticosteroids Other factors
Motley, 1988 11 54 1 QCT spine -3 Not reported No Body mass
index
Clements, 1992 12 39 7.9 SPA radius Female -0.7 p < 0.05 Not reported Not reported
Male -0.07 NS
Motley, 1993 7 70 4 QCT spine -2.7 p < 0.001 Yes (Spine) No
SPA radius -0.8 p < 0.001
Gosh, 1994 14 23 1 DXA forearm Not reported NS No No
DXA spine
Roux, 1995 6 35 1.6 (0.7) DXA spine -2.3 (6.1) Not reported Yes No
DXA femoral -6.9 (6.6)
neck
Staun, 1997 8 40‡ 4.8 (3) DPA spine -0.85 (2.9) NS No No
DPA femoral -2.2 (3.2) p < 0.001
neck
Schulte, 1999 13 80 1.6 (0.2) DXA spine +0.46 (3) NS Yes No
DXA femoral +0.06 (5.1) NS
neck
Cino, 2002 16 138 2 DPA spine -0.09# NS Yes
DPA femoral -1.05# NS
neck
Habtezion, 2002 15 112 1.9 DXA spine +0.01 NS Yes Body mass
DXA femoral -0.64 (0.3) p < 0.05 index
neck
BMD bone mineral density, DXA dual energy x-ray absorptiometry, DPA dual photon
absorptiometry, QCT quantitative computed tomography, SPA single photon
absorptiometry, NS not significant. ‡ Patients with Crohn's disease and with preserved
colon. # Results for the nonsteroid group. 
for the study if repeated BMD assessments were performed with an interval of at least
one year. All BMD assessments had to be performed by dual energy X-ray
absorptiometry (DXA) on a single device. Initial BMD assessments were performed in
patients with a suspected risk for osteoporosis due to previous use of cortocosteroids.
Demographic and disease data were obtained by review of the medical records and
patient interviews. Because a single bodyweight gives less information about the
nutritional state of a subject, body mass index (BMI) was calculated at time of the first
BMD assessment by bodyweight (in kilograms) divided by height (in square meters).
Bone mineral density assessment:
BMD of the lumbar spine (L1-L4) and right femoral neck were determined by DXA
(Hologic Inc., Waltham, MA, USA, model QDR-1000). Absolute values were given in
g/cm2. Furthermore, BMD was expressed as the number of standard deviations from
normal values of a sex and age matched reference group (Z score). Data from the
reference group were supplied by the manufacturer (9). The coefficient of variation for
repeat measurements in our medical center was 1.0% in the lumbar spine and 1.7% in
the femoral neck (10).
Statistical analysis
Differences between groups were analyzed using two sample t tests or Wilcoxon Mann
Whitney tests where appropriate. Correlations were investigated by Pearson's
coefficient of correlation. To determine predictive factors for the change in BMD Z
scores, multivariate linear regression analysis was performed with the steroid dose used
during the interval, change in body weight and change in blood sedimentation rate as
independent variables and the change in BMD. Two-tailed values were used in all tests
and p values < 0.05 were considered statistically significant. Results were expressed as
mean ± standard deviation. 
Results
Patients
Twenty-nine patients (21 females) were eligible. The clinical characteristics of the
patients are shown in table 2. Mean age at time of the first BMD assessment was 40.8 ±
12.0 years with a mean duration of Crohn's disease of 11.3 ± 8.3 years. All patients had
used corticosteroids before the first BMD assessment with a mean cumulative dose of
23.0 ± 20.5 gram. Bowel resections were performed in 69% of patients before the first
BMD assessment. The initial body mass index was 22.1 ± 3.4 kg/m2 and was below 20
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kg/m2 in 8 patients. The duration of the interval between the first and last BMD
assessment was 40.7 ± 20.2 months. During the interval 27 patients had used
corticosteroids with a mean cumulative dose of 8.6 ± 8.5 gram. The mean daily dose of
steroids used in this period was 8.6 ± 4.3 mg/day. Some form of bone protective
medication was prescribed in 21 patients. During the interval, 9 patients used
bisphosphonates, 20 patients had used calcium suppletion due to low calcium intake
and 11 patients used vitamin D suppletion. Of the female patients, 13 were pre-
menopausal and 12 of them used hormonal contraceptiva over a long period of time.
Five out of the 8 post-menopausal patients used some form of estrogen replacement
treatment. 
Longitudinal follow-up
Both the initial Z score of lumbar spine and femoral neck were significantly below zero
(-1.6 ± 1.4 and -1.4 ± 1.4 respectively). An impaired Z score of one or both sites measured
below -2.0 SD was present in 15 patients (52%). For both sites there was no significant
change in BMD measured in g/cm2 during the study period (spine -0.0096 ± 0.058
g/cm2, femoral neck -0.0034 ± 0.045 g/cm2; p = 0.3). This corresponds with a mean
annual percent change in BMD of 0.12 ± 2.9% for the lumbar spine and 0.21 ± 2.8% for
the femoral neck. Accordingly, since BMD in normals goes down with age, there was a
significant increase in the age and sex matched Z scores for the lumbar spine and
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Table 2
Clinical characteristics of patients with Crohn's disease.
Characteristics Results in 29 patients
Gender (male/ female) 8/ 21
Pre-/ post-menopausal (n) 13/ 8
Age at first DXA (yr) 40.8 ± 12.0
Duration of disease (yr) 11.3 ± 8.3
Past and current smoking history (%) 67
Body mass index (g/m2) 22.1 ± 3.4
Previous bowel resections (n(%)) 20 (69)
Dose of steroids before DXA (g) 23.0 ± 20.5
Duration of the interval (months) 40.7 ± 20.2
Dose of steroids during the interval (g) 8.6 ± 8.5
DXA Dual energy X-ray absorptiometry
Mean ± SD
femoral neck (spine +0.26 ± 0.62 SD, femoral neck +0.22 ± 0.50 SD; p < 0.05). During the
interval, there was a significant decrease in erythrocyte sedimentation rate (ESR, -8.4 ±
14.7 mm/hr; p < 0.005) and a slight increase in body weight (+3.3 ± 8.8 kg; p = 0.05). The
serum albumen remained unchanged (-0.071 ± 4.2 g/l; p = 0.9). Results in patients with
or without bisfosphonates, calcium or vitamin D suppletion are shown in table 3. No
significant differences concerning changes in Z scores were observed, but definite
conclusions may not be drawn because of the limited number of patients in the
subgroups.
Correlations and multilinear regression analysis
No correlations were found between change in Z scores and the cumulative dose of
steroids used during the interval (spine cc 0.29, femur cc 0.31; p = 0.1), the change in
body weight (spine cc 0.16; p = 0.4, femur 0.32; p = 0.1) or the change in ESR (spine cc -
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Table 3
Change in bone mineral density with regards to bone protective medication.
Patients Annual percent change in BMD*
(n)
Lumbar spine Femoral neck
Bisphosphonates
Yes 9 -0.26 (-4.60 : 4.08) -1.56 (-4.04 : 0.92)
No 20 0.27 (-0.41 : 0.95) 0.94 (-0.23 ; 2.11)
Calcium
Yes 20 0.60 (-0.36 : 1.56) 0.60 (-0.70 : 1.90)
No 9 -0.90 (-4.18 : 2.38) -0.56 (-2.95 : 1.83)
Vitamin D
Yes 11 -0.22 (-3.44 : 3.00) 0.89 (-1.88 : 3.66)
No 18 0.31 (-0.51 : 1.13) -0.14 (-1.18 : 0.89)
Bisphosphonates/ calcium/ vitamin D
Yes 21 -0.011 (-1.58 : 1.55) 0.23 (-1.23 : 1.68)
No 8 0.44 (-0.86 : 1.74) 0.23 (-1.56 : 2.02)
* Results expressed as mean (95% confidence intervals). No significant differences in
annual percent change of BMD were observed between groups with and without bone
protective medication, but the number of patients in the subgroups is low.
0.29; p= 0.1, femur cc 0.2; p = 0.4). Furthermore, change in ESR and change in body
weight were not correleted (cc -0.29; p = 0.13). Multilinear regression analysis, with
change in Z score as dependent variable and cumulative steroid dose, change in body
weight and change in ESR as covariables was performed. The change in ESR was a
significant independent negative predictor for the change in femoral neck Z score but
not for the lumbar spine, which means that the largest decrease in ESR results in the
strongest improvement in femoral neck Z score. The predictive value for the other
variables was not significant.
Discussion
A gradual decrease in BMD over time was expected in patients with Crohn's disease,
especially if risk factors for osteoporosis persisted. However, we demonstrated a stable
BMD over a mean period of 41 months in Crohn's disease patients with a low BMD at
baseline with a history of corticosteroids. Normally, BMD decreases over time in healthy
populations. According with the stable absolute BMD over time, we observed a slight
improvement of the initially impaired age and sex matched Z scores. The lack of bone
loss is remarkable, as corticosteroids were continued in 93% of patients. Moreover, an
inverse correlation between the dose of corticosteroids used and change in Z scores was
not observed. Previous longitudinal studies in patients with Crohn's disease found a
highly variable rate of decline in BMD (6-8,11-16). Roux et al reported a mean annual
bone loss of 3.1% in Crohn's disease (6), where Clements et al found a significant annual
bone loss of less then 1% in female patients only (12). Schulte et al found no average
decline in BMD in Crohn's disease at all (13), which is in accordance with the non
significant annual change of 0.12 to 0.21% in the present study. Inability to detect bone
loss over time in the present analysis may be caused by the sample size. With 29 patients
included, relatively large changes in BMD of at least 14% from baseline could have been
detected with a power of 80% and two-sided tests. However, it is unlikely that an
increased sample size would have shown bone loss since concomitant significant
improvement in Z-scores over time was observed in the present study. As the etiology
of bone loss in Crohn's disease is multifactorial, a number of potential risk factors need
to be described in a given study population. However, given the sample size of 29
patients, it is obvious that no firm conclusions can be drawn concerning multiple risk
factors for bone loss.
The lack of bone loss in the present population might be explained by a decrease in
disease activity during the study period. This is difficult to proof, because at present no
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index is available to quantify disease activity retrospectively and reliably over a period
of time. In the present study, erythrocyte sedimentation rate as surrogate marker for
disease activity was available in all patients. The ESR improved significant during the
study and multilinear regression analysis demonstrated the change in ESR to be an
independent predictor for the change in femoral Z score. In patients with the highest
decrease in ESR the highest improvement in Z score of the femoral neck was observed.
For the lumbar spine no significant correlation with the change in ESR was found. This
observed difference between the effects on lumbar spine and femoral neck is in
accordance with previous observations. A number of reports demonstrate a higher
prevalence of impaired BMD at the femoral neck compared with the lumbar spine in
patients with Crohn's disease (8,17-20). If corticosteroids were the main risk factor
instead of disease activity, bone loss would be expected most at sites with a high rate of
trabecular bone (21).
Previous studies in IBD patients demonstrated BMI as important positive predictive
factor for BMD (11,20,22-27). Over time, a change in BMI is mainly caused by a change
in body weight. Therefore the slight increase in body weight observed during the study
period could have led to an increase in Z scores. Possibly due to the number of patients,
no significant correlation was found between change in body weight and Z scores.
The lack of bone loss during the study period may also be explained by preventive
measures taken in these patients. Vitamin D was suppleted during the study period in
11 patients because of vitamin D deficiency. Calcium suppletion was prescribed in 20
patients. A protective effect of vitamin D or calcium supplementation on BMD could not
be demonstrated, probably because of the small number of patients in subgroups. In
postmenopausal women without IBD, calcium supplements can diminish the rate of
bone loss (28-30). Silvennoinen et al found an impaired calcium intake in IBD patients,
but no association between calcium intake and BMD (31). Several reports in IBD patients
found no significant correlation between vitamin D serum levels or vitamin D
supplementation and BMD (13,32,33). Others found a significant role for vitamin D
deficiency in metabolic bone disease in IBD (2,34). Therefore, the issue whether calcium
or vitamin D supplementation prevents further decline in BMD in IBD patients remains
controversial. During the study period 9 out of 29 patients used etidronate or
alendronate to prevent bone loss. Both the initial BMD and the change in BMD were not
statistically different between patients with or without the use of bisphosphonates, but
the number of patients treated with bisphosphonates was to small to draw firm
conclusions. In placebo controlled trials both etidronate and alendronate were able to
prevent bone loss in a mixed population of corticosteroid treated patients over a period
of one year (35,36). However, only one of these trials had a small subgroup of IBD
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patients (35). A small placebo controlled trial in 32 Crohn's disease patients supported
the potential beneficial effect of bisphosphonates for the lumbar spine only (37).
Therefore, the role for bisphosphonates in IBD to prevent bone loss needs to be
elucidated.
In conclusion, BMD remained stable in patients with Crohn's disease despite ongoing
use of corticosteroids in a high mean cumulative dose of 8.6 gram. For the femoral neck,
decrease in disease activity, established by ESR, was a significant independent predictor
for increase in Z score. Concerning our data, with regards to bone density,
corticosteroids are not absolutely contraindicated to treat active episodes of IBD as long
as some form of bone protective medication is considered. However, in individual
patients deleterious effects of corticosteroids may be found. 
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Abstract
Background: In Crohn’s disease, osteoporosis is frequently observed. The etiology of
increased bone loss in these patients is multifactorial. The aim of this study was to
identify genetic risk factors for osteoporosis in patients with Crohn’s disease.
Methods: Patients with Crohn’s disease were included into this retrospective cohort
study if bone mineral density (BMD) assessment had been performed by dual energy X-
ray absorptiometry. We analyzed variants in genes known to be associated with
osteoporosis encoding interleukin 6, interleukin 1 receptor antagonist, transforming
growth factor β, parathyroid hormone, the receptor for vitamin D3, the estrogen receptor
α (ESR1), and the gene coding for collagen type Iα1 for association with osteoporosis in
Crohn’s disease.
Results: Eighty-nine patients were eligible for the study (34 males). Bivariate analysis
showed association of BMD Z scores with body mass index (BMI; p<0.001) and gender
(p=0.011), whereas variation in ESR1 (p=0.053) showed borderline significance. Stepwise
regression with clinical and genetic variables resulted in a final model, which included
only BMI and gender as independent variables. BMI accounted for 17.3% of the
variation in Z scores, gender for 6.1% with the highest risk in males. None of the genetic
factors were found to be significantly correlated with BMD.
Conclusion: In Crohn’s disease, low BMI and male gender are independent predictors of
reduced BMD. In the cohort described here, none of the genetic factors studied appeared
to be strong independent risk factors for low BMD.
Introduction
A high frequency of osteopenia and osteoporosis is observed among patients with
Crohn’s disease. However, the precise etiology of increased bone loss in these patients
remains largely unknown. A number of potential clinical risk factors may predict the
extent of bone loss in Crohn’s disease. The most consistent predictor for bone mineral
density (BMD) in previous studies was the body mass index (1-8). Results were much
more heterogeneous concerning other postulated risk factors such as use of
corticosteroids (8), disease activity (9), history of bowel resections (1,3-5,7,10,11), calcium
or vitamin D deficiencies (12-16). Even if all of these clinical variables were taken into
account, the variation in BMD was explained only partially. A number of studies have
shown that genetic susceptibility may play a role in the development of osteoporosis. In
patients with inflammatory bowel disease (IBD), this was postulated for variants of the
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interleukin 6 (IL6) gene and the genes encoding the IL-1 receptor antagonist (IL1RN) and
IL-1‚ (IL1B) (17,18). Besides genes encoding inflammatory mediators, a number of
mechanisms for genetic susceptibility to osteoporosis have been postulated (19). Most of
these pathways may also play a role in Crohn’s disease patients, such as genetic
variability in transforming growth factor ß (TGF ß), parathyroid hormone (PTH),
vitamin D and estrogen signaling or the collagen network. The aim of the present study
was to identify genetic risk factors for osteoporosis in patients with Crohn’s disease. We
chose to analyze (functional) genetic variation in the genes encoding IL-6, IL-1RN,
TGFβ, PTH, the receptor for vitamin D3 (VDR), the estrogen receptor α (ESR1), and the
gene coding for collagen type Iα1 (COL1A1) for association with osteoporosis in patients
with Crohn’s disease. All of the genetic variants analyzed in this study have been
described earlier in relation to osteoporosis or bone mineral density (20-26). 
Material and methods
Patients
Consecutive patients with confirmed Crohn’s disease, consulting the out-patient clinic
of Gastroenterology and Hepatology of the University Medical Centre Nijmegen, were
eligible for the study if they consented to genetic studies and if a bone mineral density
assessment had been performed by dual energy X-ray absorptiometry (DXA). Clinical
data concerning the course of Crohn’s disease and medications were obtained through
retrospective review of the medical documents and patient interviews. Variables
recorded from these records were gender, date of birth, length, weight, age of onset of
Crohn’s disease, location of disease, disease behaviour (history of fistulae and bowel
resections), results from the first BMD assessment, and cumulative and annual dose of
corticosteroids prior to the first BMD assessment. Location of disease was divided into
4 categories according to the Vienna classification (27): ileal disease, colonic disease,
ileocolonic disease and any location proximal to the ileum. The cumulative dose of
corticosteroids was estimated with help of patient charts and included systemic
administered prednisone and prednisolone (in g). The study was approved by the local
ethical committee.
Bone mineral density assessment
BMD of the lumbar spine (vertebrae L1 to L4) and right femoral neck was measured by
DXA, using Hologic QDR1000 and QDR4500 densitometers (Hologic Inc, Waltham, MA,
USA). BMD was expressed in g/cm2 and a T-score was calculated as the number of
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standard deviations from normal values of sex matched healthy young adults, using the
Hologic reference database. Normal BMD is defined by a T score above –1, osteopenia
by a T score between –1 and –2.5 and osteoporosis by a T score below –2.5. Furthermore,
a Z score was calculated as the number of standard deviations from normal values of age
and sex matched healthy controls using the same reference database.
Genotyping
DNA was extracted from whole blood of the patients using standard procedures (28).
Specific conditions of the amplifications regarding primers used and annealing
temperature are shown in Table 1. The PCR-reactions amplifying the polymorphic
sites of interest in IL1RN (86 base pair repeat), VDR (FokI restriction fragment length
polymorphism (RFLP)), PTH (BstBI RFLP), COL1A1 (BalI RFLP) and ESR1 (promoter
variable number of tandem repeats (VNTR) polymorphism) contained 10 mM Tris-
HCl pH 9.0, 50 mM KCl, 1.5 mM MgCl2, 0.35 mM dNTPs, 0.01% (w/v) gelatin, 0.1%
Triton X-100, 62.5 to 125 ng of each primer, 100 – 200 ng of human genomic DNA and
0.5 U Taq Polymerase (Gibco, Breda, The Netherlands) in a total volume of 25 µl. The
forward primer of ESR1 was labeled with the fluorescent label FAM. The
amplification of TGFB1 (Leu10Pro encoding single nucleotide polymorphism (SNP))
and IL6 (-174G>C SNP) was performed comparably, but in a volume of 50 µl and in
the presence of a lower concentration of primers (0.4 pmol) using a biotin-labeled
reverse primer in the case of IL6 and a biotin-labeled forward primer in the case of
TGFB1. The PCR-program used for most of the reactions comprised a denaturation
step of 2 minutes at 94 °C followed by 35 cycles of 1 minute at 94 °C, 1 minute of
annealing at the optimal temperature (see Table 1) and 1 minute at 72 °C. After the
last cycle an extra extension step of 5 minutes at 72 °C was added. The PCR-program
for IL-6 comprised 40 cycles instead of 35. PCR amplifications were performed in a
PTC-200 thermal cycler (MJ-Research Inc. via Biozym, Landgraaf, The Netherlands).
Alleles of the 86 bp repeat polymorphism in IL1RN were identified by gel
electrophoresis on a 2% agarose gel as described (29). The variable number of tandem
repeats polymorphism (VNTR) in ESR1 was analyzed using GeneScan technology on
an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Nieuwerkerk a/d IJssel,
The Netherlands). Restriction fragment length polymorphism (RFLP) analysis was
used to genotype the biallelic single nucleotide polymorphisms (SNPs) in VDR, PTH
and COL1A1 (after purification of the PCR products on MultiScreen PCR plates
(Millipore, Amsterdam, The Netherlands) in the case of COL1A1). Genotyping of
VDR was performed using FokI (New England Biolabs Inc., Beverly, MA, USA) as the
restriction enzyme; PTH was analyzed using BstBI (New England Biolabs Inc.,
69
Beverly, MA, USA) (30) and the analysis of COL1A1 was performed as described
earlier by Grant et al. (25) using BalI (Promega Benelux BV, Leiden, The Netherlands).
SNPs in TGFB1 and IL6 were analyzed by Pyrosequence analysis (31) using the
pyrosequence primers shown in Table 1 according to the protocol of the
manufacturer.
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Table 1
Genes and genetic variants analyzed, with primer sequences and PCR annealing
temperature used and results of genotyping.
Optimized
Gene (reference) PCR
and genetic annealing Genotypes Frequency
variant 5´- 3´ primer sequences temperature observed (%)
4/4 51 (60.0)
4/2 20 (23.5)
IL1RN 28 CTCAGCAACACTCCTAT 54.0ºC 4/3 2 (2.4)
86 bp repeat TCCTGGTCTGCAGGTAA 4/5 1 (1.2)
2/2 9 (10.6)
2/5 2 (2.4)
VDR TGTATGAGGGCTCCGAAGGC C/C 36 (43.4)
FokI RFLP GTTACAGGCGTAATGGAAAGAC 53.0ºC C/T 35 (42.2)
(rs2228570) T/T 12 (14.5)
PTH C/C 41 (47.1)
BstBI RFLP GCTTCTCGTGAAAACCAACC 58.0ºC C/A 37 (42.5)
(rs6254) GAGCTTTGAATTAGCAGCATG A/A 9 (10.3)
IL6 GCCTCAATGACGACCTAAGC T/T 30 (34.5)
-174G>C Biotin-GTGGCTCGAGGGCAGAATG 55.0ºC C/T 40 (46.0)
(rs1800795) CCCTAGTTGTGTCTTGC (for pyrosequencing) C/C 17 (19.5)
COLIA1 24 TAACTTCTGGACTATTTGCGGACTTTTTGG G/G 60 (68.2)
BalI RFLP GTCCAGCCCTCATCCTGGCC 54.2ºC G/T 22 (25.0)
(rs1800012) T/T 6 (6.8)
ESR1* 25 FAM-GACGCATGATATACTTCACC 11-14.5 24 (28.2)
Promoter GCAGAATCAAATATCCAGATG 51.3ºC 15-17.5 36 (42.4)
VNTR 18-24 25 (28.1)
TGFB1 Biotin-CACCACACCAGCCCAGTTC A/A 39 (46.4)
Leu10Pro GTCTTGCAGGTGGATAGTCC 62.0ºC A/G 36 (42.9)
(rs1982073) CCAGTCGCCACAGCA (for pyrosequencing) G/G 9 (10.7)
* Due to the large number of different genotypes observed groups were formed, based on
the mean number of repeat units on both alleles. Frequencies of these groups are shown.
Statistics
Clinical data
Differences between males and females in body mass index (BMI), age, age at
diagnosis, number of diseased years, current and cumulative dose of corticosteroids
were tested with One-way ANOVA. As corticosteroid use was not normally
distributed, these values were ln-transformed before statistical testing (which
automatically excluded non-users from the analysis). Sex differences in presence or
absence of fistulas and in undergoing a resection were tested with Fisher’s exact tests.
The location of Crohn’s disease was compared between groups with Monte Carlo
tests. This method has been implemented in the software CLUMP (Sham & Curtis,
1995). Differences in clinical characteristics between groups with normal bone
density, osteopenia and osteoporosis were tested similarly to differences between
sexes as described above. Differences in the frequencies of males and females in these
three groups were tested with Pearson Chi-square tests. Pearson correlation and
linear regression was used to assess the effect of disease duration and age on
corticosteroid use.
Genetic data
Equal distribution of alleles on the studied loci in males and females was tested with
Fisher’s Exact test in cases of two alleles per locus, and with Pearson Chi-Square test
for more alleles per locus. However, if cell counts were lower than 5, a Monte Carlo
method was used to assess significance (CLUMP). Deviations from the Hardy
Weinberg equilibrium (HWE) were assessed with standard Chi-square test, for
genetic variants with more than two alleles, a Monte Carlo correction in Chi-square
distribution was used.
Some genotypes may affect corticosteroid effectiveness or disease severity and, thus,
corticosteroid prescription. Effect of genotype on annual corticosteroid use was
therefore tested prior to further analysis. We tested genotype effect on ln-transformed
annual corticosteroid use with ANOVA for biallelic variants, or (for polymorphisms
with more than two alleles) tested for correlation between mean number of repeat
units and ln-transformed annual corticosteroid use using the Pearson correlation
coefficient.
Multivariate analysis
To find predictive variables for bone mineral density, stepwise regression analysis was
carried out with sex, age, BMI, age at diagnosis, duration of disease, surgical state, and
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the genotypes on the various loci as independent (dummy) variables. As dependent
variable we used the minimum z score for BMD at either hip or lumbar spine.
Probability to enter an independent variable was <0.05, probability to remove >0.10. The
analysis was carried out on the complete sample, and subsequently on males and
females separately. Corticosteroid use was not included in the final analysis, because
preliminary analysis showed no effect of either annual (p=0.144) or total (p=0.108)
corticosteroid use on bone mineral density, after correction for age and sex.
Most of the studied polymorphisms had only two variants in our population, and
thus no more than three genotypes. These were included in the analysis as dummies
for either homozygote. The estrogen receptor α locus had 16 alleles varying from 8 to
25 repeat units. Following Langdahl et al. (32), we used average number of units,
subdivided into three groups (11-14, 15-17, 18-24), as predicting variable. Similarly,
for the IL1RN genetic variant four groups with mean number of 2,3,4 and 5 repeat
units were formed. 
Results
Clinical characteristics
In total, 89 patients were eligible for the study (34 males and 55 females). One male
and seven females had no history of corticosteroids prior to the BMD assessment,
whereas the dose of corticosteroids was not reliably estimated in four males and eight
females and therefore unknown. Clinical characteristics of the patients are shown in
Table 2. The average age of the patients was 40.7 ± 12.5 years (range 21-77), average
disease duration was 14.6 ± 9.2 (0-37 years). No significant differences in clinical
characteristics between males and females were found and absolute BMD
measurements showed no significant differences between males and females (see
Table 2). Significantly more males than females had osteoporosis, defined by T scores
below –2.5 (p=0.013). Table 3 gives an overview of the demographics for the three
bone density categories. BMI and age differed significantly between the BMD-
categories. There was a trend towards lower corticosteroid doses per year averaged
over the disease duration in patients with a longer disease history (r=-0.205, p=0.074).
Age had no effect on the annual amount of corticosteroids used (p =0.214).
Genetic data
Genotype frequencies for the different polymorphisms are given in Table 1. No
significant male/female differences in allele frequencies were found for most of the
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loci, with the exception of the variant in the estrogen receptor gene ESR1, where
significantly more women (44.4%) than men (11.5%) had a high repeat number allele
(mean number of repeats between 18 and 24; p=0.016) and the collagen type I·1
encoding gene COL1A1, where there were more female carriers of the variant allele
(96% compared to 88.3% in males). None of the loci deviated significantly from Hardy
Weinberg equilibrium. Corticosteroid use showed a significant correlation with
IL1RN genotype (r=-0.292, p=0.012). Individuals with a higher mean number of
repeat units of the 86 bp repeat in this gene had a lower average annual intake of
corticosteroids (Figure 1). Genotypes at the other loci did not correlate significantly
with corticosteroid use.
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Table 2
Demographic characteristics of 89 Crohn’s disease patients
Men Women
N = 34 N = 55
Age (yr) 40.6 ± 13.7 40.8 ± 11.7
Age at diagnosis (yr) 25.8 ± 10.4 26.4 ± 9.1
BMD hip (g/cm2) 0.77 ± 0.11a 0.80 ± 0.13b
BMD spine (g/cm2) 0.94 ± 0.14a 0.95 ± 0.13c
BMI (kg/m2) 24.0 ± 3.8 24.5 ± 5.0d
Cumulative GCS dose (g) 14.2 ± 12.1a 22.3 ± 27.9e
Disease duration (yr) 14.8 ± 10.4 14.5 ± 8.5
Presence of fistulae 13 (38) 28 (51)
Bowel resection 18 (53) 37 (67)
Location disease
Ileum 11 (32) 12 (22)
Colon 3 (9) 16 (29)
Ileum and colon 19 (56) 26 (47)
Proximal to ileum 1 (3) 1 (2)
BMD; bone mineral density. BMI; body mass index. GCS; glucocorticosteroid. Results
given as mean ± SD or number (%). Differences between males and females were not
significant.
Some values were not available for BMD, BMI and GCS dose. aNumber of subjects is
30, b51, c52, d54 and e49.
Predictive factors for BMD
Bivariate analysis with BMI, gender, age at diagnosis, presence of fistulae and the
genetic variants showed association of BMD Z scores with BMI (p<0.001) and gender
(p=0.011). ESR1 genotypes showed borderline significant association with the Z
scores (p=0.053). ESR1 had a Pearson correlation r=0.21 with the Z score. Stepwise
regression with all the variables mentioned above resulted in a final model, which
included only BMI and gender as independent variables. BMI accounted for 17.3% of
the variation in Z scores: Z scores increased, as expected, with increasing BMI. Being
male was a risk factor in this sample, and gender accounted for 6.1% of the variation.
The model with both BMI and gender included explained 23.4% of the variation (see
Table 4).  Since gender was a predictive variable, we performed the analysis for both
sexes individually, as well. As expected, only BMI was associated with the Z scores
for females as well as for males.
None of the genetic factors was significantly correlated with bone mineral density,
neither in the total nor in the gender specific models. 
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Table 3
Demographic characteristics of patients with normal bone mineral density,
osteopenia and osteoporosis
Normal Osteopenia Osteoporosis p-value
N = 22 N = 43 N = 22
Sex males : females 3:19 19:24 12:10 p=0.013
Age (yr) 33.9 ± 10.4 43.6 ±11.4 41.2±14.9 p=0.011
Age at diagnosis (yr) 21.9 ± 7.3 27.7 ± 9.7 27.7±10.8 P=0.050
BMI (kg/m2) 27.1 ± 5.0a 24.1 ± 4.2 21.8±3.2 p<0.001
Disease duration (yr) 12.0 ± 9.5 15.9 ± 8.6 13.6±9.5 n.s.
Cumulative GCS dose (g) 20.1 ± 33.7b 18.6 ± 19.3c 20.3±21.1b n.s.
BMD hip (g/cm2) 0.93 ± 0.09a 0.79 ± 0.08d 0.67±0.06e p<0.001
BMD lumbar spine(g/cm2) 1.06 ± 0.08a 0.94 ± 0.11b 0.82±0.10e p<0.001
BMD; bone mineral density. BMI; body mass index. GCS; glucocorticosteroid. Results
given as mean ± SD or number (%). Differences between groups were tested with One-
way ANOVA.
Some values were not available for BMI, GCS dose and BMD. aValues were missing in
1 patient, b3patients, c5patients, d4patients and e2patients.
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Figure 1
Scatterplot showing the negative correlation between the number of repeats of the
polymorphism in IL1RN and log transformed annual glucocorticosteroid use. The
mean number of repeat units is grouped into 4 groups.
Table 4
Model summary for stepwise regression on complete and gender specific datasets:
variables included in the equation.
Variable R2 change Significance Coefficient B Standard
F change error
Total sample Constant -4.621
BMI 0.173 <0.001 0.093 0.022
Gender 0.061 0.011 0.510 0.197
Male gender Constant -0.4252
BMI 0.174 0.014 0.116 0.045
Female gender Constant -0.2.899
BMI 0.188 0.001 0.0809 0.024
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Discussion
Osteoporosis is a serious and frequent manifestation in patients with Crohn’s disease,
which increases the risk for future fractures. The aim of the present study was to identify
predictive genetic risk factors for reduced bone mineral density in patients suffering
from Crohn's disease. In the present study 22 out of 87 patients (25%) were osteoporotic
and 43 patients were osteopenic (49%). This high frequency of low BMD may be
explained by a large number of risk factors, disease or therapy related. However,
previous studies were unable to elucidate the precise etiology of osteoporosis in Crohn’s
disease. In these studies, the most consistent risk factors for osteoporosis in IBD patients
(including patients with Crohn’s disease) were BMI, gender and age (1-8). Furthermore,
corticosteroid related detrimental effects on bone metabolism are well known, and
therefore, corticosteroids are considered as a major risk factor for low BMD (33).
However, an independent effect of corticosteroids on BMD remains less clear in Crohn’s
disease patients (8).
In the present study, both BMI and gender were identified as independent risk factors
for osteoporosis, together explaining 23% of variation in BMD Z scores. In accordance
with previous studies in Crohn’s disease, a low BMI was associated with reduced BMD.
In contrast to studies in the general population, male gender was an independent risk
factor associated with low BMD. In the general population, however, post-menopausal
decline in bone density may largely explain the predominance of osteoporosis in
women. In the present study, the majority of female patients were pre-menopausal with
a mean age of 41 years. The male predominance in the present study, which is in contrast
with general populations, supports the importance of disease related risk factors for the
development of osteoporosis.
With BMI and male gender as independent risk factors, more than 75% of the variation
in BMD Z scores remains unexplained. The current study aimed at finding genetic risk
factors for BMD in Crohn’s disease. A number of genetic variants have been found to be
risk factors for osteoporosis in the general population, but the size of the effect of
individual genetic variants seems to be limited. In secondary osteoporosis as in Crohn’s
disease, the effects of an underlying genetic susceptibility might be stronger due to
interactions with disease specific or therapy related risk factors. The number of previous
studies describing effects of genetic factors on bone loss in patients with IBD is relatively
limited (17,18,34). Schulte and colleagues have assessed the rate of bone loss over a mean
period of 1.6 years in relation to clinical and genetic parameters in 60 patients with
Crohn’s disease and 23 with ulcerative colitis (17). They observed an association of
variants in the IL1RN gene and in a microsatellite close to the IL6 gene on bone loss over
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time, independent from disease activity. However, in their study, none of the genetic
variations were associated with baseline or follow-up BMD. In a later study, Schulte and
colleagues were unable to demonstrate a predictive effect of a functional genetic
variation with in the IL6 gene for the degree of bone loss in IBD patients (34). Variation
in the IL6 gene was not found to be related to the results of a single BMD assessment in
our patients. Furthermore, in our patients, no association was observed between
variation in the IL1RN gene and BMD. However, significant association was observed
between average annual intake of corticosteroids and IL1RN genotypes. In previous
studies, IL1RN genotypes were associated with chronic inflammatory diseases and also
IBD (35). Therefore, the observed association between use of corticosteroids and IL1RN
variants might be caused by the course of disease activity. Nemetz and colleagues
analyzed the association of variation in the gene encoding IL-1β (IL1B) with BMD in IBD
patients. In IBD patients but not in healthy controls, carriers of the 511*2 allele of the
IL1B gene had significantly lower BMD compared to non-carriers (18). However, this
genotype may also alter the course of disease in IBD and therefore, the association with
BMD might be disease related (36). Variation in IL1B was not analyzed in the present
study. In the present study, bivariate analysis showed borderline significant association
of BMD Z scores with the ESR1 (p=0.053) variant. However, in the regression models to
determine independent predictors for BMD, none of the genetic factors studied
appeared to be significant independent risk factors for low BMD in the patients with
Crohn’s disease. The ESR1 gene is a candidate gene for osteoporosis in both men and
women (26,37-39). In the present study we have investigated the role of a TA
dinucleotide repeat polymorphism. In previous studies, the number of repeats was
correlated with BMD with the lowest number of repeats showing the lowest BMD
(38,39). Although only borderline significant (p 0.05), the correlation with the number of
TA repeats is in accordance with the previous observations. In our study, a low number
of repeats for ESR1, but also male gender were associated with low BMD. Therefore, the
significant association between ESR1 variants and gender might be an explanation for
the predominance of low BMD in males in this cohort of patients.
In conclusion, low BMI and male gender were independent predictors for impaired BMD
in the present study, together explaining about 23% of variation in BMD. None of the
genetic factors studied appeared to be strong independent risk factors for low BMD in
patients with Crohn’s disease. This might partly be due to the relatively small sample size
of our study and the limited power to detect small contributions of genetic factors to
osteoporosis risk, as well as to the existence of other genetic factors that play more
prominent roles in the pathogenesis of secondary osteoporosis in Crohn’s disease. 
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Abstract
Background: In placebo controlled trials, budesonide 6 mg once daily was able to
prolong the time to relapse in patients with quiescent Crohn’s disease. Furthermore,
budesonide 9 mg/day was effective in active Crohn’s disease with limited side effects.
The aim of the present study was to compare the effectiveness of budesonide 9 mg
versus 6 mg once daily on the maintenance of remission and occurrence of adverse
events. 
Methods: Double blind, randomized trial in patients with Crohn’s disease in remission.
Patients were randomized to 6 mg/day or 9 mg/day of budesonide (Budenofalk®).
Concomitant treatment for Crohn’s disease was discontinued. End points were the time
to relapse and relapse rates after one year. 
Results: Seventy-six patients were randomized to 6 mg/day and 81 patients to 9
mg/day. Survival analysis showed no differences in the time to relapse. One-year
relapse rates were not significantly different (6 mg group 28%; 9 mg group 21%). Any
adverse event was reported in 61% respectively 68% of patients in the 6 mg and 9 mg
groups. None of the serious adverse events (n = 12) were drug related. 
Conclusion: A one-year relapse rate of only 28% was achieved in the control group of
patients with quiescent Crohn’s disease, treated with budesonide 6 mg once daily. No
significant additional benefit was demonstrated by increasing the dose to 9 mg once
daily. The number of adverse events was similar in both treatment groups. Therefore, 6
mg daily of budesonide seems a reasonable dose for maintenance therapy in quiescent
Crohn’s disease. 
Introduction
Crohn’s disease is a chronic inflammatory disorder of the digestive tract. Medical
treatment primarily focuses on mucosal inflammation. High remission rates of active
Crohn’s disease will be achieved with corticosteroids (1,2), but the rate of relapses is
high after withdrawal of corticosteroids and long-term use of systemically active
corticosteroids is associated with a substantial number of side effects (3). Furthermore,
low doses of systemically active corticosteroids were ineffective for the prevention of
relapses in previous studies (4). The topically active synthetic steroid budesonide may
overcome these disadvantages of long-term treatment with corticosteroids in Crohn’s
disease. Budesonide combines high intrinsic corticosteroid receptor affinity with a
strong first pass effect in the liver of about 90% after oral administration (5,6). Two oral
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formulations have been developed to release budesonide in the ileum and proximal
colon (7), or in ileum and majority of the colon (8,9).
In mild and moderate active Crohn’s disease, budesonide in a dose of 9 mg daily is
almost as effective as prednisone regimens in doses up to 40 mg per day, with
significantly less corticosteroid associated side effects (10-13). Furthermore, treatment
with budesonide capsules is able to prolong the time to relapse in patients with Crohn’s
disease in clinical remission. In two out of three dose-finding studies, 6 mg daily was
superior to 3 mg daily and to placebo with respect to the time to relapse (14-16).
However, relapse rates in these groups treated with budesonide 3 or 6 mg daily were not
significantly lower compared with placebo at the end of a one-year treatment period.
These findings were recently confirmed by a pooled analysis of these 3 studies and a
similar designed trial with 2 parallel groups (placebo and 6 mg daily) (17). In the pooled
analysis, the median time to relapse was significantly prolonged from 154 days in the
placebo group to 268 days in the budesonide 6 mg daily group. The relapse rate after one
year was 59% in the placebo group, which was not significantly different from 51% in
the patients treated with budesonide 6 mg daily. Since a dose-relationship seems to exist
in these maintenance trials, administration of budesonide in a higher dose of 9 mg daily
may be more effective. The primary objective of the study was to evaluate if the time to
relapse is prolonged under budesonide 9 mg per day compared to 6 mg per day, in
patients with Crohn’s disease in remission at study entry. Secondary objectives were to
evaluate the percentage of patients in remission and to examine the safety of budesonide
6 mg and 9 mg once daily over a treatment period of one year. 
Materials and methods
Patient selection
Patients aged between 18 and 75 years with confirmed Crohn’s disease were eligible for
the study if they fulfilled the following criteria: Crohn’s disease in remission for at least
3 months, but not more than 18 months. Remission was defined as a Crohn’s Disease
Activity Index (CDAI) below 150 points (18). Disease locations confined to the ileum
and/ or colon except rectal and perianal disease. Patients who fulfilled one of the
following criteria were not eligible for the study: bowel surgery within 6 months before
randomization. History of small bowel resections exceeding 80 cm. Disease locations
proximal to the ileum. Severe hepatic disease defined by elevated liver enzymes of 3
times the upper limit of normal, or renal disease with serum creatinine levels above 2
times the upper limit of normal. Presence of diseases that may deteriorate by
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corticosteroids (such as diabetes mellitus, glaucoma, aseptic bone necrosis, acute
psychosis and severe hypertension). Need for parenteral nutrition. Presence of active
systemic infections or gastroenteritis. Pregnancy or inadequate use of contraceptives
during the trial.
This study was conducted in accordance with the ICH Harmonized Tripartite Guideline
for Good Clinical Practice (1996). Before recruitment of patients, the protocol was
reviewed and approved by the local ethics committees. All patients gave their written
informed consent before participation in the study.
Study drug and concomitant medication
Capsules containing pH-modified release pellets of budesonide (Budenofalk® 3 mg
capsule) and placebo capsules were manufactured by Losan Pharma GmbH,
Neuenburg/Germany and supplied by Dr. Falk Pharma GmbH, Freiburg/Germany.
Patients were randomly assigned to one of the two treatment groups. In group A,
patients received 3 capsules of budesonide 3 mg once daily and in group B, patients
received 2 capsules of budesonide 3 mg and one placebo capsule once daily.
At time of randomization, prednisolone or methylprednisolone was accepted in a
maximum dose of 20 respectively 16 mg per day, with a fixed tapering schedule within
6 weeks. Use of budesonide was permitted at time of randomization in a maximum dose
of 9 mg per day, which had to be discontinued that day. Additional treatment with
investigational agents, azathioprine, cholestyramine, cyclosporine or metronidazole had
to be stopped at least 2 weeks prior to randomization. Furthermore, 5-aminosalicylates
or other treatments for Crohn’s disease, protonpump inhibitors and diuretics were not
permitted after randomization during the trial.
Trial design
The study was designed as a randomized, double blind parallel group, multi-centre
clinical trial. One tertiary referral centre for inflammatory bowel disease and thirty-two
regional centers (3 in Germany and 29 in the Netherlands) were participating in the
study. By central telephone and fax contact, eligible patients were randomly allocated to
treatment with either budesonide 6 mg or 9 mg once daily for up to 52 weeks.
Outpatient visits were scheduled after 8, 24 and 52 weeks. Additional visits were
required in case of increased complains suggesting a relapse, or in case of adverse events
(AEs). At each study visit, the CDAI was determined, and physical examination and
laboratory tests were performed. All AEs, including signs and symptoms suggestive of
corticosteroid-associated side effects were recorded. Relapse was defined by a CDAI
above 150 together with an increase of at least 60 points. If an increase in CDAI was
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possibly explained by other causes, it was allowed to repeat CDAI once within a
reasonable time. In case of spontaneous normalization of the CDAI, no relapse was
assumed. Time to relapse was defined as the time between the baseline visit and the first
visit with a CDAI corresponding to a relapse.
Statistical analysis
Based on the results of previous studies, we estimated that 95 patients per group would
have to be studied to detect a clinically relevant increase of at least 50% in time to relapse
on budesonide 9 mg per day compared with 6 mg per day (α = 0.05; β = 0.20). Based on
previous studies, we assumed an exponential disease free survival and a relapse rate of
50% in the control group on budesonide 6 mg. Patients who received at least one dose
of study medication with at least one follow-up visit were included in the safety analysis
and intention-to-treat (ITT) analysis. Kaplan-Meier estimates and log-rank tests of the
survival distribution function were used for the analysis of the primary outcome
measure time to relapse. The following covariates were included in the Kaplan-Meier
analysis as strata: concomitant use of systemic corticosteroids at time of randomization,
disease location, smoking history, duration of disease, history of bowel resections,
previous use of budesonide, and centre of inclusion. As pre-defined in the Statistical
Analysis Plan, 10%, 15%, 20% and 25%-quantiles were used to obtain a 9 mg/6 mg ratio
concerning time to relapse. Additionally, the median time to relapse (= 50% quantile)
was estimated parametrically with SAS PROC LIFEREG assuming a Weibull
distribution. The 1-year relapse rates were analyzed by Fisher’s exact test. Baseline
characteristics, secondary efficacy parameters and safety parameters were analyzed by
descriptive statistics. In case of missing values at the final examination, the last
documented follow-up value was used. Results are given as mean ± standard deviation
or median (range). The statistical evaluation was performed using SAS version 8.2. 
Results
Patients
The recruitment was terminated after 160 patients were included (22 in the tertiary
referral centre), because the observed overall relapse rate was far below the estimated
rate. Three patients were excluded from the ITT analysis and safety evaluation. One
patient was lost to follow-up without any follow up values, one patient did not take
study medication and one patient was randomized twice. Of the remaining 157 patients,
76 were assigned to the 6 mg/day group and 81 were assigned to the 9 mg/day group.
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The baseline characteristics did not differ significantly between the two treatment
groups (Table 1).
Early withdrawal from treatment
Out of 157 patients, 56 discontinued the trial prior to 1 year after baseline. The number
of early terminations was equally distributed between the 2 treatment groups, 28 (37%)
in the 6 mg per day group and 28 (35%) in the 9 mg per day group. A flow chart of study
participation is shown in Figure 1. In the 6 mg per day group, 17 out of 76 patients (22%)
discontinued for inadequate efficacy, 11 (14%) for other reasons and 48 (63%) completed
the one-year follow-up in clinical remission. In the 9 mg per day group, 18 out of 81
patients (22%) discontinued for inadequate efficacy, 10 (12%) for other reasons and 53
(65%) completed the one-year follow-up in clinical remission.
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Table 1
Baseline characteristics according to study group
Budesonide 6 mg Budesonide 9 mg
(n = 76) (n = 81)
Sex (Female/Male) 47 / 29 (62% / 38%) 45 / 36 (56% / 44%)
Age (yr) 35 (19 - 73) 35 (18 - 72)
Weight (kg) 69.5 (45 - 104) 74.9 (50 - 131)
Height (cm) 172 (150 - 198) 175 (154 - 194)
History of bowel resection 24 (32%) 36 (44%)
Smoking habits (never/ever) 30 / 46 (40% / 60%) 35 / 46 (43% / 57%)
Disease duration (yr) 4.5 (0 - 32) 2.5 (0 - 49)
Disease involvement:
- Ileum 72 (95%) 77 (95%)
- Cecum 42 (55%) 41 (51%)
- Ascending colon 24 (32%) 24 (30%)
- Transverse colon 15 (20%) 18 (22%)
- Descending colon 10 (13%) 12 (15%)
- Sigmoid colon 11 (15%) 13 (16%)
CDAI at study entry** 69 (-16 - 154) 76 (-41 – 165)
Medication (last 12 months):
- Corticosteroids 33 (43%) 28 (35%)
- 5-Aminosalisylate 67 (88%) 70 (86%)
- Immunosuppressive 2 (3%) 4 (5%)
Values are given as median (range) or number (%).
** In each treatment group CDAI was above 150 in 1 patient (protocol violation).
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Figure 1
Flow chart of patients during study participation.
Efficacy of budesonide
The relapse-free survival as a function of time is shown in Figure 2 for both treatment
groups in the ITT analysis. By log-rank test, no statistically significant difference
between both groups was demonstrated (p = 0.46). From the covariates included in the
Kaplan-Meier analysis, concomitant use of corticosteroids at time of randomization was
associated with the shortest time to relapse (p = 0.03). No influence on time to relapse
was shown by the covariates disease location, smoking history, duration of disease,
history of bowel resections, previous use of budesonide and centre of inclusion. After
one year, the probability to be relapse-free was around 75% in both groups and the
median time to relapse was far outside the observation interval and could not be
estimated using non-parametric methods. Therefore, 10%, 15%, 20% and 25% quantiles
were used for the descriptive analysis. The non-parametric Kaplan Meier estimates of
the 10% quantile were 124 days in the 6 mg group and 153 days in the 9 mg group, for
the 15% quantile 165 days versus 175 days, and for the 20% quantile 232 versus 364 days,
but the upper limit of the confidence interval was not estimable for the 20% quantile.
The parametric estimates for the median time to relapse were 809 days (95%-CI: 360 -
1259) for the 6 mg group and 1049 days (95%-CI: 384 - 1713) for the 9 mg group.
However, it must be considered that the maximal observation intervals in the study
were 398 (6 mg group) and 402 days (9 mg group).
After the treatment period of one year, the relapse rate was not significantly different
between the budesonide 6 and 9 mg groups among those patients who completed the
trial or discontinued due to a relapse (6 mg 28% [18/65]; 9 mg 21% [15/71]; p = 0.43).
The frequency of relapses was higher in the IBD referral centre compared to the non-IBD
referral centers (8 out of 22 patients (36%) respectively 25 out of 135 patients (19%).
During the study period, the mean CDAI increased in the 6 mg/d group (from 71 ± 45
to 104 ± 86; not significant) and in the 9 mg/d group (from 76 ± 45 to 91 ± 84; not
significant). Furthermore, C-reactive protein increased slightly in both groups from 12 ±
12 mg/l to 18 ± 23 mg/l in the 6 mg group and from 11 ± 12 mg/l to 15 ± 20 mg/l in the
9 mg group (Figure 3). The erythrocyte sedimentation rate increased slightly in the 6 mg
group from 16 ± 13 mm/h to 22 ± 21 mm/h, whereas it remained stable in the 9 mg
group (15 ± 12 mm/h).
Adverse events
In total, 195 AEs occurred in 101 patients during the study period. In the 6 mg group, 92
AEs occurred in 46 (61%) patients and in the 9 mg group, 103 AEs in 55 (68%) patients.
An overview of all AEs classified by organ system is given in Table 2. The intensity of
the AEs, was classified as mild or moderate in 94% of the cases. During the study period,
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no deaths occurred. A total of 12 serious adverse events (SAEs) were recorded in 10
patients (Table 3). The reason to classify these 12 events as serious was hospitalization.
None of these SAEs was clearly related to the study medication. The most commonly
reported AE was acne, which was present in 9 patients (12%) receiving 6 mg/d and in 8
patients (10%) receiving 9 mg/d. Moon face appearance occurred in 6 (8%) patients in
the 6 mg/d group and 9 (11%) patients in the 9 mg/d group. Hirsutism was reported in
6 (8%) patients receiving 6 mg/d, but not at all in the 9 mg/d group. Headache occurred
in 6 patients (8%) in the 6 mg/d group and in 3 patients (4%) in the 9 mg/d group.
Abdominal pain was reported in 4 patients (5%) in the 6 mg/d group and in 5 patients
(6%) in the 9 mg/d group. External steroid related side effects such as acne; moon face
and obesity were already present at baseline in 29% of the patients randomized to 6
mg/d and 22% of the patients in the 9 mg/d group. These initially present side effects
resolved completely in 9 patients (12%) of the 6 mg group and in 6 (7%) patients of the
9 mg group.  
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Figure 2
Kaplan-Meier estimates of time to relapse with budesonide 6 mg per day and 9 mg
per day in 157 patients with Crohn’s disease in remission (ITT analysis). Censored
cases (without a relapse at study discontinuation) are marked in the figure. By log-
rank test, no significant difference between the two treatment groups was observed
(p = 0.46). The hazards ratio with its 90% confidence interval is 0.773 (0.435 – 1.375).
Su
rv
iva
lD
is
tri
bu
tio
n
Fu
n
ct
io
n
93
Figure 3
The course of secondary efficacy parameters during maintenance treatment with
budesonide. A CDAI values at prescheduled study visits. B CRP values at study
visits. Values represent mean ± SD. 
CD
AI
CR
P
(m
g/
l)
94
Table 2
Summary of adverse events
Organ system 6 mg (n = 76) 9 mg (n = 81)
Endocrine 10 (13) 10 (12)
Eye 2 (3) 1 (1)
Gastrointestinal tract 9 (12) 11 (14)
Hepatobiliary tract 0 1 (1)
Infections 6 (8) 13 (16)
Injury, poisoning and procedure related 0 3 (4)
Metabolism and nutrition 4 (5) 9 (11)
Musculoskeletal and connective tissue 2 (3) 4 (5)
Nervous system 8 (11) 4 (5)
Pregnancy 2 (3) 0
Psychiatric 1 (1) 4 (5)
Renal and urinary tract 1 (1) 1 (1)
Reproduction and breast disorders 1 (1) 0
Skin and subcutaneous tissue 17 (22) 20 (25)
Surgery and medical procedures 1 (1) 0
Vascular 3 (4) 3 (4)
General disorders 5 (7) 5 (6)
Number of events (% of patients effected)
Table 3
Serious adverse events during budesonide treatment
Patient Dose Serious adverse Event Sex Age Time Causal 
(mg) (yr) (d) relation
1 6 Bartholini cyst surgery F 21 34 Unlikely 
2 6 Hypertensive crisis M 67 354 Unrelated 
3 6 Anal fistula M 25 302 Unrelated
4 6 Extrauterine gravidity F 34 290 Unrelated
5 9 Inguinal Hernia M 43 101 Unrelated
6 9 Vomiting, abdominal pain M 22 164 Unlikely
7 9 Stab wound M 23 62 Unrelated
8 9 Abdominal pain, diarrhea F 69 286 Unlikely
9 9 Psoas abscess M 42 353 Unrelated
10 9 Ileus M 34 141 Unlikely
F; Female, M; Male. Time is given in days from start of study medication to the first
appearance of the serious adverse event. 
Discussion
This double blind, prospective, randomized, multi-centre clinical trial was conducted to
evaluate the time to relapse, comparing 6 mg/d and 9 mg/d of budesonide, in patients
with quiescent Crohn’s disease. In previous maintenance trials, one-year relapse rates
were relatively high in patients treated with budesonide 3 mg or 6 mg daily and placebo
treated controls (Figure 4). The sample size of the present study was based on an expected
relapse rate of 50% after one year in patients treated with budesonide 6 mg daily. 
However, during a recruitment period of 3 years, a much lower frequency of relapses was
observed among patients who have completed the one-year follow-up. Although it was
planned to include 190 patients in the present study, the recruitment was stopped after
160 patients. Because of the unexpected low frequency of relapses, it was highly unlikely
that addition of 30 more patients in the trial would result in different outcomes. Within
one year, only 28% of patients treated with budesonide 6 mg/d relapsed, compared with
21% of patients treated with 9 mg/d. The magnitude of the difference in relapse rates
compared with previous placebo controlled studies may have various explanations. At
first, the majority of patients (259 out of 270) in the studies by Greenberg, Löfberg, and
Ferguson and colleagues were initially treated for active Crohn’s disease with
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Figure 4
One-year relapse rates from prospective randomized fixed-dose budesonide
maintenance trials. 
O
n
e
ye
a
r
re
la
ps
e
ra
te
(%
)
corticosteroids and randomized for the maintenance trials 8 to 16 weeks after the onset of
corticosteroid therapy if clinical remission was achieved (14-16). In contrast, in the
present study, clinical remission was induced by a variety of therapy modalities and the
use of systemic corticosteroids at time of randomization was associated with the shortest
time to relapse. Therefore, this may partly explain the unexpected low relapse rate in the
budesonide 6 mg group. The lower rate of relapses may also be explained by a potentially
longer interval (3 to 18 months) between the onset of therapy for active Crohn’s disease
(i.e., treatment of last relapse) and inclusion in the present trial, compared with the
previous maintenance trials. Due to the inclusion of patients with a longer disease free
period, selection of patients with a more benign course may have occurred, because the
natural course of Crohn’s disease may differ considerably between patients (19). This
potential selection bias was limited by excluding patients with an active disease free
period of more than 18 months. Finally, in the present study, the majority of patients were
included by regional non-referral IBD clinics. In these clinics, 25 out of 135 patients (19%)
relapsed during the study period compared with 8 out of 22 patients (36%) in the IBD
referral centre. It may be true that patients treated in referral centers have more
aggressive disease and are more refractory to therapy. To our opinion, the present study
design is more in accordance with the daily clinical practice. Including a placebo group
in the present trial would have solved the issue of the unexpected low relapse rates.
Although scientific justified, difficulties with patient recruitment were expected if a
placebo group was included in the trial because several maintenance modalities such as
mesalamine, budesonide and azathioprine were widely available during the trial period.
The low relapse rates observed in the present study were confirmed by Green and
colleagues comparing budesonide 6 mg per day with a flexible dose between 3 and 9 mg
per day in patients with Crohn’s disease in remission (20). They observed treatment
failures within 1 year in 19% and 15% of patients respectively. However, treatment
failure was defined somewhat different as moderate to severe symptoms over an 8
weeks period despite treatment at the highest dose level (6 mg in the fixed group and 9
mg in the flexible group) or a CDAI > 200 and moderate to severe symptoms at trial
withdrawal.
In the present study, the probability to be relapse-free at the end of the one-year period
was around 75% in both groups. Due to the low frequency of relapses within the study
period, median time to relapse could not be estimated non-parametrically. Parametric
estimates for the median time to relapse were 809 days for the 6 mg/d group and 1049
days for the 9 mg/d group. This corresponds with an increase in the median time to
relapse of 30%, which agrees well with the estimated hazard ratio (0.773) derived from
a Cox regression model. However, these estimates are weak, considering that the
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maximal observation intervals in this study were only 398 (6 mg/d) and 402 days (9
mg/d). In the trial design, a difference of 50% in time to relapse was considered
clinically relevant. Therefore it remains unclear if longer follow-up would have resulted
in a significant difference between both groups.
The evaluation of the secondary efficacy parameters showed a tendency of a mild
increase in inflammation during the follow-up in both treatment groups. For all
secondary efficacy parameters this tendency was less pronounced in the budesonide 9
mg/d group, but differences between groups were not significant. This may indicate
that budesonide 9 mg/d suppresses disease activity somewhat better than 6 mg/d.
In the present study, the frequency of adverse events was not different between both
treatment groups. Any adverse event occurred in 46 patients (61%) of the 6 mg/d group
and in 55 patients (68%) of the 9 mg/d group, but only half of these events were related to
the study medication (32% of patients in the 6 mg/d group and 36% of patients in the 9
mg/d group). In addition Greenberg and colleagues reported no significant differences in
over-all frequencies of adverse events within one year between groups treated with
budesonide 3 mg/d or 6 mg/d or placebo. Adverse events were reported in 89% of
patients treated with placebo, 70% with budesonide 3 mg/d and 78% with budesonide 6
mg/d (14). Focusing on potential corticosteroid related events, no significant differences
between placebo and budesonide 3 mg/d or 6 mg/d groups were observed in the
previous studies (14-16). However, cortisol stimulation tests demonstrated mild adrenal
suppression in the budesonide groups, compared with placebo (14,16).
In the present study, over 90% of the adverse events were of mild or moderate intensity
and were mostly resolved at the end of the study. None of the 12 serious adverse events
had a probable relationship with the study medication. All these events were classified
as serious because of hospital admission. The most frequently reported adverse events
during the study period were likely related to corticosteroid treatment, such as acne,
moon face and hirsutism. However, already at baseline, 29% of the patients receiving 6
mg/d and 22% of the patients receiving 9 mg/d showed external steroid related side
effects due to prior use of prednisone. Only 11% of patients in the 6 mg/d group and
15% in the 9 mg/d group developed corticosteroid related side effects after baseline.
Overall, the spectrum of adverse events during treatment with budesonide 6 mg/d is
mild, which is in agreement with the previous reports. By increasing the dose to 9 mg/d
for a one-year period, no significant increase in adverse events occurred in the present
study. However, safety issues concerning osteoporosis due to long-term treatment with
corticosteroids remains unanswered by this study. Corticosteroids are considered as an
established risk factor for osteoporosis, but also Crohn’s disease by itself is a risk factor
for osteoporosis. Therefore, in Crohn’s disease, the definite effects of corticosteroids on
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bone mineral density (BMD) remains less clear than initially thought (21). Furthermore,
treatment with budesonide results in significantly less systemic effects compared with
prednisolone treatment (22), which may result in less detrimental effects on bone
metabolism. In the present study no BMD assessments were performed for several
reasons. At first, BMD assessment devices were not widely available in the participating
centers during the initiation of the trial. Furthermore, a large variability in BMD
assessment devices was present in the remainder of centers. Referral of all patients to a
single centre for BMD assessments would have reduced recruitment of patients
dramatically. Recently, Cino and colleagues reported a small but significant decrease in
BMD over a 2 year period in patients treated with budesonide compared with low dose
prednisone or non-steroid therapy (23). However, no firm conclusions can be drawn,
because this was not a prospective randomized trial, which resulted in different
phenotypes of Crohn’s disease in the three cohorts. In contrast, in a prospective
randomized trial, Schoon and colleagues demonstrated significantly less corticosteroid
related side effect including loss in BMD during treatment with budesonide compared
with prednisolone over a 2 year period in corticosteroid naive patients (24).
In conclusion, a remarkably low relapse rate was achieved in patients with quiescent
Crohn’s disease, treated with budesonide 6 mg/d. No significant additional benefit was
demonstrated by routinely increasing the dose to 9 mg/d. At the other hand, the number
of adverse events was similar in both treatment groups. Therefore, budesonide 6 mg/d
seems a reasonable dose for maintenance therapy in Crohn’s disease. When dose
escalation seems to be indicated in individual cases, the dose may be increased to 9
mg/d without a significant increase in adverse events. 
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Abstract
Thiopurines have proven efficacy in inflammatory bowel disease. However, concerns
regarding toxicity have limited the use these agents as first line of medical therapy. In
clinical trials, up to 15% of patients discontinued 6-mercaptopurine or its pro-drug
azathioprine prematurely due to adverse events. These events may be divided in
dose-independent idiosyncratic reactions and dose related, pharmacologically
explainable toxicity. Dose independent reactions include skin rash, fever, diarrhoea
and pancreatitis. Most frequently observed dose-dependent adverse events are
nausea, malaise and myelotoxicity. Furthermore, dose-dependent and dose-
independent hepatotoxicity may occur. Recent insights obtained by therapeutic drug
monitoring in patients on azathioprine or 6-mercaptopurine have led to strategies to
reduce toxicity. One strategy is to detect poor metabolisers of thiopurines by
establishing the activity of the key-enzyme thiopurine methyltransferase. However,
the clinical relevance of this strategy is still a point of debate. Another strategy is to
administer 6-thioguanine, which is an agent close to the effective 6-thioguanine
nucleotides. In conclusion, therapeutic drug monitoring of thiopurines resulted in
strategies to reduce toxicity. The value of these strategies has yet to be proven in
prospective randomised trials. 
Adverse events of azathioprine and 6-mercaptopurine
The thiopurines azathioprine (AZA) and 6-mercaptopurine (6-MP) have proven
efficacy in patients with inflammatory bowel disease (IBD). Therefore, these agents
are prescribed on a large scale  in IBD patients. However, safety concerns do exist,
because serious adverse events due to thiopurines may occur. In previous clinical
trials, 0-15% of patients discontinued AZA or 6-MP prematurely due to adverse
events (1). Furthermore, in a retrospective study in paediatric IBD patients, cessation
of therapy was needed in 18% due to side effects (2). The side effects of thiopurines
can be divided in dose-independent and pharmacologically explainable dose-
dependent events. Most frequently observed dose-independent events are rash, fever
and arthralgia, but also pancreatitis and hepatitis may be idiosyncratic reactions. The
dose-dependent toxicity of AZA and 6-MP may largely be explained by the complex
metabolism of the thiopurines, which results in a number of potentially effective or
toxic metabolites. Nausea and general malaise are the most frequently observed dose-
dependent reactions. Hepatotoxicity may also be dose-dependent, but the most
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important and potentially lethal dose-dependent adverse event is myelosuppression.
The reported frequency of clinically relevant leukopenia in IBD patients varies
between 2-11% depending on the definition of leukopenia and the dose of thiopurines
that was prescribed (1-5). A large survey in 739 IBD patients demonstrated
leukopenia below 3.0 x109/l in about 4% of patients, treated with AZA in a dose of
2mg/kg/day (3). 
Another safety concern is that thiopurines have been implicated in the development
of malignant lymphoma among patients with rheumatoid arthritis and in patients
with a solid organ transplantation (6-8). Contrary to these findings in patients with
organ transplantations, the risk of developing lymphoma in AZA or 6-MP treated IBD
patients seems not different from the general population (9). However, some cases of
non-Hodgkin's lymphoma have been reported in IBD patients treated with AZA or 6-
MP. Recently, Lewis and colleagues concluded in a decision analysis that the benefits
of thiopurines outweigh the potential risk of lymphoma in patients with moderate to
severe Crohn's disease in remission (10). 
Thiopurine metabolism
After administration of AZA, the pro-drug is cleaved into nitromethylimidazole and
6-MP (11). Thereafter, 6-MP may be metabolised under influence of 3 different
enzymatic pathways, as illustrated in Figure 1 (12). At first, activation to 6-
thioguanine nucleotides (6-TGN) occurs by several enzymatic steps and depends
critically on the enzyme hypoxanthine guanine phosphoribosyl transferase (HPRT).
Secondly, extensive inactivation of 6-MP to 6-thiouric acid occurs by xanthine
oxidase. The third pathway inactivates 6-MP by the enzyme thiopurine
methyltransferase (TPMT), which methylates 6-MP to 6-methylmercaptopurine (6-
MMP). Furthermore, TPMT enables methylation of other compounds in the metabolic
pathway, which may result in additional potentially toxic or active metabolites.
TPMT activity exhibits high interindividual variation due to genetic heterogeneity.
The frequency distribution of TPMT activity in Caucasian populations is trimodal:
homozygous wild type alleles with high enzyme activity in about 89% of the
population, heterozygous alleles with intermediate enzyme activity in about 11% and
homozygous variant alleles resulting in absence of functional activity in 1 in 300
subjects (13). Patients with low to absent TPMT activity accumulate 6-TGN, which
results in an increased risk for myelosuppression.
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Therapeutic drug monitoring of thiopurines
Besides TPMT analysis, therapeutic drug monitoring of AZA and 6-MP contributes to the
understanding of thiopurine toxicity and efficacy in IBD. Cuffari and colleagues
demonstrated an active immunosuppressive role for 6-TGN and an association of 6-MMP
with hepatotoxicity in particular (14). These findings were confirmed by Dubinsky and
colleagues in paediatric IBD patients, demonstrating an optimised clinical response to 6-
MP with 6-TGN levels of above 235 pmol/ 8x108 red blood cells (RBC) (12). Belaiche and
colleagues reported the results of therapeutic drug monitoring in 28 Crohn’s disease
patients, treated with AZA or 6-MP (15). In 6 patients with 6-TGN levels above 250
pmol/8x108 RBC, 5 (83%) were complete responder to 6-MP, compared with 14 (63%) in 22
patients with levels below 250 pmol/8x108 RBC. This was not significantly different,
possibly due to the small numbers. More recently, Dubinsky and colleagues demonstrated
increased dose-related hepatotoxicity of 6-MP, which was associated with  a rise in 6-MMP
ribonucleotide levels (6-MMPR) (16). These results implicate that optimal treatment with
thiopurines, concerning efficacy and safety, will be obtained in case adequate 6-TGN levels
have been reached, without high levels of methylated metabolites.
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Figure 1
Thiopurine metabolism.
AZA, azathioprine; 6-MP, 6-mercaptopurine; 6-MMP, 6-methylmercaptopurine;
6-TU, 6-thiouric acid; 6-MMPR, 6-methylmercaptopurineribonucleotides;
6-TIMP, 6-thioinosine monophosphate; 6-TXMP, 6-thioxanthosine monophosphate;
6-TGN, 6-thioguaninenucleotides;  6-MTGN, 6-methylthioguaninenucleotides;
6-TG, 6-thioguanine; 6-MTG, 6-methylthioguanine; XO, xanthine oxidase; TPMT,
thiopurine S-methyl transeferase; HPRT, hypoxanthine phosphoribosyl
transferase; IMPD, inosine monophosphate dehydrogenase; GMPS, guanosine
monophosphate synthetase.
Strategies to reduce toxicity
TPMT analysis
Several studies suggested TPMT pheno- or genotype assessment before thiopurine
therapy (17-19). This information can guide dosing regimes in order to reduce
toxicity. In patients with intermediate TPMT activity or heterozygous TPMT
genotype, 50% initial dose reduction of AZA or 6-MP minimises the risk of
leukopenia. In a recent case report in 3 IBD patients with low to absent TPMT activity
(homozygous variant TPMT genotype), dose reduction of AZA to approximately 10%
(0,25 mg/kg/day) of the generally advised dose was effective without toxicity (20).
On the other hand, Colombel and colleagues previously reported that TPMT activity
appeared normal in 73% of Crohn's disease patients with confirmed leukopenia
below 3x109/l during treatment with AZA or 6-MP (21). Furthermore, in their study,
all 4 patients (10%) with low TPMT genotype, developed leukopenia within 6 weeks,
which was detected with routine monitoring of blood cell counts. This means that
despite knowledge of TPMT activity in a particular patient, monitoring of blood cell
counts is needed after onset of AZA or 6-MP. Furthermore, the correlation of adverse
events other than myelosuppression with TPMT activity remains unclear. Therefore,
in clinical practice, pre-treatment TPMT assessment in addition to blood cell count
monitoring after the onset of a thiopurine is not performed routinely.
Thiopurine metabolite monitoring
Besides confirmation of a patient’s compliance, thiopurine metabolite monitoring is a
powerful instrument, because of a clear correlation between 6-TGN levels and
efficacy. Furthermore, methylated metabolites contribute to thiopurine toxicity.
Metabolite monitoring can classify patients into 4 separate groups (16). At first,
patients with underdosing of AZA or 6-MP, which result in low 6-TGN and 6-MMPR
levels. Secondly, refractory patients with absence of clinical efficacy despite high 6-
TGN levels. Thirdly, patients with extremely high 6-TGN levels, resulting in
increased risk of developing myelotoxicity. Finally, AZA or 6-MP intolerant patients
can be identified with predominant 6-MMPR formation, resulting in low 6-TGN
levels. Therefore, therapeutic drug monitoring enables rational dose adjustments in
individual patients.
6-Thioguanine as down-stream metabolite
In our opinion, the most promising way to reduce dose-dependent toxicity of
thiopurines is to administer a down-stream metabolite. Preferably, this compound
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should  lead to predominant 6-TGN formation instead of methylated metabolites
without the major implications of genetic heterogeneity for the TPMT enzyme. 6-
Thioguanine (6-TG), which is used in paediatric leukaemia, could meet these
requirements. It is converted to 6-TGN by HPRT in a single step. Although methylation
of 6-TG by TPMT may occur, the clinical relevance of methylated 6-TG remains unclear
(22). At present, several small open label studies demonstrated that administration of 6-
TG in a dose of 20 to 40 mg/day in IBD patients is effective with acceptable toxicity (23-
25). The kind of adverse events on 6-TG corresponds with those observed on AZA or 6-
MP. Despite high 6-TGN levels, a relatively low frequency of leukopenia was observed
(3 out of 79 patients, all 3 on at least 40 mg/day). Obviously, 75% of IBD patients,
previously intolerant to AZA or 6-MP, tolerated 6-TG well. In a recent case report, an
increase of liver enzymes during 6-TG therapy was reported in one patient (26).
However, the mechanism of hepatotoxicity in this patient remained unclear. At present,
no long-term data concerning safety and efficacy of 6-TG in IBD patients are available.
In patients with leukaemia on maintenance therapy with 6-TG, development of non-
cirrhotic portal hypertension was reported (27). However, in these patients, much higher
doses of 6-TG have been used (i.e. 60-200 mg/m2) together with other cytostatic agents.
Controlled trials are needed to determine long-term efficacy and safety of 6-TG in IBD
patients, before 6-TG may be added to the standard medical therapy in IBD. At present,
6-TG is a promising alternative in AZA or 6-MP intolerant IBD patients.
Conclusion
New insights obtained by therapeutic drug monitoring studies and pharmacogenetics
has resulted in strategies to improve efficacy and to reduce toxicity of thiopurines. The
most promising strategies are therapeutic drug monitoring as guidance to dose AZA or
6-MP and direct administration of the down-stream metabolite 6-thioguanine. However,
the value of these strategies  has yet to be proven in prospective randomised trials.
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Abstract:
Objective: In clinical trials 0-15% of patients discontinued azathioprine due to side
effects. The aim of the study was to assess the rate of side effects leading to
discontinuation of azathioprine and to determine predictive factors for
discontinuation.
Design: A retrospective cohort analysis of clinical data regarding adverse events of
azathioprine in Crohn's disease.
Patients: In 54 of 112 consecutive patients with Crohn’s disease, azathioprine was
prescribed. Because incomplete data were available in 4 patients, 50 patients were
analysed.
Results: In 15 out of 50 patients azathioprine was preliminary discontinued due to
adverse events and in 11 of these patients (22%) adverse events were probably related
to azathioprine. After onset of therapy, a small, but significant decrease in leucocyte
count was observed within 6 weeks (median from 10.6 to 9.5 x109/L) and
asymptomatic leukopenia (<3.0.109/L) occurred in 2 patients. Serious adverse events
leading to hospitalisation occurred in 3 patients. All events were reversible after
discontinuation of therapy. Patients who discontinued Aza due to adverse events
used significantly lower initial doses of prednisone compared to patients who were
able to continue Aza. The occurrence of side effects was not related to the initial dose
of azathioprine or concomitant use of 5-aminosalicilates.
Conclusion: Twenty-two percent of patients discontinued AZA prematurely due to
probably related adverse events. Patients who discontinued Aza prematurely used
lower doses of prednisone initially. Therefore, concomitant use of prednisone may
prevent some of the adverse events. 
Introduction
Crohn's disease is a chronic inflammatory disease of the gastrointestinal tract. Until
now, no definite surgical or medical therapy is available. Aim of medical therapy is
to relief symptoms and to prevent complications of Crohn's disease. The immune
modulatory thiopurines 6-mercaptopurine (6-MP) and its prodrug azathioprine (Aza)
have proven efficacy in active Crohn's disease and to prolong clinical remission [1,2].
Furthermore, during treatment with Aza or 6-MP, the need for corticosteroids is
reduced [2]. On the other hand, concerns regarding both short- and long-term toxicity
have limited the use of Aza and 6-MP on a large scale. Adverse events of thiopurines
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may be divided in allergic events, which are dose independent and dose dependent
events. Most frequently observed adverse events are nausea, vomiting, general
malaise and myelosuppression [3-5]. Less frequent, but potentially serious are
hepatotoxicity and pancreatitis. Furthermore, concerns have been raised among
induction of malignancies after long-term treatment with thiopurines [6].
Dose dependent events may be explained by the metabolism of thiopurines. Aza is
metabolised to 6-MP by an non-enzymatic pathway and 6-MP will be metabolised by
an enzymatic pathway into active and or toxic metabolites [7,8]. The enzyme
thiopurinemethyltransferase (TPMT) plays a key-role in the metabolism of the
thiopurines and genetic heterogeneity with implications for TPMT enzyme activity
does exist [9]. However, the correlation of TPMT genotypes with the occurrence of
adverse events other than myelosuppression is still under debate [8,10,11].
The rate of adverse events leading to discontinuation of Aza/ 6-MP was 0-15% in
clinical trials [1]. For Crohn's disease patients, intolerant for Aza or 6-MP, alternatives
with proven long-term efficacy are scarce. Therefore, the aim of the study was to
assess the rate of side effects leading to discontinuation of Aza in patients with
Crohn’s disease and to determine potential predictive factors for discontinuation of
Aza therapy. 
Methods
Patients
Chart review was performed in 112 consecutive patients with confirmed Crohn’s
disease, visiting the outpatient clinic of the department of Gastroenterology and
Hepatology, University Medical Centre Nijmegen. All patients with a history of Aza
prescription were eligible for the study. Data were collected retrospectively from the
medical records. Data concerning behaviour of Crohn’s disease, Aza prescriptions,
concomitant medication and adverse events after onset of Aza were obtained. For
statistical analysis, laboratory parameters were obtained before the onset of Aza and
4 ± 2 weeks and 8 ± 2 months after onset of therapy. In order to determine potential
adverse events, all available laboratory parameters after the onset of Aza were
reviewed for deviations from the normal range. In our centre, we recommended
blood cell count monitoring in patients initiating thiopurine therapy every 2 weeks
until week 8 and every three months thereafter. Furthermore, if Aza therapy was
discontinued, reasons for discontinuation were recorded.
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Adverse events 
The severity of all events leading to discontinuation were classified by the attending
physician using the following system:
• Mild - awareness of event, but no intervention required
• Moderate - discomfort that was enough to interfere with usual 
activity and may warrant intervention
• Severe - significant interference with usual activities or clinical 
status which warrants intervention
• Life threatening - immediate risk of death
The relationship of the adverse event with the use of Aza was established by the
following method:
• Unrelated - no temporal relation and other aetiology likely
• Possible related - potential temporal relation, other aetiologies possible
• Probable related - potential temporal relation, other aetiologies unlikely
• Related - clear temporal relation not otherwise explained
Statistical analysis
Data are given as median values with range where appropriate. Statistical analysis was
performed with SPSS software (version 9.0). Differences between groups were analysed
by Mann-Whitney-U tests. Changes in laboratory parameters were analysed by paired
samples T tests and correlations were tested by Spearman Rank analysis. Two-sided p-
values < 0.05 were considered significant. 
Results
Patients
In 54 out of 112 consecutive patients, Aza was prescribed in their history of Crohn’s
disease. In 4 patients no clinical data were available during the use of Aza. Therefore, 50
patients were eligible for the study. The characteristics of these patients are given in
Table 1. Age at onset of Aza therapy was 32 (19–71) years and duration of Crohn’s
disease was 8.8 (0–40) years. The median initial dose of Aza was 50 (25-150) mg once
daily, which corresponds with 1.0 (0.23–3.2) mg per kilogram bodyweight. In the
treatment period, the highest dose of Aza was 100 (50–150) mg/day, which corresponds
with 1.6 (0.5–3.2) mg/kg. The duration of treatment with Aza was 831 (12–3757) days. In
48 of 50 patients (96%), prednisone was used at time of onset of Aza in a daily dose of
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16.3 (0–60) mg and budesonide capsules were used in 9 patients (18%) in a daily dose of
8 (0–9) mg. Mezalazine was used in 39 patients (78%) in a dose of 3.0 (0–4.5) g.
Adverse events leading to drug discontinuation
In 15 out of 50 patients (30%), Aza therapy was discontinued prematurely due to adverse
events after 79 (12–666) days. The adverse events leading to Aza discontinuation are
shown in Table 2. In 4 patients there was a clear relationship of the adverse event with Aza,
which was established by rechallenge. In another 7 patients there was a potential temporal
relation, demonstrated by the onset and discontinuation of the adverse event concurrently
with the prescription of Aza. In 4 patients the relation of the adverse event with Aza was
unlikely due to absence of a time relationship. In three patients, serious adverse events
leading to hospitalisation were observed. In one patient, acute interstitial pancreatitis
occurred 21 days after the first prescription of Aza without organ failure. In this patient,
no other risk factors for pancreatitis were observed and symptoms gradually resolved
after discontinuation of Aza. One patient was hospitalised because of high fever and chills,
which resolved immediately after discontinuation, but recurred after rechallenge with
Aza. A third patient was hospitalised because of pneumonia with Serratia and Candida
species in cultures of sputum. In this patient, Aza was discontinued, concomitant
corticosteroids were tapered and antibiotics and Amphotericin B were prescribed. With
this treatment the pneumonia resolved.
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Table 1
Characteristics of patients with Crohn's disease at initiation of azathioprine.
Characteristics Result (n=50)
Gender (male/female) 24/26
Age (yr) 32 (19 – 71)
Length (cm) 172 (155 – 196)
Bodyweight (kg) 66 (45 – 112)
Duration of disease (yr) 8.8 (0 – 40)
Location of disease
• Small bowel 15 (30%)
• Large bowel 8 (16%)
• Small and Large bowel 24 (48%)
History of bowel resection 36 (72%)
History of fistulae 31 (62%)
Results given as number (%) or median (range). 
Between patients with and without adverse events leading to discontinuation of Aza, no
differences were observed concerning age of onset of Crohn's disease, age at Aza
prescription or concerning disease location. However, a significant difference in the dose
of prednisone at time of Aza initiation was observed. Patients who discontinued Aza
prematurely used significantly lower doses of prednisone at time of Aza initiation (10
(0–20) mg versus 20 (0–60) mg/day; p < 0.01). Furthermore, these patients reached lower
maximum Aza doses during the prescription period (mean ± SD: 98 ± 33 mg per day
versus 119 ± 31 mg per day; median for both groups 100 (50–150) mg; p = 0.05). No
significant differences in the initial dose of Aza or dose of concomitant Mezalazine were
observed between these groups. In Table 3 differences in concomitant medication and in
Aza dosing between patients with and without discontinuation due to adverse events
are shown.
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Table 2
Adverse events leading to discontinuation of azathioprine in 50 patients with Crohn's
disease.
Patient Dose mg Time to Character of AE Severity Relation Rechal- Comments
(mg/kg) AE (d) lenge
1 100 (1.5) 602 General malaise Moderate Possible No Clear time relation
2 150 (1.9) 79 Nausea and flu-like symptoms Moderate Possible Yes 75 mg now tolerated 
3 100 (1.3) 559 Pneumonia with Candida Severe Possible No No consent for 
species* rechallenge
4 75 (1.4) 56 Fever and chills Moderate Related Yes Similar AE
5 150 (1.8) 177 Myelosuppression Severe Probable No No consent for 
rechallenge
6 150 (2.1) 181 Myelosuppression Severe Related Yes Similar AE on 100 mg
7 50 (0.7) 73 Nausea Moderate Possible Yes Pancreatitis on 6-MP
50mg
8 50 (0.5) 70 Nausea and vomiting Moderate Related Yes Similar AE
9 50 (0.8) 12 Nausea and diarrhoea Moderate Unrelated No Due to Crohn’s 
disease
10 100 (1.5) 384 Diarrhoea Mild Unrelated No No time relation, no 
consent
11 100 (2.3) 666 Bloated feeling Mild Unrelated Yes No time relation
12 100 (1.6) 21 Interstitial pancreatitis* Severe Probable No Not rechallenged 
(severity)
13 100 (1.9) 44 Increased serum Amylase Mild Probable Yes Malaise after 
(319 u/l) rechallenge
14 100 (1.6) 143 Rash Moderate Unrelated Yes No time relation
15 150 (2.7) 33 Fever and chills* Severe Related Yes After 1 day similar AE
* Serious adverse events, leading to hospitalisation. Aza, azathioprine; AE, adverse event; 6-MP, 6-mercaptopurine.
Time to adverse event is given in days from most recent dose adjustment to discontinuation of therapy. 
Myelotoxicity and hepatotoxicity
In 2 patients, leukopenia (<3.0 .109/L) was observed by routine blood evaluation,
leading to discontinuation of Aza, 177 and 181 days after the first prescription of Aza.
In both these patients, previous leukocyte counts were within the normal range. In one
patient the relationship was established by rechallenge with Aza, in the other patient
the relationship was probable, due to a time relationship with complete recovery after
cessation of Aza. In these patients no serious infections were observed. After onset of
Aza, a small but significant decrease in leukocyte count was observed within 6 weeks
from 10.6 (3.8–17.8) to 9.5 (2.5–15.5) x109/L (p < 0.01). The change in leukocyte count
was not correlated to the initial dose of Aza (r 0.14; p = 0.5). Within 6 weeks after onset
of Aza, no significant changes in Haemoglobin level (from 7.9 (4.2–10.1) to 7.9 (4.8–11.2)
mmol/L) or platelet counts (from 325 (80–642) to 326 (74–732) x109/L) were observed.
The results of leukocyte counts before and after onset of Aza are shown in figure 1.
No clinical hepatotoxicity was observed, but in 15 of 50 patients no serum levels of liver
enzymes were obtained after onset of Aza. At the defined intervals, serum levels of
alkaline phosphatase (AP) were available in 16 patients and of alanine
aminotransferase (ALT) in 13 patients. No significant changes were observed after
onset of Aza (AP from 65 (36-248) to 63 (36–175) U/L and ALT from 15 (6–75) to 17.5
(5–60) U/L). 
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Table 3
Dose of azathioprine and concomitant medication in patients with and without
adverse events leading to discontinuation of azathioprine.
Medication (dose) Patients without Patients with p-value
AE* AE*
n = 35 n = 15
Aza initial (mg) 75 ± 34 71 ± 31 0.5
50 (25 - 150) 50 (50 – 150)
Aza maximal (mg) 119 ± 31 98 ± 33 0.05
100 (50 – 150) 100 (50 – 150)
Prednisone (mg) 20 ± 12 11 ± 7 0.007
20 (0 – 60) 10 (0 – 20)
Mesalazine (g) 2.1 ± 1.3 2.4 ± 1.2 0.3
3.0 (0 – 4.5) 3.0 (0 – 3.0)
Differences analysed by Mann-Whitney-U tests. Results given as mean ± standard
deviation and median (range). AE, adverse event; Aza, azathioprine.
* Adverse events leading to discontinuation of azathioprine.
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Figure 1
Leukocyte counts before and 4 ± 2 weeks after onset of azathioprine.
Boxplot of leucocyte counts (x109/l) before (t = 0) and 4 ± 2 weeks after onset of
azathioprine (t = 1). The box represents the interquartile range and contains 50% of the
values. The inner line of the box represents the median value. Leukocyte counts are
depicted in 2 categories defined by dose of prednisolone at time of onset of
azathioprine. The low dose and high dose categories contain half of patients with the
lowest and highest doses of prednisolone respectively. Overall, a significant decrease
in leukocyte count was observed from t = 0 to t = 1 (from 10.6 (3.8 – 17.8) x109/L to 9.5
(2.5 – 15.5) x109/L), but the change in leukocyte count were not different between both
dose categories.
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Discussion
The evidence for the efficacy of the thiopurines Aza and 6-MP is growing in the
treatment of active Crohn's disease and in Crohn's disease in remission. Therefore, Aza
and 6-MP are the most commonly used immune modulatory drugs in the treatment of
Crohn's disease today [12]. However, the potential occurrence of serious adverse events
had limited the use of thiopurines on a large scale. In previous clinical trials, 0-15% of
patients discontinued Aza or 6-MP due to adverse events [1,3] and in a retrospective
study in paediatric IBD patients, cessation of therapy was needed in 18% due to side
effects [4]. We examined a well-defined group of patients with Crohn's disease, treated
in the outpatient clinic of a tertiary referral centre for IBD. In 48% of these patients Aza
was prescribed in a median initial daily dose of 1.0 mg/kg. This is a relatively low dose
compared with the currently advised maintenance dose for Aza of 2.0-3.0 mg/kg
bodyweight [13]. In our centre, it was common practice to initiate Aza with 50-100 mg/d
and to escalate the dose to 1.5-2.0 mg/kg/d. This may explain why patients who
discontinued Aza prematurely had lower maximal doses. Despite the low initial dose,
15 out of 50 patients (30%) discontinued Aza prematurely because of possibly related
adverse events. In case of non-serious adverse events, we have the policy to rechallenge
Aza. In case of relapsing events, it may proof the relation with azathioprine.
Furthermore, desensitisation may occur [14,15]. However, consent from the patient is
not always obtained as demonstrated in table 2. In 11 of these patients (22%) there was
a potential temporal relationship with the Aza treatment. In 4 of these patients the
relationship was proven by similar adverse events after rechallenge. All possibly related
events resolved after discontinuation of Aza. Therefore, no irreversible toxicity was
observed in the present study with a median prescription period of 2.3 years (range 12
days to 10.3 years). In 3 patients, adverse events after onset of Aza were leading to
hospitalisation due to a pneumonia, pancreatitis and high fever with chills respectively.
In the patient with fever and chills, the etiologic relationship with Aza was proven by
rechallenge resulting in the same adverse event within one day. In the patient with
pancreatitis and the patient with pneumonia, no rechallenge with thiopurines was
performed due to the severity of the events. In case of the pancreatitis, a relationship
with Aza was likely, because it was the first episode of pancreatitis, which developed
within 3 weeks after onset of Aza. Furthermore, in this patient no other causal factors for
pancreatitis were present. In the patient with pneumonia, the role for Aza remains
unclear, because a clear time relationship was lacking and no leukopenia was observed.
Furthermore, concomitant use of corticosteroids in this patient may have contributed in
the development of the pneumonia.
122
Naturally, not all potential side effects of azathioprine that has been reported previously
were observed in the present study. A major concern of therapy with thiopurines is the
potential induction of malignancies on the long-term. Thiopurines have been implicated
in the development of malignant lymphoma among patients with rheumatoid arthritis
and in patients with a solid organ transplantation [16-18]. In patients with inflammatory
bowel disease (IBD), treated with Aza or 6-MP, cases of non-Hodgkin's lymphoma have
been reported, but the risk seems not different from the general population [6]. Recently,
Lewis and colleagues concluded in a decision analysis that the benefits of thiopurines
outweigh the potential risk of lymphoma in patients with moderate to severe Crohn's
disease in remission [19]. In the present study, no malignancies were observed, but the
median time of follow-up and the number of patients is too small to draw firm
conclusions on this issue.
Myelosuppression is a known adverse effect of treatment with thiopurines with
potentially serious complications such as life threatening infections [5]. Therefore our
policy is to monitor leukocyte and platelet counts and serum haemoglobin levels before
and after onset of therapy (every 2 weeks until week 8 and every 3 months thereafter).
Leukopenia (<3.0 x109/L) was observed in only 2 patients (4%) without clinical
symptoms, like infections. In both these patients leukocyte counts normalised after
discontinuation of Aza. In all other patients, leukocyte counts remained within the
normal range. The observed small decrease in leukocyte count was not correlated with
the initial dose of Aza, possibly due to the number of patients. The decrease in leukocyte
count may not be a true effect of Aza, but may also be explained by decrease in disease
activity or a decrease in prednisolone dose. However, the change in leukocyte counts
was not different between patients with low or high initial concomitant doses of
prednisolone. Colombel and colleagues reported the absence of a correlation between
dose of thiopurines and severity of leukopenia in 41 Crohn's disease patients with
established myelosuppression during Aza therapy [10], which supports our findings.
Thiopurines have a complex metabolism via a multistep enzymatic pathway. The
enzyme TPMT plays a key role in inactivation of thiopurines. Genetic heterogeneity for
this enzyme results in about 0.3% of individuals with low to absent enzyme activity and
about 10% of individuals with intermediate enzyme activity [9,20]. Several studies
suggested TPMT activity or genotype assessment before therapy in order to reduce the
frequency of leukopenia. However, in a previous study in patients with Crohn’s disease,
73% of patients with myelosuppression (leukocyte count < 3.109/L) during treatment
with Aza or 6-MP had normal TPMT activity [10]. This means that despite knowledge of
TPMT activity in a particular patient monitoring of blood cell counts is needed after
onset of Aza or 6-MP. Furthermore, the correlation of adverse events other than
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myelosuppression with TPMT activity remains unclear. Therefore, in our department no
routine TPMT assessment is performed in addition to blood cell count monitoring. It is
unlikely that the serious adverse events in the present study would have been prevented
by TPMT assessment before initiation of therapy.
The use of concomitant medication might interact with thiopurines. Particularly
corticosteroids may reduce allergy-based side effects, but also leukopenia might be
prevented by corticosteroids, which has been suggested by Korelitz [21]. This hypothesis
is supported by the present study, as patients who discontinued Aza prematurely used
significantly lower doses of prednisolon compared with patients who were able to
continue Aza (median 10 mg versus 20 mg). The higher initial dose may prevent some
adverse events on the short term, but it is unlikely that a higher initial dose of
prednisolone is able to reduce the occurrence of side effects long thereafter. Furthermore,
one of the advantages of thiopurines is the corticosteroid sparing effect. Therefore, we
still advocate to taper corticosteroids as soon as clinically feasible. Previously, an
interaction between 5-aminosalisylates and thiopurines was observed due to inhibition
of TPMT activity [22]. In the present study no difference in the dose of 5-aminosalisylates
was observed between patients with and without adverse events. 
In conclusion, despite relatively low doses, 22% of patients in this cohort discontinued
Aza prematurely due to probably related adverse events. In the present study no
irreversible adverse events of Aza were observed. In two patients (4%), asymptomatic
leukopenia was observed by routine blood cell count monitoring. Blood cell count
monitoring instead of pre-treatment TPMT assessment seems an appropriate policy in
patients initiating Aza. Patients who discontinued Aza prematurely used lower doses of
prednisone initially. Therefore, concomitant use of prednisone may prevent some of the
adverse events.
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Abstract
Objective: 6-Mercaptopurine (6-MP) and azathioprine (AZA) have proven efficacy in the
treatment of inflammatory bowel disease (IBD). However, adverse events leading to
discontinuation may occur in 10-20% of patients. The efficacy of AZA and 6-MP is based
on formation of their active metabolites, the 6-thiogunaninenucleotides (6-TGN).
Therefore, 6-thioguanine (6-TG), an agent more directly leading to formation of 6-TGN
and until recently only used in patients suffering from leukaemia, may be an alternative
in case of AZA or 6-MP intolerance. The purpose of our study was to assess short-term
safety of 6-TG.
Methods: 32 IBD patients with previously established AZA or 6-MP intolerance were
treated with 6-TG as such in a dose of 20 mg (n=19) or 40 mg (n=13) once daily. Safety
parameters were obtained at 0, 1, 2, 4 and 8 weeks after start of medication. Primary
outcome measures were the ability to tolerate 6-TG and the occurrence of adverse
events. Secondary outcome definitions included laboratory parameters.
Results: 26 (81%) patients were able to tolerate 6-TG during the first 8 weeks. In 3 of 6
patients, side effects leading to discontinuation were probably (n=2) or obviously (n=1)
6-TG related. No clinically relevant hematological events or hepatotoxicity occurred in
the observed period. Steady state 6-TG levels were significantly higher on 40 mg
(1621±828 picomoles/8x108 RBC) than on 20 mg once daily (937±325 picomoles/8x108
RBC, p=0.001).
Conclusions: 6-TG treatment seems promising in AZA or 6-MP intolerant IBD patients.
However, long-term safety and efficacy have yet to be determined. 
Introduction
Thiopurine analogues 6-mercaptopurine (6-MP) and its prodrug azathioprine (AZA) are
widely used in the second-line treatment of inflammatory bowel disease (IBD). These
immunosuppressive agents have proven to be effective for both inducing and maintaining
long-term remission of Crohn’s disease (CD) and ulcerative colitis (UC) [1-3]. AZA is
rapidly converted to 6-MP by a non-enzymatic reaction, which is further metabolised to the
pharmacological active 6-thioguaninenucleotides (6-TGN) and 6-methylmercaptopurine
(6-MMP). 6-TGN are purine nucleotides, which are incorporated into DNA, inducing
cytotoxicity and immunosuppression [4]. In patients treated with 6-MP it is shown that red
blood cell (RBC) 6-thioguanine (6-TG) levels correlated with drug efficacy and bone
marrow suppression and 6-MMP levels, on the other hand, correlated with hepatotoxicity
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[5]. In patients treated with AZA or 6-MP the lower limit therapeutic 6-TG level has recently
been established on 235 picomoles per 8x108 RBC, whereas 6-MMP levels above 5700
picomoles per 8x108 RBC were associated with hepatotoxicity [6]. 
A drawback of AZA and 6-MP is the occurrence of side effects. Adverse events leading
to discontinuation may occur in approximately 10-20% of patients [7-9]. In general,
adverse events may be distinguished in hypersensitivity reactions and dose dependent
events. Hypersensitivity reactions to thiopurines or their metabolites occur mostly
within 3-4 weeks and result in immune-mediated symptoms such as fever, rash, and
arthralgia [10,11]. 
Furthermore dose-dependent, pharmacological explainable reactions characterised by
myelosuppression, increased susceptibility to infections and hepatotoxicity may occur.
These reactions seem to be directly associated with high RBC 6-TG or 6-MMP levels and
often reveal themselves in a subsequent stage. 
Toxicity due to the 6-TG metabolite may be explained by polymorphisms in the gene
encoding thiopurinemethyltransferase (TPMT), the enzyme that methylates 6-MP to 6-
MMP. In case of reduced enzyme activity toxic 6-TG levels may be reached on regular
doses of AZA or 6-MP [12]. Alternatively, some patients develop high 6-MMP levels,
whereas 6-TG levels remain subtherapeutic. In these patients the available 6-MP is
largely transformed into 6-MMP due to preferential metabolism through TPMT, while
the enzymatic pathway through hypoxanthine phosphoribosyltransferase (HPRT)
leading to the formation of 6-TGN is hardly exploited. Recently Dubinsky and
colleagues successfully treated 7 out of 10 non-responding IBD patients with preferential
6-MMP formation on 100 mg 6-MP with 6-TG 40 mg once daily. In these patients 6-MMP
levels were undetectable and no hepatic or hematologic toxicity was observed [13]. Until
recently 6-TG as such only was used in patients suffering from lymphoblastic
leukaemia. 
Theoretically, therapy with 6-TG is a good alternative in patients with AZA and 6-MP
intolerance of any kind. The idea of using a metabolite at the end of the enzymatic
pathway seems to be an attractive approach. In this study we prospectively studied 6-
TG short-term safety in AZA and 6-MP intolerant IBD patients. 
Methods
Patient Selection
Patients aged between 18 and 75 years attending the out-patient clinics of Maasland
Hospital Sittard, University Medical Center Nijmegen or Rijnstate Hospital Arnhem
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were eligible for the study if CD or UC was diagnosed for more than 6 months and an
established AZA or 6-MP intolerance was observed. Exclusion criteria were: pregnancy
or expected pregnancy within 6 months, inadequate contraception in women, lactation,
presence of active infection, history of tuberculosis, HIV, hepatitis B or C, severe
pancreatitis (necrotizing pancreatitis or pancreatitis leading to multi organ failure),
malignancy, ongoing treatment with other immunosuppressive drugs like ciclosporine,
methotrexate, thalidomide or infliximab, impaired renal function (serum creatinin > 2
times normal upper limit), impaired hepatic function (> 2 times normal upper limit) and
persistent bone marrow suppression. 
Study Design
The trial design was a prospective open-label multicentre study. At entry patient
demographics and anamnesis were recorded and medication-use during the past year
was obtained from the community pharmacy. 6-TG (LanvisTM, tablet 40 mg, Glaxo
Wellcome) was administered orally once daily in the evening in a dose of 20 mg (2
centres) or 40 mg (1 centre). Concomitant medication was continued. Safety parameters
were obtained at 0 (base-line), 1, 2, 4 and 8 weeks after start of medication. Blood was
drawn each visit for measurement of RBC 6-TG and 6-MMP levels, alanine transaminase
(ALT), aspartate transaminase (AST), bilirubins, amylase, lipase, leukocytes (plus
differentiation), platelets and haemoglobin (Hb). Dose-adjustments of 6-TG were carried
out by the attending physician based on one or more of the parameters mentioned
above. 
Ethics
The protocol was approved by the local medical ethics committee and in accordance
with the Helsinki Declaration. Informed written consent was obtained before enrolment.
Outcome Measures
Primary outcome measures were the ability to tolerate 6-TG and the occurrence of
adverse events during 8 weeks of 6-TG treatment. The relationship of the adverse event
with the use of 6-TG was established by the following method: unrelated, no temporal
relation and other aetiology likely; possibly related, potential temporal relation and
other aetiologies possible; probable related, potential temporal relation and other
aetiologies unlikely; related, clear temporal relation not otherwise explained. Secondary
outcome definitions included RBC 6-TG and 6-MMP levels, the occurrence of
haematological events (leukocyte count < 4.0x109/l, platelet count < 100x109/l) and the
occurrence of hepatic toxicity (ALT > 80 U/l, AST > 80 U/l, bilirubins >40 µmol/l,
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amylase > 220 U/l, or lipase >120 U/l (elevations > 2 times normal upper limit)). 
Analytical Procedures
Blood samples were taken at least 12 hours after medication intake. The samples were
centrifuged to isolate erythrocytes and after washing with PBS buffer solution,
erythrocyte counts were done. Samples were stored at  –20 °C until required. RBC 6-TG
and 6-MMP levels were measured in the laboratory of the Department of Clinical
Pharmacy, Maasland Hospital Sittard, using a slightly modified assay previously
reported by Lennard and colleagues [14]. In brief, the thiopurines are separated by
reversed-phase HPLC and quantified using UV-detection. For measurement of
intracellular thionucleotides the free base is obtained by acid hydrolysis of the
nucleotide back to the purine. The resulting purines are extracted from the biological
matrix by forming a phenyl mercury adduct into dichloromethane. During back-
extraction with hydrochloric acid the adduct is splitted and the free thiopurine is
liberated into the acid layer once again. The run-to-run coefficient of varation was 6.6%
and 9.7% for 6-TG and 6-MMP respectively. The detection limit of the assay was 30
picomoles/8x108 RBC for 6-TG and 300 picomoles/8x108 RBC for 6-MMP. 
Statistical Analysis
Data are expressed as means ± standard deviation. Significance was evaluated by the
Student t test for paired or independent data, p values < 0.05 were considered
significant. Pearson’s correlation was used to test the relationship between the measured
parameters. SPSS for Windows (version 10.0) software was used to perform statistics.
Role of the funding source
This study was not sponsored by external sources.
Results
Patients
Thirty two patients were enrolled, of whom 7 (22%) were male and 25 (78%) were female.
The mean age at entry was 37 years (range 19-64). Twenty-two patients (69%) were
suffering from CD and in 10 patients ( 31%) UC was diagnosed. Twenty-one patients (66%)
emerged AZA-intolerant, 5 (16%) could not tolerate 6-MP and 6 (19%) patients showed
intolerance for both thiopurines. AZA or 6-MP intolerance was established with
rechallenge in 12 patients (38%). The adverse events leading to discontinuation of AZA or
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6-MP included total malaise (41%), nausea & vomiting (38%), fever (25%), arthralgia
(13%), amylase elevations (13%), epigastric pains (13%), pancreatitis (amylase elevations
with symptoms) (9%), indefinite symptoms (9%), headache (6%), diarrhoea (3%), myalgia
(3%), erythema nodosum (3%), edema (3%) and pruritus (3%). In 10 patients  AZA or 6-
MP intolerance manifested itself within 2 weeks, in 5 within 1 month, in 6 within 2 months
and in 6 after 2 months. In 4 patients time to intolerance was not documented. The initial
dose of 6-TG was 20 mg daily in 19 patients and 13 received 40 mg a day. The mean initial
6-TG dose was 0.40 ± 0.03 mg/kg/day. The mean 6-TG dose during the 8 week period was
25.9 mg/day (range 10-40). 
Primary Outcomes
Twenty-six (81%) of the 32 subjects were able to tolerate 6-TG 20 or 40 mg 1dd during
the first 8 weeks. In 6 patients (19%) 6-TG was discontinued because of adverse effects.
Data of the 6-TG intolerant patients are summarised in table 1.
In 2 patients indefinite joints pains occurred on 40 mg 1dd that resolved after dose-
reduction to 20 mg 1dd. One patient temporary stopped after developing nausea on 40
mg 1dd that disappeared after restart on 20 mg 1dd. Another patient had a dry cough
and was not feeling well on 20 mg 1dd which resolved after dose-reduction to 20 mg
every 2 days. 
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Table 1
Adverse events leading to discontinuation of 6-thioguanine therapy
No. Initial Final Time Character of AE Relationship
dose dose to AE AE/6-TG 
(mg) (mg) (days)
1 20 20 24 nausea*, diarrhoea*, probable related
stomach cramps*
2 20 10 42 total malaise* possible related
3 20 20 7 fever*, erythema nodosum*, related
arthralgia*
4 20 10 7 nausea*, stomach cramps, probable related
headache*
5 20 20 35 rigid fingers possible related
6 40 40 10 indefinite stomach symptoms possible related
AE, adverse events; 6-TG, 6-thioguanine; *same AE as previously shown on AZA or 6-MP
Secondary Outcomes
RBC 6-TG and 6-MMP levels
Base-line RBC 6-TG levels were negative in all but 4 patients who just recently stopped
AZA (n=2) or 6-MP (n=2) therapy. Steady state 6-TG levels were significantly higher on
40 mg 1dd (1621 ± 828 picomoles/8x108 RBC) than on 20 mg 1dd (937 ± 325
picomoles/8x108 RBC, p=0.001) according on treatment analysis. RBC 6-TG levels were
considered to reach steady state after 4 weeks, having a half life of approximately 5 days
[15]. RBC 6-MMP levels were undetectable at all times during treatment with 6-TG,
except at base-line in the 4 patients mentioned before. Correlation was found between
dose and RBC 6-TG level (0.70, p=0.01). The mean RBC 6-TG level increased most during
in the first part of the 8 week period and levelled out between 4 and 8 weeks (figure 1).
Haematological events
No clinically relevant myelotoxicity occurred in the 8 week period. However, the mean
leukocyte count decreased significantly from base-line (11.4 ± 3.9x109/l) to 8 weeks of 6-
TG treatment (10.0 ± 4.1x109/l, p=0.008). Leukocyte counts were never below 4.0x109/l,
no leukopenia was observed. RBC 6-TG levels showed moderate correlation with
leukocyte counts (-0.29, p=0.01). A minor thrombocytopenia was observed in one patient
(platelet count: 130x109/l). In this cohort of 32 patients, platelet count neither decreased
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Figure 1
Mean RBC 6-TG levels during the first 8 weeks of 6-TG treatment
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nor correlated with RBC 6-TG level in the observed period. In addition no change in Hb
was established.
Hepatotoxicity
The ALT level was elevated > 80 U/l in one patient, but this was the case at base-line
already. The mean ALT level did increase significantly from 19.8 ± 19.9 U/l at base-line to
23.5 ± 25.7 U/l at 8 weeks, even though not clinically relevant. Amylase level was above
220 U/l (234 U/l) in one patient. Moderate correlation was found between RBC 6-TG level
and amylase level (0.30, p=0.01). No AST, bilirubins or lipase elevations were observed
and mean levels did not change during the 8 weeks. No correlation was found between
RBC 6-TG level on the one hand and ALT, AST , bilirubins or lipase for another. 
Discussion
6-TG was well tolerated during the first 8 weeks of treatment in 81% of patients with
previously established AZA or 6-MP intolerance. In some patients intolerance for AZA or
6-MP manifested itself after 8 weeks. Therefore, we must be reserved in drawing firm
conclusions as the number of patients with adverse events on 6-TG may increase over
time. Six patients (19%) were unable to complete the 8 week period on 6-TG. The
relationship of adverse events with 6-TG was unclear but possible in 3 of the 6 patients
whose 6-TG treatment ended prematurely. In 2 patients the side effects were probably 6-
TG related. In these patients, adverse events on 6-TG were very similar to the previous
side effects on AZA or 6-MP, suggesting a causal role for 6-TGN in the development of
these events. Moreover, these adverse events resolved after discontinuation of 6-TG. In
one patient the side effects were obviously 6-TG related, being identical and occurring at
exactly the same time as previously shown on AZA. Also, in this patient adverse events
disappeared with discontinuation of 6-TG. In 4 other patients transient side-effects
occurred, which all dissolved after a 50% dose-reduction (3 patients from 40 mg to 20 mg
daily and 1 patient from 20 mg to 10 mg daily). 
Mean RBC 6-TG levels were high in comparison with 6-TG levels measured in AZA or
6-MP treated patients. In the latter group we previously measured mean 6-TG level of
246 and 264 picomoles/8x108 RBC on AZA 100 mg 1dd and 6-MP 100 mg 1dd
respectively [16]. The mean steady state 6-TG levels after 6-TG as such once daily (20
mg: 937 picomoles /8x108 RBC; 40 mg: 1621 picomoles/8x108 RBC) were approximately
four- to sevenfold higher. This is consistent with the observations of Dubinsky and
colleagues [13]. In present study, RBC 6-TG levels were well above the proposed lower
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limit of 235 picomoles/8x108 RBC for therapy with AZA and 6-MP, which was associated
with efficacy. However, it remains unclear whether the same level should be used when
6-TG is given as such. Therefore, efficacy data from prospective randomised trials are
needed. 
RBC 6-TG level correlated significantly with the dose given. However, major inter-
individual differences occur as is seen with the other thiopurines [17,18]. Therapeutic
drug monitoring (TDM) may be a helpful tool in dosing 6-TG. In this study we used
TDM to control patient compliance and to prevent extremely high RBC 6-TG levels (>
2500 picomoles/8x108 RBC). The presumed period necessary to reach steady state of 4
weeks seems reliable, as the RBC 6-TG concentrations levelled out somewhere between
4 and 8 weeks after start of medication. In patients treated with AZA or 6-MP,
myelotoxicity is a major concern, which seems to be associated with 6-TG. However, in
the present study, despite high RBC 6-TG levels no leukopenia was observed in our 6-
TG treated patients. Although the mean leukocyte count decreased from base-line
(11.4x109/l) to 8 weeks of 6-TG treatment (10.0x109/l), the clinical relevance is restricted
as there still is a large margin to the critical lower limit of 4.0x109/l. A moderate inverse
correlation of leukocyte count with RBC 6-TG level was observed and because 6-TG
levels seemed to have reached a steady state, further leukocyte count reduction is
unlikely. The 6-MMP metabolite, which seems to have antiprolerative properties of its
own, may be an explanation for this finding [5,19]. No 6-MMP is formed, when a patient
is given 6-TG as such. In AZA or 6-MP treated patients however, substantial 6-MMP
levels arise, which may contribute to myelotoxicity. The role of 6-MMP needs further
elucidation. In spite of absence of leukopenia in this cohort of patients, alertness remains
mandatory as leukopenia is a serious complication. 
Mild thrombocytopenia occurred in one patient. This patient had a history of open heart
surgery and was still receiving antithrombotic prophylaxis during 6-TG treatment.
Thrombocyte count normalised without 6-TG dose-reduction and therefore a
relationship between thrombocytopenia and 6-TG treatment seems unlikely.
No serious hepatotoxic events occurred in the observed period, not even in the 5
patients which showed earlier hepatic or pancreatic events (amylase- or ALT elevations)
on AZA or 6-MP. In one patient the ALT level was elevated, but as this already was the
case before inclusion this elevation can not be accounted for by 6-TG treatment.
Furthermore in this patient ALT level decreased with ongoing therapy with 6-TG.
Although mean ALT levels builded up during 6-TG treatment to a value of 23.5 U/l, the
increase was of no clinical importance, as this is far from the standard upper limit of 40
U/l. In another patient the amylase level was slightly elevated which normalised after
6-TG dose was reduced from 40 mg to 20 mg once daily. Three patients with non-severe
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pancreatitis within 4 weeks of AZA or 6-MP treatment, did not develop pancreatitis in 8
weeks of 6-TG treatment. Unfortunately in only one of these patients a RBC 6-MMP level
was previously measured on 6-MP treatment and this level was substantial (4893
picomoles/8x108 RBC after 2 weeks on 6-MP 50 mg once daily). This may indicate a role
for 6-MMP in the development of pancreatitis in this patient. Although high RBC 6-
MMP levels are often detected in patients developing pancreatitis, sometimes
pancreatitis ensues despite the absence of 6-MMP [5,6]. The role of 6-MMP levels in the
occurrence of pancreatitis is still unclear.
Treatment with 6-TG seems a promising alternative in AZA and 6-MP intolerant IBD
patients. The results on short-term safety are encouraging for the future. However, long-
term safety in IBD has yet to be determined as adverse events like veno-occlusive
disease and portal hypertension are reported in 6-TG treatment of leukaemia. Also
efficacy has to be proven before 6-TG can be added to standard therapy. For future trials
a dose of 20 mg once daily results in presumably adequate RBC 6-TG levels and seems
well tolerated. The impact of high 6-TG levels during a longer period of time remains
unclear and merits further exploration for both efficacy- and safety reasons. 
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Abstract
Background: The use of 6-thioguanine may lead to an avoidance of toxic pathways as it
is directly converted to the pharmacologically active metabolites (the 6-
thioguaninenucleotides (6-TGN)). The aim of our study was to determine the tolerability
and safety profile of a low-dose maintenance therapy of 6-TG in azathioprine (AZA) or
6-mercaptopurine (6-MP) intolerant IBD patients over a treatment period of at least one
year. 
Method: Database analysis.
Results: Twenty out of 95 (21%) patients discontinued 6-TG (mean dose 24.6 mg) within
one year. Reasons for discontinuation were GI-complaints (31%), malaise (15%) and
hepatotoxicity (15%). Haematological events occurred in three patients, one
discontinued treatment. In the 6-TG tolerant group, 9% (7/75) could be classified as
hepatotoxicity. An abdominal ultrasound was performed in 54% of patients, one patient
had splenomegaly.
Discussion and Conclusions: The majority of AZA or 6-MP intolerant IBD patients (79%)
is able to tolerate maintenance treatment with 6-TG (dosaged between 0.3 to 0.4
mg/kg/day). 6-TG may still be considered as an escape maintenance
immunosupressant in this difficult to treat group of patients, taking into account
potential toxicity and efficacy of other alternatives. The recently reported hepatotoxicity
is worrisome and 6-TG should therefore only be administered in prospective trials. 
Introduction
Until now, no definite medical or surgical therapy is available for the treatment of
inflammatory bowel disease (IBD) as the aetiology remains essentially unknown.
Therefore, the aims of medical therapy in IBD are to relief symptoms and to prevent
long-term complications. Maintenance therapy should preferable be efficient, safe and
cost-effective. The immune modulating thiopurines 6-mercaptopurine (6-MP) and its
pro-drug azathioprine (AZA) have proven efficacy in active IBD and in maintenance of
an induced clinical remission (1). These thiopurines are prescribed on a large scale in
IBD. However, issues concerning delayed onset of activity, refractoriness and toxicity
have limited the general use of AZA and 6-MP. In previous reports, up to 20% of patients
discontinued AZA or 6-MP prematurely due to adverse events (2). The metabolism of
thiopurines has been partly elucidated in recent years (figure 1). The toxicity profile
depends at least partly on the generated metabolites of AZA and 6-MP (3). At first, AZA
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is converted to 6-MP by a non-enzymatic reaction, which is then converted by a multi-
step enzymatic pathway into a number of active, inactive or toxic metabolites. The
efficacy of AZA and 6-MP appears to be correlated with the formation of the 6-
thioguaninenucleotides (6-TGNs). During this complex metabolisation process possible
hepatotoxic metabolites are generated under influence of the enzyme thiopurine
methyltransferase (TPMT). The methylation products of 6-MP, 6-methylmercaptopurine
(6-MMP) and their ribonucleotides (6-MMPR), may be associated with hepatotoxicity
(3). Furthermore, flu-like symptoms, rash, pancreatitis and neutropenia induced by AZA
or 6-MP have recently been related to mutations in the inosine triphosphate
pyrophosphatase (ITPase) gene leading to accumulation of the proposed metabolite thio
inosine triphosphate (4). A possible strategy to avoid AZA or 6-MP induced toxicity is
the administration of a thiopurine, which is metabolically closer to the 6-TGNs. The
thiopurine 6-thioguanine (6-TG) is an attractive candidate, which has the advantage of
being directly converted to 6-TGNs (5). Therefore, treatment and safety outcomes might
be less sensitive for intra- and inter-individual metabolic variations. Furthermore, due
to the relative simple metabolisation, the number of possibly toxic metabolites is
strongly reduced. Several open label studies in patients with IBD have shown promising
efficacy and acceptable short-term toxicity of 6-TG (6,7). More recently, the use of 6-TG
has been associated with the induction of nodular regenerative hyperplasia of the liver
(NRH). The aim of the present study was to determine the tolerability and safety profile
of a low-dose maintenance therapy with 6-TG in AZA or 6-MP intolerant IBD patients
over a treatment period of at least one year. 
Material and Methods
Patient selection
The study is a retrospective database analysis exploring the tolerability and safety of 6-
TG over at least a one-year treatment period in AZA or 6-MP intolerant IBD patients,
treated in participating university and district hospitals in the Netherlands. In each
patient, the attending physician judged the indication for administration of 6-TG. Some
patients have been described earlier in a short safety assessment of 6-TG (6). Patients
were eligible for the study if they met the following in- and exclusion criteria. Inclusion
criteria were: age between 18 and 75 years, presence of confirmed CD or UC with an
indication for immunosuppressive therapy but in whom standard AZA or 6-MP therapy
failed due to adverse events. Immunosuppression was indicated in case of chronic active
disease, corticosteroid dependency or recurrent disease. Exclusion criteria were
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pregnancy, lactation, presence of active infection, history of tuberculosis, HIV, hepatitis
B or C, history of severe pancreatitis (necrotizing pancreatitis or pancreatitis leading to
multi-organ-failure), ongoing treatment with concomitant immunosuppressive drugs
(e.g. cyclosporine, methotrexate, thalidomide or infliximab), impaired renal function
(serum creatinin > 2 times normal upper limit), impaired hepatic function (> 2 times
normal upper limit) and persistent bone marrow suppression. 
Study design
In all patients, 6-TG (Lanvis®, tablet 40 mg, Glaxo Wellcome) was administered orally in a
dose of 20 to 40 mg once daily based on the decision of the attending physician. The
following data were collected: patient demographics, history of thiopurine exposure, type
of thiopurine intolerance, the use of concomitant medication, blood cell counts and liver
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Figure 1
Metabolisation process of thiopurines
Azathioprine (AZA) is degraded to 6-mercaptopurine (6-MP) and nitromethyl-
imidazole, via a non-enzymatic step. Three competing enzymes metabolize 6-MP.
Xanthine oxidase (XO) inactivates 6-MP to thiouric acid (TUA). Thiopurine methyl
transferase (TPMT) methylates 6-MP, the formed 6-methylmercaptopurine (6-MMP) is
associated with hepatotoxicity. By hypoxanthine phosphoribosyl transferase (HGPRT)
6-MP is catalysed to 6-thio inosine monophosphate (6-TIMP), then via inosine
monophosphate dehydrogenase (IMPD) to 6-thioxanthosine monophosphate (6-
TXMP), ultimately leading to the pharmacologically active 6-thioguaninenucleotides
(6-TGN) via the enzyme guanosine monophosphate synthetase (GMPS). 6-TIMP can
also be methylated to 6-methyl thio inosine monophosphate (6-MTIMP). In a normal
useless cycle 6-TIMP is phosphorylated by monophosphate kinase (MPK) to 6-thio
inosine diphosphate (6-TIDP), subsequently by diphosphate kinase (DPK) to 6-thio
inosine triphosphate (6-TITP) and ultimately back to 6-TIMP due to the inosine
triphosphate pyrophosphatase (ITPase). When ITPase activity is impaired or lacking,
6-TITP accumulates. 6-Thioguanine (6-TG) is directly converted by HGPRT to the
6TGNs. XO and TPMT metabolize 6-TG to 6-methyl-thioguanine (6-MTG) and 6-
thiouric acid, respectively. ITPase has no known role in the metabolism of 6-TG. 
enzymes were recorded. During the one-year follow-up, dose and duration of 6-
thioguanine, occurrence of adverse events, blood cell counts and liver enzymes were
collected. During the described period the genotyping of TPMT became available and in
a subgroup of patients the TPMT status was determined. Red blood cell (RBC) 6-
thioguanine nucleotide (6-TGN) levels were determined at least four weeks after giving
a stable dose in order to obtain steady-state levels of 6-TGN. Dose adjustments were left
to the discretion of the attending physician, but when 6-TGN levels were above 1000-
1500 pmol/8x108 RBC, dose reduction was contemplated. In case of a leukocyte count
below 3.5 .109/l, dose reduction was advocated and in case of severe leucopenia (below
1.0 x 109/l) 6-TG had to be discontinued. Additionally, in order to explore signs of
hepatotoxicity, an abdominal ultrasonography was advised after at least one-year 6-TG
administration. Special attention was paid to splenomegaly, signs of portal hypertension
and hepatic changes.
Outcome measurements
Primary outcome measures were the ability to tolerate 6-TG and the occurrence of
adverse events leading to discontinuation of 6-TG over the one-year period. The
relationship of any adverse event with the use of 6-TG was established by the
following method: unrelated, no temporal relation and other aetiology likely;
possibly related, potential temporal relation and other aetiologies possible; probable
related, potential temporal relation and other aetiologies unlikely; related, clear
temporal relation not otherwise explained. Secondary outcome measures were the
occurrence of haematological events (defined as leukocyte count < 4.0x109/l or
platelet count < 100x109/l), the occurrence of hepatotoxicity (defined as a rise of at
least two times the upper normal limit of a single liver enzyme level),
pancreaticotoxicity (serum amylase > 220 U/l) and signs of liver related
abnormalities on the abdominal ultrasound. Although the present study was not
focused on 6-TG efficacy, erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), serum albumin and a global physician assessment score (features were same,
better or worse) were analysed as surrogate efficacy measures.
6-TG metabolite monitoring and genotyping of TPMT 
Blood samples for 6-TGN measurements were obtained at least 4 weeks after the onset
of a stable 6-thioguanine dose. The samples were centrifuged to isolate erythrocytes and
after washing with PBS buffer solution, erythrocyte counts were done. Samples were
stored at –20 °C until required. RBC 6-TGN levels were measured in the laboratory of
the Department of Clinical Pharmacy, Maasland Hospital Sittard, using a proprietary
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modified previously published assay (8). The lower limit of quantification of the assay
was 30 picomoles/8x108 RBC for 6-TGN levels with a run-to-run coefficient of variation
of 6.6%. Extra blood samples were drawn once during the one-year period to assess
TPMT (G238C, G460A and A719G, i.e. TPMT*1, TPMT*2, TPMT*3A, TPMT*3B,
TPMT*3C) genotypes in a sub-group of patients, independent of the biochemical or
clinical status. The genotyping was performed at the Department of Gastroenterology
and Hepatology at the Academic Medical Centre in Amsterdam.  
Statistical analysis
Data are expressed as mean ± standard deviation. Significance was evaluated by the
Student t test for paired or independent data; P values of less than 0.05 were considered
significant. Pearson’s correlation was used to determine relationships between
parameters. A chi square test was used to determine the significance between the TPMT
genotype and 6-TG intolerance. SPSS for windows version 11.0 was used for statistical
analysis. 
Results
Patients
Ninety-five patients were enrolled in the period June 2001 to July 2003. Fifty-eight
patients (61%) were female (mean age: 40 years, range:20-74) and 37 (39%) were male
(mean age:47 years, range: 20-71). Forty-two (44%) patients were diagnosed with UC
compared to 53 (56%) patients with CD. All patients were intolerant to AZA, 6-MP or
both. The adverse events leading to discontinuation of AZA or 6-MP use were
gastrointestinal complaints, general malaise, allergic reactions, hepatotoxicity or
myelotoxicity. The patients characteristics are given in detail in table 1. The mean initial
6-TG dose was 24.6 mg (range 20-40 mg). The mean initial 6-TG dose adjusted to
bodyweight was 0.37 mg/kg (SD 0.16).
Primary outcomes
Seventy-five (79%) of the 95 patients were able to tolerate 6-TG during one year use. In
20 (21%) patients the administration was discontinued due to side effects. The 20
intolerant patients encountered 26 side effects. The data concerning the adverse events
leading to withdrawal and the relationship with 6-TG use are summarized in Table 2. No
mortality was reported. The mean 6-TG dosage was 0.30 mg/kg in the tolerant group
compared to 0.34 mg/kg in the intolerant group (n.s.). 
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Table 1
Patient characteristics
N=95 patients
Female : male 58 : 37 patients
Age 43 years (range 20-74)
UC : CD 42 : 53 patients
Duration of IBD at start 6-TG 10.4 years (SD 9.4)
AZA intolerance 78 patients (82%)
6-MP intolerance 4 patients (4%)
AZA and 6-MP intolerance 13 patients (14%)
AZA or 6-MP rechallenge 36 patients (38%)
Adverse events on AZA or 6MP: 30% = gastrointestinal complaints 
20% = general malaise
14% = allergic reactions
10% = pancreaticotoxicity
6%   = hepatotoxicity
5%   = myelotoxicity 
14%  = miscellaneous (e.g. myalgia or alopecia)
6-TG dosage at the start 24.6 mg (range 20-40 mg)
Table 2
Adverse events (N=26) leading to discontinuation of 6-TG use in 20 patients
AE on 6-TG Frequency Mean time Relationship with 6-TG
to AE (days) 
G.I. complaints 8/26 (31%) 43 Probably 6/8 Possibly 2/8
Hepatotoxicity 4/26 (15%) 182 Probably 2/4 Possibly 1/4 Unrelated 1/4
Myelodepression 1/26 (4%) 50 Related
Pancreaticotoxicity 1/26 (4%) 103 Possibly
General malaise 4/26 (15%) 51 Probably 3/4 Possibly 1/4
Allergic reaction 1/26 (4%) 1 Related 
Other AE 7/26 (27%) 39 Related 1/7 Probably 2/7 Possibly 4/7   
AE = adverse event; 6-TG=6-thioguanine; G.I. complaints= gastrointestinal complaints
Secondary outcomes
Haematological events
Three patients had signs of myelosuppression. One patient had a leukocyte count of 3.2
x 109/l and a platelet count of 70 x 109/l after 50 days of 6-TG use (20 mg). Subsequently,
6-TG was discontinued. The second patient had a leucopenia (leucocytes 3.5 x 109/l) and
a third patient had a thrombocytopenia (platelets 87 x 109/l) at one year measurements,
both did not discontinue 6-TG. All other patients, both tolerant and intolerant to 6-TG,
had platelet and leucocyte counts above the set lower limits. However, the mean platelet
count decreased significantly from baseline (309 x 109/l) to one year of 6-TG treatment
(290 x 109/l, P=0.033). The mean leucocyte count decreased as well (from 11.9 to 7.8 x
109/l) though not significantly. The 6-TGN level did not correlate with the decrease in
both leucocytes or platelets counts. Haemoglobin levels remained unchanged in both
patient groups. 
Hepatotoxicity and pancreaticotoxicity
In the 6-TG tolerant group the ASAT, ALAT, gGT and AF levels were determined in 65%,
71%, 60% and 68% of patients at one year 6-TG use, respectively. The mean levels of
ASAT, ALAT, gGT and AF were 24.7 U/l (range 6-118), 24.5 U/l (range 5-206), 48 U/l
(range 6-535) and 84 U/l (range 42-322), respectively. A significant increase in liver
enzymes during treatment in the tolerant group was not established. No correlation was
found between the 6-TGN level and ALAT, ASAT, gGT or AF levels. At one year use, in
nine percent of patients (7/75) hepatotoxicity occurrence on 6-TG treatment could be
classified. Four patients (4/20) of the intolerant group discontinued 6-TG use due to
hepatotoxicity. All had normal liver tests at entry and three of these patients encountered
allergic reactions but no hepatotoxicity on the prior AZA therapy. Three patients had a
serum amylase level above 220 U/l before the start of 6-TG that all became normal
during treatment. One patient developed a transitory symptomatic pancreatitis with a
serum amylase level of 430 U/l during 6-TG treatment and discontinued treatment. 
Abdominal ultrasonography and liver histology
In 51 patients (54%) an abdominal ultrasonography was performed after at least one
year 6-TG use. Five ultrasounds were considered as abnormal; three patients with
steatosis, one patient had a choledocholithiasis and the last patient had a hydrops of the
gallbladder and a splenomegaly (spleen size 13 cm). The latter two patients were
classified as hepatotoxicity on 6-TG treatment. A liver biopsy was performed in one 6-
TG tolerant patient with elevated liver enzymes during 6-TG administration. Steatosis
was found but no nodular regenerative hyperplasia could be detected. 
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Efficacy of 6-TG
No significant decrease in CRP (15 to 11 mg/l) or ESR level (15 to 14 mm) was
established in the 6-TG tolerant group. The albumin level increased (37.6 to 40.1 g/l)
significantly in the tolerant group (P=0.002). A significant decrease of albumin level (38.5
to 36.6 g/l) was established in the intolerant group (P=0.03). The global physician score
was determined at one year 6-TG use in 85% (64/75) of the tolerant patients. Forty-seven
patients (73%) were classified as better, 15 patients (23%) as the same and four patients
(6%) as worse during 6-TG treatment.     
6-TG metabolite monitoring and genotyping of TPMT
The mean steady state 6-TGN level, determined in 63% (47/75) of the tolerant patients,
was 540 picomoles/8x108 RBC (SD 245, range 0 – 1404). In the eight intolerant patients
in whom metabolite levels were measured (40%), the 6-TGN level was 725
picomoles/8x108 RBC (SD 422, range 229 – 1563). The TPMT genotyping was performed
in 51 patients (54%). Two patients (3.9%) had one mutant non-functional allele
(TPMT*3A and TPMT*3C) and both patients were intolerant for 6-TG (myelodepression
and hepatotoxicity) (significant, P=0.003). The 6-TGN level was not determined in both
patients. Patients with two mutant non-functional alleles of TPMT (homozygous
mutants) were not found in our population. 
Discussion
In this group of AZA or 6-MP intolerant IBD patients, we demonstrated that 6-TG in
dosages of 0.3 to 0.4 mg/kg daily was well tolerated over a period of one year as a
maintenance immunosuppressant in 79% of the patients. This result suggests that
during the metabolisation process of AZA or 6-MP metabolites are generated that
induce side effects which at least in part are not generated during the 6-TG
metabolism. No mortality was reported due to 6-TG use and no irreversible side
effects were observed. In case 6-TG was discontinued due to side effects, these effects
resolved spontaneously. One patient developed a myelodepression that may be
explained by the impaired TPMT activity, probably shunting 6-TG away from
methylation by TPMT towards the formation of 6-TGNs, which have been associated
with myelotoxicity. Unfortunately, no 6-TGN level was determined in this patient.
The real incidence of 6-TG related hepatotoxicity in the present study remains
unknown, as no liver biopsies were performed. However, the incidence of 6-TG
related increase in liver enzymes probably will be lower than 7 out of 75 patients,
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because two patients already had abnormal liver tests before the start of 6-TG and one
patient had a symptomatic choledocholithiasis. 
In the present study we found a mean 6-TGN level of 540 picomoles/8x108 RBC in the
tolerant group which is above the proposed therapeutic threshold of 250
picomoles/8x108 RBC and even higher than the proposed upper limit of efficacy (400
picomoles/8x108 RBC) under AZA or 6-MP therapy (9,10). This is consistent with
previous observations (6,7). It remains to be elucidated whether the same 6-TGN limits
should be used when 6-TG is administered. In this study 73% clinically benefited from
6-TG use by using surrogate efficacy markers as a global physician score and albumin
levels. However, due to the retrospective nature of the study, we must be reserved in
drawing firm conclusions as no standard efficacy parameters as the Crohn’s disease
activity index (CDAI) or Truelove-Witts index were used. Therapeutic drug monitoring
seems a helpful tool in dosing 6-TG, especially, as there is a large inter-patient variability
in 6-TGN levels. Extremely high 6-TGN levels can be prevented and compliance can be
monitored.  
The TPMT status has been associated with the ability to tolerate AZA or 6-MP. Patients
with impaired TPMT activity are more prone to develop a myelodepression (11).
However, our study demonstrates that in AZA or 6-MP intolerant patients only two
patients (3.9%) had one mutant TPMT allele which is even lower than the incidence in
the normal Caucasian population (12). Interestingly, both patients did not develop a
myelodepression on AZA therapy. This indicates that other metabolic pathways may
lead to toxicity of AZA or 6-MP as was recently demonstrated for the ITPase routing
(Zelinkova et al., submitted for publication). However, both patients with one mutant
TPMT allele discontinued the use of 6TG. Unfortunately, in these patients no 6-TGN
concentrations were measured before discontinuation of 6-TG. Possibly, an impaired
TPMT activity leads to more 6-TG being metabolised by the enzymes hypoxanthine
guanine phosphoribosyl transferase or xanthine oxidase leading to higher 6-TGN and 6-
thiouric acid levels, respectively (figure 1). The accumulation of these metabolites may
lead to intolerance of 6-TG.  
Recently, the use of 6-TG in IBD patients has been associated with the induction of NRH
and VOD (13). In the present study, we performed an abdominal ultrasonography after
at least one year 6-TG use to screen for possible hepatotoxicity in 51 patients. Only one
patient showed signs of portal hypertension indicated by an enlarged spleen. NRH has
been associated with a thrombocytopenia (13) and in our evaluation only two patients
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had platelets counts below 100 U/l. We are well aware of the fact that by using
biochemistry and ultrasound outcomes, we probably underestimate the real incidence
of 6-TG induced NRH, as the golden standard is based on histology. Additionally, liver
tests abnormalities were shown not to be indicative for NRH. Conversely, it should be
taken into account that AZA and 6-MP can induce NRH or VOD as well but performing
liver biopsies during treatment with these compounds is not recommended in clinical
practice. 
Currently, the use of 6-TG in IBD is abandoned due to potential hepatotoxicity (13).
However, low dose 6-TG may still be considered as an escape maintenance strategy in
AZA or 6-MP intolerant IBD patients whom are refractory for alternative therapies. The
number of proven effective medical maintenance options is scarce for these patients.
Methotrexate (MTX) has a reasonable toxicity profile and seems effective in CD,
comparable with AZA or 6-MP (14) but the potential use of MTX in UC patients has yet
to be proven. In addition, long-term use of MTX may be limited (15). Cyclosporine
seems to have no role as a maintenance immunosuppressive alternative in IBD (16).
Infliximab can be administered as a maintenance option in CD with acceptable toxicity
and may be effective in treating UC. However, concomitant immunosuppressive
therapy with thiopurines or MTX next to the infliximab therapy seems mandatory to
reduce the immunogenic response (17). 
Treatment with 6-TG is well tolerated in AZA and 6-MP intolerant IBD patients and
seems to be effective. We believe that low dosed 6-TG (0.3 to 0.4 mg per kilogram daily)
maintenance therapy may still be an escape option for this difficult to treat group of
patients. The benefit of 6-TG use in this sub-group may balance its toxicity profile,
especially taking into account the toxicity and efficacy of other therapeutic alternatives.
Still, the reported hepatotoxicity is worrisome and 6-TG should therefore only be
administered in prospective clinical trials. 
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In deze bijdrage wordt een overzicht gegeven van de huidige inzichten in de
medicamenteuze behandeling van patiënten met een inflammatoire darmziekte. Er
wordt niet ingegaan op ondersteunende behandelingen zoals symptoombestrijding of
bijvoorbeeld vitamine suppleties. In de introductie wordt besproken met welke factoren
rekening gehouden dient te worden bij de therapie van keuze. Na de introductie komen
verschillende categorieën geneesmiddelen aan bod die frequent gebruikt worden bij de
behandeling van deze patiënten. 
Achtergrond
De inflammatoire darmziekten colitis ulcerosa en de ziekte van Crohn worden
gekenmerkt door chronische idiopatische ontsteking in het maagdarm kanaal. Met de
thans beschikbare medicamenteuze opties zijn beide ziekten niet te genezen. De
medicamenteuze behandeling is dan ook gericht op verbetering van symptomen en
preventie van complicaties. Daardoor kan de noodzaak van herhaald operatief
ingrijpen beperkt worden. Aangezien inflammatoire darmziekten chronisch zijn
dient het behandelplan bij iedere patiënt gericht te zijn op de lange termijn. In het
algemeen kunnen twee fasen in de behandeling worden onderscheiden, te weten een
inductie fase met als doel om actieve ziekte tot rust te brengen en een onderhoudsfase
met als doel om ziekte in een rustige fase te houden en complicaties te voorkomen.
Voor beide fasen geldt dat de keuze voor de meest geschikte middelen afhangt van
de diagnose, de ziektelokalisaties en van de mate van ziekteactiviteit. Hoewel er
grote overlap bestaat tussen de middelen die bij de ziekte van Crohn en colitis
ulcerosa worden gebruikt, kan de effectiviteit belangrijk verschillen tussen beide
ziektebeelden. Dit kan voor een deel verklaard worden door verschillen in de aard
van de ontsteking in de darm. Voor de keuze van middelen die gebruik maken van
een lokaal effect of van gereguleerde afgifte is kennis van betrokken ziektelokalisaties
van belang. De ernst van ziekte activiteit is van belang omdat er niet alleen
verschillen bestaan in effectiviteit, maar ook in de snelheid waarmee het effect
verwacht kan worden. Daarnaast is bij de therapiekeuze de balans tussen
werkzaamheid en veiligheid van belang. Van oudsher worden de gebruikte
medicamenten onderverdeeld in categorieën oplopend in mogelijke effectiviteit en
potentiële toxiciteit (Tabel 1). Deze volgorde aanhoudend zullen we de verschillende
categorieën bespreken.
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5-Aminosalicylaten
Het oudste middel uit deze groep is salazopyrine, hetgeen bestaat uit 5-
aminosalisylzuur (5-ASA) en sulfapyridine, verbonden door een dubbele stikstof
binding. Deze binding wordt gesplitst door de darm flora, zodat de werkzame
component 5-ASA pas in de dikke darm vrijkomt. Het sulfapyridine is verantwoordelijk
voor het merendeel van de bijwerkingen. Wanneer 5-ASA oraal wordt gegeven zal vrij
5-ASA proximaal in de dunne darm worden geresorbeerd. Daarom zijn preparaten
ontwikkeld om 5-ASA gereguleerd af te geven. Olsalazine is een 5-ASA dubbel
molecuul, waarbij gebruik gemaakt wordt van dezelfde dubbele stikstof binding,
waardoor twee 5-ASA moleculen vrijkomen. In geval van mesalazine wordt de 5-ASA
verpakt in een coating met gereguleerde afgifte, zodat 5-ASA vrij kan komen in het
ileum en/of de dikke darm (1). Naast verschillende preparaten voor orale toediening is
mesalazine ook lokaal in het rectum toe te dienen in de vorm van een zetpil of klysma.
Bij patiënten met een milde tot matig actieve colitis ulcerosa zijn vele placebo
gecontroleerde studies verricht. In een systematische review bleken de 5-ASA
preparaten bewezen effectief in het verkrijgen van remissie met een Odds ratio van 0.51
voor 5-ASA versus placebo (95% CI 0.35-0.76) (2). Bovendien laten de gecontroleerde
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Tabel 1
Geregistreerde geneesmiddelen voor de behandeling van inflammatoire darmziekten.
Categorie Geneesmiddel Toediening
Oraal Rectaal Intraveneus
5-Aminosalicylaten Salazopyrine + + --
Mesalazine + + --
Olsalazine + -- --
Corticosteroïden Betamethason + + +
Beclomethason -- + --
Budesonide + + -
Dexamethason + -- +
Methylprednisolon -- -- +
Prednisolon + + +
Immunosuppressiva Azathioprine + -- +
Infliximab -- -- +
Van de geregistreerde geneesmiddelen wordt de beschikbaarheid aangegeven voor
verschillende toedieningsvormen (+ beschikbaar; -- niet beschikbaar) Bij rectale
toediening is in deze tabel geen onderscheid gemaakt tussen een zetpil of klysma. 
studies zien dat 5-ASA preparaten effectief zijn in het behouden van remissie van colitis
ulcerosa (Odds ratio 0.47, 95% CI 0.36-0.62). In deze studies waren mesalazine en
salazopyrine nagenoeg vergelijkbaar ten aanzien van effectiviteit met een gering
voordeel voor salazopyrine (Odds ratio 0.84, 95% CI 0.57-1.24). Deze effectiviteit gaat
gepaard met een mild bijwerkingen profiel met slecht een zeer geringe kans op ernstige
bijwerkingen. Hoewel er inmiddels meerdere beschrijvingen zijn verschenen van 5-ASA
geïnduceerde niertoxiciteit, hepatitis of pancreatitis zijn deze bijwerkingen zeldzaam.
Omdat de nierfunctie stoornissen vaak nog reversibel zijn na tijdig staken van de
behandeling wordt geadviseerd om een serum kreatinine te controleren vóór en relatief
kort na aanvang van behandeling en 1x per jaar daarna.
Anders dan bij colitis ulcerosa staat de effectiviteit van 5-ASA bij de ziekte van Crohn
sterk ter discussie. Bij milde ziekte activiteit laten de meeste placebo gecontroleerde
studies een geringe winst zien van 5-ASA, waarbij remissie verkregen werd bij circa 40%
van de patiënten ten opzichte van circa 20% bij placebo. De resultaten van remissie
studies zijn niet consistent en laten geen duidelijk aantoonbare effectiviteit zien op de
langere termijn ten aanzien van behoud van remissie. Wel lijkt er enige relatie te zijn met
de gebruikte dosis ten voordele van doseringen boven de 2 gram per dag. Omdat 5-ASA
preparaten weinig bijwerkingen laten zien werden ze ondanks geringe effectiviteit toch
op grote schaal voorgeschreven bij de ziekte van Crohn.
Mogelijk komt er een extra argument bij om patiënten langdurig met 5-ASA
preparaten te behandelen. Er zijn inmiddels aanwijzingen dat deze middelen de kans
op het ontwikkelen een dikke darm carcinoom kunnen verkleinen. Dit is belangrijk
omdat patiënten met dikke darm lokalisaties van een inflammatoire darmziekte een
verhoogde kans hebben op ontwikkelen van dikke darm kanker. Het
chemopreventieve effect van 5-ASA is echter nog onvoldoende aangetoond om alleen
op grond hiervan langdurige therapie voor te schrijven.
Corticosteroïden
Uitgaande van prospectief gecontroleerde studies zijn corticosteroïden zeer krachtig bij
het in remissie brengen van actieve inflammatoire darmziekten. Bij actieve colitis
ulcerosa werden remissie percentages bereikt van 60-70% en bij de ziekte van Crohn 50-
60% volgens de harde criteria in deze studies. Toch staan deze middelen zowel bij
patiënten als bij hun behandelaars in een kwaad daglicht. Deze schijnbare discrepantie
valt voornamelijk te verklaren door de hoge frequentie van hinderlijke bijwerkingen die
met deze therapie gepaard gaan. Bovendien ontbreken bewijzen van effectiviteit op de
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lange termijn (3). Corticosteroïden hebben dan ook voornamelijk een plaats bij het
induceren van een rustige ziektefase. In de dagelijkse praktijk worden hiervoor vele
schema’s gebruikt. Bij actieve ziekte lijkt prednison in een aanvangsdosering van 40 mg
per dag per os adequaat, waarna de dosis geleidelijk wordt afgebouwd, bijvoorbeeld
twee weken 40 mg, twee weken 30 mg en daarna per 2 weken 5 mg verminderen.
Er zijn strategieën ontwikkeld om met behoud van effectiviteit minder bijwerkingen
te induceren. Dit kan door locale behandeling met behulp van klysma’s toe te passen
die beclometason of budesonide bevatten. Deze stoffen worden na opname in de
circulatie snel onwerkzaam gemaakt door een hoge afbraak in de lever. Budesonide
is eveneens voor orale toediening beschikbaar in de vorm van capsules met een
gereguleerde afgifte. Doordat de afgifte plaats vindt in het ileum en tenminste in het
rechtszijdige colon, is budesonide geregistreerd voor patiënten met de ziekte van
Crohn. De 2 beschikbare varianten verschillen in samenstelling van de coating
waardoor er mogelijk relevante verschillen zijn in het afgifte profiel. In
gecontroleerde studies bij actieve Crohn is budesonide 9 mg per dag bijna even
effectief in het induceren van remissie als prednison 40 mg met een afbouw schema
in 2 tot 3 maanden (4). Bovendien treedt er tijdens behandeling met budesonide een
sterke reductie op van corticosteroïd gerelateerde symptomen zoals acné en het
vollemaansgezicht. Deze reductie van corticosteroïd gerelateerde symptomen wordt
ondersteund door bijnier functietesten die in meerdere studies zijn verricht. Er is dan
ook een plaats voor budesonide bij het induceren van remissie bij patiënten met de
ziekte van Crohn, gelokaliseerd in het ileum en of rechtszijdige colon. Tot op heden
is niet duidelijk aangetoond dat budesonide effectief is als onderhoudsbehandeling
zodra patiënten in remissie zijn gekomen. Placebo gecontroleerde studies laten
namelijk wel een verlenging zien van de periode tot aan het weer actief worden van
de ziekte, maar na een behandelperiode van 1 jaar met doseringen tot 6 mg per dag
is er geen winst ten aanzien van het behouden van remissie (5). In een recente
prospectief gerandomiseerde remissie studie lijkt structurele verhoging van 6 mg
naar 9 mg per dag gedurende 1 jaar geen verhoging te geven van het remissie
percentage.
Immunosuppresiva
Thiopurines
Er is een belangrijke rol weggelegd voor medicamenten die in staat zijn om ziekte
activiteit langdurig te voorkomen. Corticosteroïden zijn hiervoor niet geschikt en 5-
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ASA preparaten veelal onvoldoende effectief. Daarom worden immuunsuppressieve
middelen op grote schaal gebruikt. De regelmatig gebruikte geneesmiddelen uit deze
categorie staan samengevat in Tabel 2. Van deze middelen is alleen azathioprine
(AZA) geregistreerd voor inflammatoire darmziekten. De thiopurines 6-
mercaptopurine (6-MP) en AZA zijn bewezen effectief in het behouden van klinische
remissie en in reductie van corticosteroïden gebruik. In een systematisch overzicht
met betrekking tot behoud van remissie bij de ziekte van Crohn werd ten opzichte
van placebo een Odds ratio van 2.2 (95% CI 1.35-3.47) gevonden ten gunste van AZA
(6). Grootschalige toepassing van deze thiopurines wordt beperkt door potentieel
ernstige bijwerkingen zoals beenmerg en lever toxiciteit en de verhoogde kans op
pancreatitis. In totaal komen bijwerkingen die leiden tot het voortijdig staken van
AZA of 6-MP voor bij circa 20% van de patiënten. De meeste van deze bijwerkingen
zijn echter niet ernstig en van tijdelijke aard. Klinisch relevante beenmerg toxiciteit
wordt bij circa 4% van de IBD patiënten waargenomen die behandeld worden met
AZA of 6-MP en klinische tekenen van lever of pancreas toxiciteit bij minder dan 4%
van deze patiënten. Recent zijn nieuwe inzichten verkregen in het complexe
metabolisme van thiopurines. AZA is een pro-drug dat eerst wordt omgezet in 6-MP,
waarna 6-MP via een serie enzymatische stappen wordt omgezet in 6-thioguanine
nucleotiden (6-TGN), welke de meest effectieve metabolieten van AZA blijken te zijn.
Onder invloed van het enzym thiopurine methyltransferase (TPMT) kunnen de
verschillende tussenproducten gemethyleerd worden. Door de vele stappen van AZA
tot 6-TGN en door de genetisch bepaalde variatie in TPMT activiteit is er slechts een
matige correlatie tussen de AZA dosis en bloedspiegels van 6-TGN. In studies
bedraagt de optimale dosering van AZA 2 tot 2,5 mg per kilo lichaamsgewicht,
hetgeen overeenkomt met 1-1,5 mg/kg 6-MP. Bepaling van het bloedbeeld na
aanvang van behandeling is noodzakelijk om een leukopenie tijdig op te sporen. Het
lijkt voldoende om dit te controleren bij aanvang van therapie en na 2 en 8 weken,
gevolgd door 1x half jaar. Bij een leukopenie (< 3.0 x109/l) als uiting van beenmerg
toxiciteit dient de dosering verlaagd te worden of bij ernstige leukopenie (< 1.0
x109/l) gestaakt te worden. Er bestaat veel discussie over de waarde van TPMT
bepalingen voorafgaande aan behandeling. Hiermee kunnen 1 op de 300 patiënten
geïdentificeerd worden met nagenoeg afwezige TPMT activiteit en daardoor hoge
kans op ernstige leukopenie. De meerderheid van leukopenieën ontstaan echter bij
patiënten met een normale TPMT activiteit en niet in de eerste weken, zodat het
noodzakelijk blijft om het leukocyten aantal ook na langere tijd te monitoren bij alle
patiënten.
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Methotrexaat
Methotrexaat (MTX) heeft als immuun suppressief middel een duidelijke plaats in de
behandeling van reumatoïde artritis (RA) en psoriasis. Al vanaf 1989 zijn er enkele
trials met MTX in lage doseringen beschreven bij inflammatoire darmziekten. MTX
kan wekelijks oraal, subcutaan of intramusculair worden toegediend, maar in de
beschikbare trials lijkt parenterale toediening effectiever te zijn. De biologische
beschikbaarheid na orale toediening varieert van 45-100%. Uit studies bij RA blijkt de
farmacokinetiek van subcutane en intramusculaire toediening niet te verschillen,
zodat uit oogpunt van patiënt vriendelijkheid de subcutane toediening de voorkeur
heeft. Bij patiënten met een chronisch actieve Crohn die onvoldoende reageren op
prednison zijn er aanwijzingen dat MTX in een dosis van 15 tot 25 mg per week
effectief is in het induceren van remissie (7). Bovendien lijkt onderhoudsbehandeling
met MTX effectief in behoud van remissie bij patiënten met een initiële respons op
MTX over een periode van 40 weken (8). In een kleine gerandomiseerde studie (54
patiënten) was er geen verschil in effectiviteit tussen wekelijkse toediening van MTX
en dagelijks toediening van AZA 2 mg/kg over een periode van 6 maanden, waarbij
deze patiënten tevens behandeld werden met prednison. Er is momenteel slechts 1
gerandomiseerde gecontroleerde studie met MTX beschikbaar bij patiënten met
colitis ulcerosa, waarbij geen verschil ten opzichte van placebo werd waargenomen.
Het betrof echter een kleine (67 patiënten) studie met een lage dosis en oraal
toegediende MTX (12.5 mg/week). Het bijwerkingen profiel verschilt van de
Tabel 2
Gebruik van immunosuppressiva bij inflammatoire darmziekten.
Geneesmiddel Toediening Remissie inductie Behoud van remissie
Crohn CU Crohn CU
Azathioprine p.o. en i.v. +/- +/- ++ +
Ciclosporine p.o. en i.v. -- ++ -- +/-
6-Mercaptopurine p.o. +/- +/- ++ +
Methotrexaat p.o., i.m. en s.c. +/- -- + --
CU = colitis ulcerosa; p.o. = per os; i.v. = intraveneus; i.m. = intramusculair; s.c. =
subcutaan.
Weergegeven is de mate van effectiviteit per genoemde indicatie: -- geen bewijs
voorhanden, +/- enig effect waargenomen in studies, + effect aangetoond in placebo
gecontroleerd onderzoek, ++ Bewijs voor effectiviteit geleverd in meerdere
gecontroleerde studies. 
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thiopurines. De belangrijkste beperking van MTX is aangetoonde teratogeniteit,
omdat een belangrijk deel van de patiënten vrouwen betreft in de vruchtbare
levensfase. De meest voorkomende bijwerking  is misselijkheid. Klinisch manifeste
leukopenie komt voor bij 1-5% van de patiënten en allergische pneumonitis bij
minder dan 1%. Bij patiënten met psoriasis is levertoxiciteit beschreven met
ontwikkeling van leverfibrose of zelfs cirrose bij 7% van de patiënten, zodat bij deze
patiënten in de follow-up een leverbiopsie wordt geadviseerd. Bij patiënten met RA
of een inflammatoire darmziekte lijkt dit duidelijk minder dan 1% te zijn bij
wekelijkse toediening van MTX, zodat er bij deze patiënten niet routinematig een
leverbiopsie wordt verricht. Wel is het om deze reden belangrijk om terughoudend te
zijn met MTX bij patiënten met suikerziekte of fors alcohol gebruik. Omdat MTX een
foliumzuur antagonist is wordt geadviseerd om tijdens de behandeling met MTX ook
een lage dosis foliumzuur te gebruiken (1 tot 5 mg per dag) om een deel van de
bijwerkingen te voorkomen. Theoretisch kan hierdoor de effectiviteit wel
verminderen, maar dit is in de studies niet aangetoond. Samenvattend is MTX een
zinvolle aanvulling bij patiënten met de ziekte van Crohn. Met de huidige gegevens
vooral in de situatie waarbij behandeling met thiopurines heeft gefaald.
Ciclosporine
Bij patiënten met een inflammatoire darmziekte lijkt ciclosporine slechts een beperkte
rol te spelen. Bij de ziekte van Crohn bleek ciclosporine onvoldoende effectief te zijn
ten aanzien van het induceren van remissie. Wel zijn er gunstige (niet gecontroleerde)
observaties bij patiënten met actieve peri-anale fistels. Bij ernstig actieve
corticosteroïd refractaire colitis ulcerosa is ciclosporine effectief in het induceren van
remissie, waarmee een colectomie in de acute fase voorkomen kan worden. In een
klinische setting  bij intraveneuze toediening reageert meer dan 80% van deze ernstig
zieke patiënten goed op de korte termijn, maar bijna 30% van de responders werd
binnen 6 maanden alsnog geopereerd (9). Langdurige toepassing van orale
ciclosporine wordt beperkt door de kans op niertoxiciteit, zodat ciclosporine na
initieel goede respons meestal omgezet wordt in een andere therapie.
Biologische therapieën
Momenteel is onderzoek met zogenaamde biologische therapieën snel aan het
toenemen. Deze therapieën zijn selectief gericht zijn tegen humane eiwitten met een rol
in het ontstekingsproces. De toename in belangstelling voor biologische therapie is te
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verklaren vanuit een aantal zaken. Allereerst is het inzicht in de immunologie bij de
ziekte van Crohn en colitis ulcerosa snel aan het toenemen. Tevens is de kennis om
monoklonale eiwitten te produceren sterk toegenomen. Tenslotte heeft de succesvolle
introductie van infliximab bij de ziekte van Crohn het enthousiasme versterkt om te
zoeken naar nieuwe aangrijpingspunten. Vooralsnog is infliximab de enige
geregistreerde biologische therapie bij patiënten met een inflammatoire darmziekte,
zodat we deze verder zullen bespreken. Infliximab is een monoklonale antistof gericht
tegen TNF-α, welke deels uit niet humaan eiwit bestaat. Inmiddels is een groot aantal
trials gepubliceerd en op basis daarvan is er een plaats voor infliximab in de
behandeling van voorheen therapie resistente Crohn (10). Een belangrijk nadeel van
infliximab is dat het uitsluitend intraveneus wordt toegediend, waarbij een
oplaadschema van 3 infusen (0, 2 en 6 weken) effectiever lijkt dan een éénmalige dosis
van 5 mg/kg (respons percentages na 10 weken 52-65%). Bij circa 35% van de patiënten
trad er echter binnen 12 weken na de initiële behandeling hernieuwde ziekteactiviteit
op. Tijdens onderhoudsbehandeling waarbij infliximab iedere 8 weken werd toegediend
was na 1 jaar nog 53% van de patiënten in remissie, versus 20% in de placebo groep. Uit
dezelfde studie bleek dat, indien er bij onderhoudstherapie sprake was van verlies van
respons, het ophogen van de infliximab van 5 naar 10 mg/kg resulteerde in een
hernieuwde respons bij 80-90% van de patiënten (11). Gelijktijdig gebruik van een
thiopurine of MTX bleek de respons enigszins te verbeteren. Zeer opzienbarend waren
de initiële resultaten bij patiënten met een fistelende Crohn. Voorheen was er nauwelijks
gepubliceerd geneesmiddelen onderzoek voorhanden waarin gunstig effect op Crohnse
fistels werd beschreven. Infliximab in een oplaadschema van 3 maal 5 mg/kg (0, 2, 6
weken) leidde tot een klinische respons bij 68% van de patiënten en volledig verdwijnen
van fistelproductie bij 56% ten opzichte van 26% en 13% van de met placebo behandelde
patiënten. Echter bij het overgrote deel van de patiënten keerde fistels terug na staken
van de behandeling (mediaan na 12 weken). Recent onderzoek liet zien dat met een
onderhoudsbehandeling met infliximab 5 mg/kg, elke 8 weken, 36% van de patiënten
met fistels nog in remissie waren versus 19% in het geval van placebo (12). De
behandeling met infliximab kent echter ook belangrijke bezwaren zodat andere vormen
van behandeling waaronder chirurgie sterk overwogen moeten worden. Allereerst is
behandeling kostbaar zodat de kosten effectiviteit ter discussie staat. Ten tweede is
slechts intraveneuze toediening mogelijk. Ten derde is infliximab door de niet-humane
component zelf immunogeen. Antilichamen tegen infliximab (ATI) worden
gerapporteerd in 10 tot 61% van de behandelde patiënten. Dit is geassocieerd met
(vertraagde) overgevoeligheidsreacties en met een verminderde respons. ATI worden
vaker gezien bij episodische behandeling zodat reguliere onderhoudsbehandeling
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ontwikkeling van ATI kan voorkomen. Mogelijk dat ook gecombineerde behandeling
met immunosuppresiva of profylactische toediening van corticosteroïden tijdens het
infliximab infuus ATI voorkomen. Tenslotte zijn er vele meldingen van ernstige
opportunistische infecties beschreven waaronder vooral reactivering van tuberculose.
Daarom is tuberculose screening essentieel vóór aanvang met infliximab. Dit gebeurt
met behulp van een Mantoux huidtest en een thorax foto. Er zijn ongecontroleerde
waarnemingen beschreven waarin melding gemaakt wordt van redelijke effectiviteit
van infliximab bij patiënten met colitis ulcerosa. Momenteel worden de resultaten
uitgewerkt van een tweetal grote internationale placebo gecontroleerde studies om te
beoordelen of er een plaats voor infliximab bij colitis ulcerosa. Anders dan bij RA is tot
op heden geen van de overige TNF-α blokkers vergelijkbaar effectief gebleken. Het blijft
dan ook wachten op een minder immunogeen, eenvoudiger toe te dienen en minder
kostbaar alternatief voor infliximab.
Conclusies
• Definitieve genezing van inflammatoire darmziekten is nog een illusie.
• 5-ASA preparaten zijn zowel bij actieve colitis ulcerosa als in de remissiefase
bewezen effectief. Bij de ziekte van Crohn zijn 5-ASA preparaten weliswaar
effectiever dan placebo, maar is de winst zeer gering.
• De thiopurines azathioprine en 6-mercaptopurine spelen een belangrijke rol bij het
in remissie houden van patiënten met een ernstigere ziekte presentatie en bij
patiënten waarbij afbouwen van corticosteroïden faalt. Dit geldt zowel voor colitis
ulcerosa als de ziekte van Crohn.
• Infliximab is een belangrijke aanvulling op het therapeutische arsenaal bij de ziekte
van Crohn, waarbij risico’s van behandeling kritisch afgewogen dienen te worden.
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Chapter 13
Summary and general discussion

This thesis describes clinical aspects of medical treatment in patients with Crohn’s
disease, with emphasis on conventional therapies. Currently, a number of new
compounds are on the way in order to improve therapeutic goals concerning efficacy
and safety. However, for judgement of the advantages of new compounds, knowledge
of older therapies is warranted. Therefore, the aim of the present thesis is to determine
the safety profile of conventional treatment strategies including budesonide and 6-
thioguanine in Crohn’s disease.
Summary
Chapter 2 reviews disease specific activity indices, which have been used in previous
trials. Every index has its own strength and weakness, which is important for the
judgement of results in clinical trials. None of these indices is suited for use in
retrospective studies, to obtain a value for long-term disease activity over the past.
Chapter 3 deals with 5-aminosalicylates, which are used on a large scale in patients with
Crohn’s disease and ulcerative colitis. Concerns have been raised among potential
nephrotoxicity, but proofs for long-term dose-related nephrotoxicity of these
compounds were lacking. This chapter describes a retrospective cohort analysis
exploring the dose relationship between changes in renal function and the history of 5-
aminosalycilates. The study population consisted of 153 patients, whom were exposed
to a wide variety in amounts of 5-aminosalicylates, ranging from 0 to 55 kg. In this study
long-term use of 5-ASA had no detrimental effects on renal function, because the mean
negative annual change in ECC in these patients seems not to exceed changes due to
physiologic aging.
In chapter 4, a retrospective cohort analysis is presented, exploring risk factors for low
bone mineral density in Crohn’s disease patients at high risk for osteoporosis. The study
population consisted of 91 patients with a mean disease duration of 12 years (range 0,2
to 37 years). The exposure to prednisolone over time was ranging from 0 to 79 gram.
Measured by dual energy X-ray absorptiometry, only 19% of the patients had a bone
mineral density (BMD) of both the lumbar spine and femoral neck in the normal range.
This study confirmed that the body mass index is a major independent predictive
variable for BMD in patients with Crohn’s disease, which accounted for 22% of variation
in BMD Z-scores. A history of bowel resections was also a significant predictive variable
for BMD, although it accounted for only an extra 6% of variation. Despite high
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cumulative doses of corticosteroids used in the present study, no independent
detrimental effect on BMD was demonstrated.
Chapter 5 describes a longitudinal study, exploring changes in BMD over time in relation
with potential risk factors for osteoporosis. Furthermore, previous longitudinal studies
were reviewed. The present study population consisted of 29 patients with Crohn’s
disease, in whom repeated BMD assessments were performed. Because the exposure to
potential risk factors for osteoporosis persisted in these patients, further decline in bone
density over time was expected. However, during a mean interval of 41 months, no
change in mean BMD was observed over time, despite ongoing use of corticosteroids.
This is in accordance with some previous trials, although a highly variable rate of bone
loss was observed in patients with Crohn’s disease. The lack of bone loss in the present
study may be partially explained by a reduction in disease activity over time, as change
in blood sedimentation rate was an independent predictor for change in BMD.
Chapter 6 describes a cohort analysis concerning genetic susceptibility to osteoporosis in
Crohn’s disease. As shown in chapters 4 and 5, variation in BMD is only explained
partially by variations in clinical determinants. The evidence for genetic susceptibility to
osteoporosis is growing in general populations. Therefore, in the present study,
associations between both genetic and disease related factors with BMD were studied.
The study population consisted of 89 patients. A number of genetic variants, which were
associated with osteoporosis in previous trials, were analysed. However, in this relative
small group of patients, none of the genetic factors studied appeared to be strong risk
factors for low BMD in Crohn’s disease. From the clinical determinants, low body mass
index and male gender were independent predictors for impaired BMD.
In chapter 7, a randomised, prospective, double blind, multi-centre study with
budesonide is presented, in patients with quiescent Crohn’s disease. Budesonide is a
locally active corticosteroid, which combines low bioavailability after oral
administration, with high receptor affinity. Therefore, its use resulted in good efficacy
with limited corticosteroid related adverse events compared with conventional
prednisolone, as was demonstrated in a number of trials in active Crohn’s disease.
Furthermore, in a pooled analysis of 4 maintenance trials, comparing budesonide with
placebo, the median time to relapse was significantly prolonged from 154 days in the
placebo groups to 268 days in the budesonide 6 mg daily groups. However, the relapse
rate after one year was 59% in the placebo group, which was not significantly different
from 51% in the patients treated with budesonide 6 mg daily. Since a dose-relationship
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seems to exist in these maintenance trials, administration of budesonide in a higher dose
of 9 mg daily may be more effective. Therefore, the primary objective of the study was
to evaluate if the time to relapse is prolonged under budesonide 9 mg per day compared
to 6 mg per day, in patients with Crohn's disease in remission at study entry. Secondary
objectives were to evaluate remission rates after one year and to examine the safety of
budesonide 6 mg and 9 mg once daily. The study population consisted of 157 patients.
In conclusion, a remarkably low relapse rate was achieved in patients with quiescent
Crohn’s disease, treated with budesonide 6 mg/day and no significant additional
benefit was demonstrated by routinely increasing the dose to 9 mg/day. At the other
hand, the number of adverse events was similar in both treatment groups. This means
that budesonide 6 mg/day seems a reasonable dose for maintenance therapy in Crohn’s
disease. However, when dose escalation seems to be indicated in individual cases, the
dose may be increased to 9 mg/day without a significant increase in adverse events. 
Chapter 8 reviews strategies in order to reduce potential toxicity of frequently used
thiopurines. 
In chapter 9, a retrospective cohort analysis is presented, concerning the use of
azathioprine in 112 consecutive patients with Crohn’s disease. Almost 50% of these
patients had a history of azathioprine. Of these patients, 22% discontinued azathioprine
prematurely due to probably drug related adverse events. An additional 8%
discontinued due to probably non-related events. None of the adverse events was
irreversible. Remarkably, patients who discontinued azathioprine prematurely, used
lower doses of prednisone initially and therefore, concomitant use of prednisone may
have prevented some of the adverse events.
Chapter 10 describes a short-term prospective open label study with 6-thioguanine in
previously azathioprine or 6-mercaptopurine intolerant patients with inflammatory
bowel disease. The aim of this study was to determine the short-term safety of 6-
thioguanine in high- risk patients due to their previous thiopurine intolerance. Thirty-
two previous thiopurine intolerant patients were treated with 6-thioguanine in a dose of
20 to 40 mg/day over an 8 weeks period and 80% of them tolerated 6-thioguanine well.
No clinically relevant hepatotoxicity or myelotoxicity was observed, despite high blood
levels of 6-thioguanine nucleotides. These blood levels were even 4-7 fold higher as
described in patient using effective doses of azathioprine. Because of the good
tolerability, low dose 6-thioguanine seems an attractive candidate for azathioprine
intolerant patients, but both efficacy and long-term safety have to be proven before 6-
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thioguanine may be added to the standard arsenal in inflammatory bowel disease.
Especially because concerns have been raised among long-term hepatotoxicity and
veno-occlusive disease.
In chapter 11, a multi centre database analysis is presented, exploring the one-year safety
of 6-thioguanine in patients with inflammatory bowel disease. The study population
consists of 95 patients with either Crohn’s disease or ulcerative colitis, whom were
previously intolerant for azathioprine or 6-mercaptopurine. The aim of the study was to
determine the tolerability and safety profile of low-dose maintenance therapy with 6-
thioguanine over a treatment period of at least one year, in these high-risk patients.
Twenty out of 95 (21%) patients discontinued 6-thioguanine within one year because of
adverse events. Haematological events occurred in three patients and one of these
discontinued treatment. In those patients who tolerated 6-thioguanine (n=75), 7 (9%)
could be classified as having potential drug related hepatotoxicity. By abdominal
ultrasound, which was performed in 54% of patients, splenomegaly was found in one
patient. In conclusions, the majority of previously thiopurine intolerant patients (79%)
was able to tolerate maintenance treatment with 6-thioguanine in a low dose of 0.3 to 0.4
mg/kg/day. Therefore, 6-thioguanine may still be considered as an escape
immunosuppressive therapy in this difficult to treat group of patients. However, the
recently reported 6-thioguanine related hepatotoxicity is worrisome and therefore, 6-
thioguanine should be reserved as rescue therapy for highly selected patients or for
administration in prospective trials, awaiting new data concerning hepatotoxicity.
Chapter 12 is a review in Dutch about the status of medical therapy in patients with
inflammatory bowel disease, focussing on currently registered therapies.
General discussion
In clinical practice, treating patients with Crohn’s disease, is challenging. In each patient,
a large number of relevant questions may raise during the course of disease. A number
of these questions deal with the therapeutic options, which are available. Evidence-
based guidelines may give some help in order to select an appropriate treatment, but the
majority of issues will have open answers yet. For example, an important issue is if we
have to step up from light strategies to more powerful, but also potentially more
harmful compounds, or should we give all patients the most powerful option first and
try to taper down afterwards? Furthermore, even if an evidence-based answer seems to
172
exist to a specific issue, an individual patient may not fulfil the restricted in- and
exclusion criteria from studies providing the assumed truth. Therefore, optimal
management of patients with Crohn’s disease needs to be individualised, based on all
available knowledge. This should encourage anyone involved in the management of
patients to deliver pieces of the large puzzle of Crohn’s disease. 
Studies presented in this thesis, have shown that conventional treatment strategies in
patients with Crohn’s disease may have disadvantages regarding side-effects. However,
for each category of compounds studied, the majority of patients is able to tolerate
relative long-term treatment without clinically relevant adverse events. This is certainly
true for compounds containing 5-ASA, which are prescribed for long-term treatment in
relative high doses on large scale. Although renal toxicity due to 5-ASA may occur
incidentally, no relationship was shown between cumulative dose of 5-ASA and changes
in renal function over time in the present thesis.
Historically, corticosteroids have been used on a large scale because of good short-term
efficacy. However, long-term use is strongly discouraged, mainly due to a wide range of
side effects. Furthermore, long-term efficacy of corticosteroids remains unproven in
Crohn’s disease. A major disadvantage of corticosteroids is an increased risk for
osteoporosis due to negative effects on bone metabolism. However, in Crohn’s disease
the aetiology of osteoporosis is complex, as shown in this thesis. The cumulative dose of
corticosteroids was no independent predictor for bone mineral density, while body mass
index was the strongest predictor. Furthermore, no decline in bone mineral density was
observed over time, despite ongoing use of corticosteroids. An attractive strategy to
diminish corticosteroid related side effects during long-term treatment is to administer
locally active corticosteroids, such as budesonide instead of prednisone. As shown in the
present thesis, the majority of patients treated with budesonide in doses of 6 to 9 mg per
day over a one-year period had no clinically apparent steroid related side effects.
Although the number of relapses during mono-therapy with budesonide was
remarkably low, questions among efficacy as maintenance therapy for Crohn’s disease
remain open.
At present, the standard maintenance strategy in moderate and more severe Crohn’s
disease is azathioprine. However, this thesis demonstrated that in more than 20% of
patients azathioprine will be discontinued due to adverse events. Several strategies in
order to reduce adverse events have been discussed in this thesis. One of the strategies
is to administer downstream metabolites of azathioprine, such as 6-mercaptopurine or
6-thioguanine. Extensive experience is available with 6-mercaptopurine in Crohn’s
disease, because this is the first choice thiopurine in large areas. In the Netherlands, the
value of 6-mercaptopurine seems underestimated, as this compound is registered for
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oncology indications only. As shown in this thesis, about 80% of patients intolerant for
azathioprine or 6-mercaptopurine will tolerate 6-thioguanine in relative low doses
below 40 mg per day. Drug metabolic monitoring during low dose treatment
demonstrated sufficiently high metabolite levels. However, several reports have shown
signs of liver toxicity and portal hypertension during treatment with 6-thioguanine in
higher doses. Therefore, at present 6-thioguanine should be reversed for highly selected
patients.
For patients, intolerant or refractory to conventional compounds, newer biological
therapies were introduced. Until now, infliximab is the only compound from this group,
which made it to the bedside in routine clinical praxis. A number of controlled trials with
infliximab demonstrated efficacy in inducing remission in active refractory Crohn’s
disease and in maintaining remission later on. However, it is highly unlikely that
infliximab will replace all conventional medical therapy, because only about 40% of the
patients will stay in remission with infliximab. Furthermore, it is expensive, impractical
because of intravenous application and potentially unsafe as serious adverse events do
occur. At the other hand, the successful introduction of infliximab in the treatment of
Crohn’s disease encourages the search for other biological agents with at least equal
efficacy without the disadvantages of infliximab. 
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Chapter 14
Nederlandse samenvatting

Dit proefschrift beschrijft klinische aspecten van medicamenteuze behandeling van
patiënten met de ziekte van Crohn. De nadruk in dit proefschrift ligt op bijwerkingen
van geneesmiddelen die op grote schaal worden gebruikt. Op dit moment zijn er
verschillende nieuwe middelen in ontwikkeling die mogelijk kunnen bijdragen aan de
behandeling van de ziekte van Crohn. Echter om de meerwaarde van nieuwe
behandelingsvormen op waarde te kunnen schatten is kennis van de reeds beschikbare
middelen onontbeerlijk. Het doel van dit proefschrift is dan ook de toepassing van de
reeds langer bestaande geneesmiddelen te onderzoeken, met de nadruk op
bijwerkingen, bij patiënten met de ziekte van Crohn. Een van oudsher veel gebruikt
geneesmiddel is prednison, omdat hiermee op korte termijn een relatief krachtig effect
op de ziekte verkregen kan worden. Prednison is echter ongeschikt voor langdurige
behandeling omdat de resultaten op langere termijn sterk tegenvallen en door het
frequent optreden van bijwerkingen. Daarom worden op grote schaal andere
geneesmiddelen gebruikt om de ziekte langdurig onder controle te houden. Op dit
moment lijkt het middel azathioprine daarvoor het meest geschikt, maar ook het
gebruik van azathioprine wordt beperkt door mogelijke bijwerkingen. In dit proefschrift
worden tevens de geneesmiddelen budesonide als vervanger van prednison en 6-
thioguanine als vervanger van azathioprine besproken.
Hoofdstuk 2 geeft een overzicht van beschikbare manieren om ziekte activiteit te meten,
welke zijn gebruikt in klinische studies. Dit is van belang om de resultaten van
verschillende onderzoeken met elkaar te kunnen vergelijken. Echter geen van de
beschikbare methoden is geschikt om een maat te geven aan ziekte activiteit over een
periode in het verleden.
Hoofdstuk 3 heeft betrekking op een groep geneesmiddelen die 5-aminosalicylaten (5-
ASA) worden genoemd. Deze van aspirine afgeleide middelen worden op grote schaal
gebruikt bij patiënten met de ziekte van Crohn en colitis ulcerosa. Hoewel deze
middelen in het algemeen als veilig worden beschouwd, bestaan er zorgen over
schadelijkheid voor de nieren. Er zijn meerdere patiënten beschreven met nierschade
door 5-ASA. Recente onderzoeken lieten zien dat optreden van acute en of ernstige
nierschade door deze middelen relatief zeldzaam is. Echter gegevens over nierschade
door langdurig gebruik van 5-ASA in hoge dosering ontbreken. Deze kennis is
belangrijk omdat 5-ASA meestal langdurig wordt voorgeschreven in relatief hoge
doseringen. Dit hoofdstuk beschrijft een studie naar de relatie tussen verandering in
nierfunctie op de lange termijn en blootstelling aan 5-ASA in het verleden. De
onderzochte groep bestaat uit 153 patiënten die zijn blootgesteld aan totale doseringen
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5-ASA, variërend van 0 tot 55 kg, gedurende de ziekte. In deze studie was er geen relatie
aantoonbaar tussen de totale hoeveelheid 5-ASA die werd gebruikt en verandering in
nierfunctie in de tijd. Tevens leek de gemiddelde achteruitgang in nierfunctie per jaar in
de studie niet groter dan op grond van gegevens bij normale veroudering te verwachten
was. Daarmee versterkt deze studie de conclusies van eerdere studies dat langdurig
gebruik van 5-ASA geen dosis afhankelijk schadelijk effect lijkt te hebben op de
nierfunctie.
In Hoofdstuk 4 wordt een studie beschreven, waarin klinische risicofactoren uit het
verleden worden onderzocht voor het ontstaan van osteoporose bij patiënten met de
ziekte van Crohn. Aan de studie namen 91 patiënten met de ziekte van Crohn deel, met
een verondersteld hoog risico op osteoporose. De cumulatieve blootstelling aan
prednison varieert van 0 tot 79 gram en de ziekteduur varieert van 0,2-37 jaar
(gemiddelde 12 jaar). De botdichtheid werd gemeten met behulp van een röntgen
techniek die dual energy X-ray absorptiometry (DXA) wordt genoemd. Slechts 19% van
de onderzochte patiënten had een normale botdichtheid van zowel de heuphals als de
lumbale wervelkolom. De sterkste voorspeller voor de botdichtheid was de body mass
index (BMI), welke voor 22% bijdroeg aan de variatie in botdichtheid. Tevens was een
voorgeschiedenis van darm resecties een onafhankelijke voorspeller voor verlaagde
botdichtheid, hoewel deze factor voor slechts 6% van de variatie verantwoordelijk was.
Ondanks de gemiddeld grote blootstelling aan prednison met een grote variatie tussen
de patiënten bleek de cumulatieve dosis geen onafhankelijke  voorspeller voor de
botdichtheid.
Hoofdstuk 5 beschrijft een longitudinale studie, waarin de relatie tussen klinische
variabelen en verandering in botdichtheid in de tijd wordt onderzocht. Tevens wordt
een overzicht gegeven van de beschikbare longitudinale studies bij patiënten met een
chronische inflammatoire darmziekte. De studie populatie bestond uit 29 patiënten bij
wie meerdere botdichtheidsmetingen plaatsvonden. Ten tijde van de eerste
botdichtheidsmeting was er reeds sprake van een verlaagde botdichtheid bij de
meerderheid van de patiënten. Omdat deze patiënten gedurende de studie periode
blootstonden aan veronderstelde risicofactoren voor osteoporose, werd een daling in
botdichtheid over de tijd verwacht. Echter, gedurende het studie interval van gemiddeld
41 maanden werd geen verandering in botdichtheid waargenomen. Dit terwijl 27 van de
29 patiënten in die periode prednison bleven gebruiken. Het ontbreken van een verdere
daling in botdichtheid in de tijd komt overeen met eerdere waarnemingen, hoewel de
eerdere studies een grote spreiding laten zien. Het ontbreken van verdere daling in
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botdichtheid zou in deze studie verklaard kunnen worden door een daling in ziekte
activiteit, omdat verandering in bloed bezinking (als veronderstelde maat voor ziekte
activiteit) een onafhankelijke voorspeller bleek te zijn voor de verandering in
botdichtheid.
Hoofdstuk 6 beschrijft een cohort analyse met betrekking tot genetische variabelen als
voorspellers voor osteoporose bij patiënten met de ziekte van Crohn. Zoals wordt
beschreven in hoofdstukken 4 en 5, kan slechts een beperkt gedeelte van de variatie in
botdichtheid verklaard worden uit de onderzochte klinische variabelen. Bovendien zijn
in toenemende mate aanwijzingen voorhanden dat genetische factoren een rol spelen in
het ontstaan van primaire osteoporose. Daarom werden in de huidige studie associaties
onderzocht tussen met osteoporose geassocieerde genetische variaties, ziekte
gerelateerde factoren en botdichtheid. Aan de studie namen 89 patiënten deel met de
ziekte van Crohn, waarbij de botdichtheid met behulp van DXA werd gemeten. Geen
van de onderzochte genetische variaties bleek een onafhankelijke voorspeller te zijn
voor verlaagde botdichtheid, terwijl dat wel het geval was voor verlaagde BMI en
mannelijk geslacht. De onderzochte genen waren in eerder onderzoek bij andere
populaties wel geassocieerd met de botdichtheid. Op grond van deze resultaten lijkt
geen van de onderzochte genen sterk geassocieerd te zijn met botdichtheid  bij de ziekte
van Crohn.
In hoofdstuk 7 wordt een prospectieve dubbel blind gerandomiseerde studie besproken
met budesonide als onderhoudsbehandeling bij patiënten met een rustige Crohn.
Theoretisch combineert budesonide een goede effectiviteit met een beperkt aantal
corticosteroïd gerelateerde bijwerkingen, omdat het door de lever snel wordt
afgebroken zodra het in het bloed komt. Dit werd bevestigd in meerder trials bij
patiënten met actieve Crohn, waarbij 9 mg per dag een optimale dosis bleek te zijn.
Daarnaast werd in een viertal studies budesonide 3 of 6 mg per dag vergeleken met
placebo als onderhoudsbehandeling over de periode van 1 jaar. In de 4 studies werd de
mediane tijd tot het opnieuw optreden van ziekteactiviteit significant verlengd van 154
dagen in de placebo groepen naar 268 dagen in de budesonide 6 mg groepen. Echter, het
percentage patiënten met een terugval van de ziekte was na 1 jaar 59% in de placebo
groep, hetgeen niet significant verschilde van 51% in de budesonide 6 mg groep. Er leek
een dosis effect relatie te bestaan, zodat budesonide 9 mg per dag effectiever zou kunnen
zijn. Het primaire doel van de huidige studie was te onderzoeken of budesonide 9 mg
per dag beter in staat is om opnieuw optreden van ziekte te voorkomen dan 6 mg per
dag, gedurende een periode van 1 jaar. Tevens werd onderzocht of er verschil in
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optreden van bijwerkingen werd waargenomen. Er werden 157 patiënten in de studie
opgenomen. Gedurende de studie werd in de laagste dosering van 6 mg per dag een
opvallend lager aantal recidieven van ziekte waargenomen dan verwacht. Er werd dan
ook geen significante verbetering waargenomen met 9 mg per dag ten opzichte van 6 mg
per dag. Ten aanzien van bijwerkingen waren er ook geen verschillen tussen beide
groepen. Deze bevindingen betekenen dat budesonide 6 mg per dag voor
onderhoudsbehandeling een effectieve dosis kan zijn bij patiënten met de ziekte van
Crohn. Als echter dosisescalatie nodig is bij een individuele patiënt, dan kan de dosis
verhoogd worden naar 9 mg per dag zonder dat ernstige toename van bijwerkingen te
verwachten is.
Hoofdstuk 8 geeft een overzicht van behandeling met thiopurines bij patiënten met een
inflammatoire darmziekte. Een aantal strategieën wordt besproken om de kans op
bijwerkingen van veel gebruikte thiopurines mogelijk te reduceren.  
In hoofdstuk 9 wordt een retrospectieve cohort analyse gepresenteerd, met betrekking tot
het gebruik van azathioprine bij 112 opeenvolgende patiënten met de ziekte van Crohn.
Bijna de helft van deze patiënten heeft in het verleden azathioprine gebruikt of gebruikt
dit nog. Van deze patiënten heeft 22% azathioprine voortijdig gestaakt door
bijwerkingen die waarschijnlijk gerelateerd waren aan het gebruik van azathioprine.
Daar bovenop heeft nog 8% de azathioprine gestaakt wegens niet gerelateerde redenen.
Geen van de beschreven bijwerkingen was irreversibel. Als opvallende bevinding
hebben patiënten die voortijdig de azathioprine staakten gemiddeld lagere doseringen
prednison gebruikt bij aanvang van de azathioprine. Mogelijk dat gelijktijdig gebruik
van prednison bij aanvang van de azathioprine enkele bijwerkingen voorkomt.
Hoofdstuk 10 beschrijft een prospectieve studie naar de veiligheid van 6-thioguanine
gedurende de eerste 8 weken bij patiënten die eerder een conventionele thiopurine niet
konden verdragen. In totaal namen 32 patiënten aan dit onderzoek deel, waarbij 6-
thioguanine niet-geblindeerd werd toegediend in een dosis van 20 tot 40 mg per
dag,gedurende 8 weken. 80% van deze patiënten kon de 6-thioguanine goed verdragen.
Geen klinisch relevante lever toxiciteit of beenmerg toxiciteit werd waargenomen,
ondanks hoge bloedspiegels van de effectieve metabolieten 6-thioguanine nucleotiden.
Deze bloedspiegels waren zelfs 4 tot 7 keer hoger dan wanneer gangbare doseringen
azathioprine worden toegediend. De 6-thioguanine wordt opvallend goed getolereerd
door deze patiënten, terwijl ze een hoog risico op thiopurine bijwerkingen hebben
doordat eerder sprake was van een intolerantie voor azathioprine en/ of 6-
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mercaptopurine. Daarom lijkt 6-thioguanine een veelbelovend alternatief voor
azathioprine intolerante patiënten. Echter, zowel de lange termijn veiligheid als
effectiviteit moeten verder uitgezocht worden voordat 6-thioguanine opgenomen kan
worden in het standaard arsenaal. Met name omdat er meldingen gedaan zijn van 6-
thioguanine gerelateerde lever toxiciteit en tekenen van portale hypertensie.
In hoofdstuk 11 wordt een database analyse gepresenteerd waarin de 1 jaars gegevens van
het gebruik van 6-thioguanine bij patiënten met een inflammatoire darmziekte worden
geëvalueerd. De studie populatie betreft 95 patiënten met de ziekte van Crohn of colitis
ulcerosa, die allen eerder intolerant waren voor azathioprine of 6-mercaptopurine. De
vraagstelling van dit onderzoek betrof de tolerantie en veiligheid van 6-thioguanine
gedurende 1 jaar bij deze patiënten categorie. 20 van de 95 (21%) patiënten stopte
voortijdig met 6-thioguanine binnen 1 jaar door bijwerkingen. Geen ernstige
irreversibele bijwerkingen werden waargenomen. Beenmerg toxiciteit trad op bij 3
patiënten, waarvan er 1 de behandeling staakte. Van de patiënten die 6-thioguanine
goed konden verdragen (n=75) ontwikkelden er 7 (9%) mogelijk gerelateerde lever
toxiciteit (stijging lever enzymen). Bij de helft van alle patiënten werd na 1 jaar een
echografie van de bovenbuik gemaakt om te beoordelen of er sprake was van portale
hypertensie of splenomegalie. Bij 1 patiënt werd na 1 jaar een geringe milt vergroting
waargenomen. Concluderend kon de meerderheid van deze patiënten 6-thioguanine
goed verdragen (79%) in een lage dosering van 0.3 tot 0.4 mg/kg/dag. Echter omdat 6-
thioguanine gerelateerde lever toxiciteit en tekenen van portale hypertensie zijn
beschreven in een vrij hoge frequentie, moet 6-thioguanine in afwachting van
aanvullende gegevens slechts als reserve middel beschouwd worden voor toepassing bij
geselecteerde patiënten of in klinische trials.
Hoofdstuk 12 betreft een overzicht in het Nederlands over de medicamenteuze
behandeling van patiënten met een chronische inflammatoire darmziekte. Het accent
ligt op voor deze indicatie geregistreerde geneesmiddelen. 
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